

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

220304US0XPCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/070804

INTERNATIONAL APPLICATION NO.
PCT/JP00/06165INTERNATIONAL FILING DATE
8 September 2000PRIORITY DATE CLAIMED
9 September 1999

TITLE OF INVENTION

PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THEM

APPLICANT(S) FOR DO/EO/US

YASUDA Atsushi et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
- a. ☐ is attached hereto (required only if not communicated by the International Bureau).
- b. ☒ has been communicated by the International Bureau.
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
- a. ☒ is attached hereto.
- b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
- a. ☐ are attached hereto (required only if not communicated by the International Bureau).
- b. ☐ have been communicated by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☒ have not been made and will not be made.
- ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
- ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Request for Priority/Form PTO-1449

Form PTO-1595

PCT/IB/304

PCT/IB/308

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 107070804	INTERNATIONAL APPLICATION NO. PCT/JP00/06165	ATTORNEY'S DOCKET NUMBER 220304US0XPCT
--	--	--

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1040.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$890.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$740.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS PTO USE ONLY****\$890.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	11 - 20 =	0	x \$18.00
Independent claims	6 - 3 =	3	x \$84.00

\$0.00**\$252.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,142.00**☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.**\$0.00****SUBTOTAL =****\$1,142.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).**\$0.00****TOTAL NATIONAL FEE =****\$1,142.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☒**\$40.00****TOTAL FEES ENCLOSED =****\$1,182.00**

Amount to be:

refunded

\$

charged

\$

- ☒ A check in the amount of **\$1,182.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030**. A duplicate copy of this sheet is enclosed.
- ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**22850**

SIGNATURE

William F. Beaumont

NAME

Registration Number 80,996

24,618

REGISTRATION NUMBER

DATE

March 11, 2002

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

220304US0XPCT

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

10/070804

INTERNATIONAL APPLICATION NO.

PCT/JP00/06165

INTERNATIONAL FILING DATE

8 September 2000

PRIORITY DATE CLAIMED

9 September 1999

TITLE OF INVENTION

PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THEM

APPLICANT(S) FOR DO/EO/US

YASUDA Atsushi et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Request for Priority/Form PTO-1449

Form PTO-1595

PCT/IB/304

PCT/IB/308

U.S. APPLICATION NO. (IF ENCLOSED SEE 37 CFR 1.492(a)(1))	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/070804	PCT/JP00/06165	220304US0XPCT

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	11 - 20 =	0	x \$18.00
Independent claims	6 - 3 =	3	x \$84.00

\$0.00

\$252.00

Multiple Dependent Claims (check if applicable). ☐

\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,142.00

Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

\$0.00

SUBTOTAL =

\$1,142.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

\$0.00

TOTAL NATIONAL FEE =

\$1,142.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☒

\$40.00

TOTAL FEES ENCLOSED =

\$1,182.00

Amount to be refunded	\$
charged	\$

- a. ☒ A check in the amount of \$1,182.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



22850

[Signature]
SIGNATURE

William E. Beaumont
Norman F. Oblon

NAME
Registration Number 30,990

24,618

REGISTRATION NUMBER

March 11, 2002
DATE

220304US-0XPCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
ATSUSHI YASUDA ET AL : ATTN: APPLICATION DIVISION
SERIAL NO: NEW U.S. PCT APPLN :
(Based on PCT/JP00/06165)
FILED: HEREWITH :
FOR: PYRIMIDINE DERIVATIVES AND :
HERBICIDES CONTAINING THEM

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

7. (Amended) A herbicide containing the pyrimidine derivative as defined in Claim 1, as an active ingredient.

Please add the following new claims.

8. (New) A herbicide containing the pyrimidine derivative as defined in Claim 2, as an active ingredient.

10070804-0110

9. (New) A herbicide containing the pyrimidine derivative as defined in Claim 3, as an active ingredient.

10. (New) A herbicide containing the pyrimidine derivative as defined in Claim 4, as an active ingredient.


11. (New) A herbicide containing the pyrimidine derivative as defined in Claim 5, as an active ingredient.

REMARKS

Claim 7 has been amended to remove multiple dependencies. Claims 8-11 are new claims. Support for the new claims is found in the original claims. Claims 1-11 are active in the present application. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmeider, Ph.D.
Registration No. 50,238



22850

(703) 413-3000
Fax #: (703) 413-2220
SUK/law

I:\atty\SUKOS\220304us-PR.WPD

220304US-0XPCT

Marked-Up Copy Serial No: <u>3-11-2002</u> Amendment Filed on:
--

IN THE CLAIMS

Please amend the claims as follows.

--7. (Amended) A herbicide containing the pyrimidine derivative as defined in [any one of Claims 1 to 5] Claim 1, as an active ingredient.--

Claims 8-11 (New).

DOCKET NO.: 220304US0XPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Atsushi YASUDA et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HERewith

INTERNATIONAL APPLICATION NO.: PCT/JP00/06165

INTERNATIONAL FILING DATE: September 8, 2000

FOR: PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THEM

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119
AND THE INTERNATIONAL CONVENTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

<u>COUNTRY</u>	<u>APPLICATION NO</u>	<u>DAY/MONTH/YEAR</u>
Japan	11-255029	09 September 1999

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/JP00/06165. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted,
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

William E. Beaumont

Registration Number 30,990

Norman F. Oblon
Attorney of Record
Registration No. 24,618
Surinder Sachar
Registration No. 34,423



22850

(703) 413-3000
Fax No. (703) 413-2220
(OSMMN 1/97)

20070804-031100

DESCRIPTION

PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THEM

TECHNICAL FIELD

The present invention relates to novel pyrimidine
5 derivatives and herbicides containing them as active
ingredients.

BACKGROUND ART

Pyrimidine derivatives are known, for example, by
the specification of international application
10 WO95/12582, the specification of international
application WO96/22980 and the specification of
international application WO97/12877. However, the
pyrimidine derivatives of the present invention have not
been known.


15 A herbicide to be used for crop plants is desired to
be a chemical which exhibits a sufficient herbicidal
effect at a low dose and yet provides selectivity between
crop plants and weeds, when applied to an upland field or
to a paddy field. Accordingly, it is an object of the
20 present invention to provide a compound which has an
excellent herbicidal activity and selectivity between
crop plants and weeds.

DISCLOSURE OF THE INVENTION

Under these circumstances, the present inventors
25 have synthesized various substituted pyrimidine
derivatives and have studied their physiological
activities. As a result, it has been found that novel

10070804-031102

substituted pyrimidine derivatives as the compounds of the present invention have excellent herbicidal activities and selectivity between crop plants and weeds, and the present invention has been accomplished. Namely, the present invention provides a pyrimidine derivative represented by the formula (I)




wherein R^1 is a hydrogen atom (except for a case where R^2 =hydrogen atom, and $W=SO_2$), a halogen atom, a C_1 - C_6 alkyl group, a C_1 - C_6 alkylcarbonyl C_1 - C_6 alkyl group, a hydroxyl group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_3 - C_6 cycloalkyl group (this group may be substituted by a halogen atom, a C_1 - C_6 alkyl group, a C_1 - C_6 alkoxy group or a C_1 - C_4 haloalkyl group), a C_1 - C_4 haloalkyl group, a C_1 - C_6 alkoxy group, a C_1 - C_4 haloalkoxy group, a C_2 - C_6 alkenyloxy group, a C_2 - C_6 alkynyloxy group, a C_3 - C_6 cycloalkyloxy group, a phenyl group (this group may be substituted by a halogen atom, a C_1 - C_6 alkyl group, a C_1 - C_6 alkoxy group, a C_1 - C_4 haloalkyl group, a C_1 - C_4 haloalkoxy group, a cyano group, a cyano C_1 - C_6 alkyl group, a nitro group, a C_1 - C_6 alkylthio group, a C_1 - C_6 alkylsulfinyl group or a C_1 - C_6 alkylsulfonyl group), a C_1 - C_6 alkylthio group (except for a case where R^2 =phenyl

group, and $W=SO_2$), a C_2-C_6 alkenylthio group, a C_2-C_6 alkynylthio group, a C_3-C_6 cycloalkylthio group, a C_1-C_6 alkylsulfinyl group, a C_2-C_6 alkenylsulfinyl group, a C_2-C_6 alkynylsulfinyl group, a C_3-C_6 cycloalkylsulfinyl group, a C_1-C_6 alkylsulfonyl group, a C_2-C_6 alkenylsulfonyl group, a C_2-C_6 alkynylsulfonyl group, a C_3-C_6 cycloalkylsulfonyl group, a C_1-C_6 hydroxyalkyl group, a C_2-C_7 acyl group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, a cyano group, a C_1-C_6 alkoxycarbonyl group, a C_1-C_6 alkoxycarbonyl C_1-C_6 alkyl group, a C_1-C_6 alkoxycarbonyl C_2-C_6 alkenyl group, a carboxyl group, a carboxyl C_1-C_6 alkyl group, a di C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkoxyimino C_1-C_6 alkyl group, a hydroxyimino C_1-C_6 alkyl group, a dioxolanyl group (this group may be substituted by a C_1-C_6 alkyl group), an aldehyde group, an oxiranyl group, a NR^9R^{10} group or a $CONR^9R^{10}$ group, R^9 is a hydrogen atom, a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_2-C_6 alkynyl group, a C_1-C_4 haloalkyl group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkylthio C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group, a C_2-C_7 acyl group or a C_1-C_6 alkylsulfonyl group, R^{10} is a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_2-C_6 alkynyl group, a C_1-C_4 haloalkyl group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkylthio C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group, a C_2-C_7 acyl group, a C_1-C_6 alkylsulfonyl group, a C_1-C_6 alkoxycarbonyl group or a benzyloxycarbonyl group, here R^9 and R^{10} may, together with the carbon atom to which they are bonded,

10070804-031102


form a 5- to 7-membered saturated ring, R^2 is a hydrogen atom, a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_2-C_6 alkynyl group, a C_1-C_6 alkylthio group, a C_1-C_4 haloalkyl group, a C_1-C_6 alkoxy group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkylthio C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group (this group may be substituted by a halogen atom, a C_1-C_6 alkyl group, a C_1-C_6 alkoxy group or a C_1-C_4 haloalkyl group), a C_2-C_7 acyl group, a cyano group, a di C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkoxyimino C_1-C_6 alkyl group, a hydroxyimino C_1-C_6 alkyl group, a dioxolanyl group (this group may be substituted by a C_1-C_6 alkyl group), a cyano C_1-C_6 alkyl group, a C_1-C_6 hydroxyalkyl group, a C_1-C_6 alkoxycarbonyl group, a C_1-C_6 alkoxycarbonyl C_1-C_6 alkyl group, a $CR^{11}R^{12}NR^9R^{10}$ group, a $CONR^9R^{10}$ group, a $CR^{11}R^{12}CONR^9R^{10}$ group or a group represented by any one of the formulae R^2-1 to R^2-13 :



(wherein X is a hydrogen atom, a halogen atom, a C_1-C_6

alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group,
 a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a
 NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a
 C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a
 5 C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆
 alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆
 alkylsufonyl group, a cyano group, a nitro group or a
 C₁-C₄ haloalkyl group, n is an integer of from 1 to 3,
 when n is an integer of 2 or 3, the plurality of X may be
 10 the same or different, and two adjacent lower alkoxy
 groups may be bonded to each other to form a C₁-C₃
 alkylenedioxy group), each of R¹¹ and R¹² is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group or a C₁-C₆ alkoxy group, R³ is a hydrogen
 15 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group, a C₁-C₆ alkoxy group, a di C₁-C₆ alkylamino
 group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl
 group, a cyano C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl C₁-C₆
 alkyl group, an oxiranyl C₁-C₆ alkyl group or a C₁-C₆
 20 alkoxycarbonyl C₁-C₆ alkyl group, W is a -C(=Q)Z- group
 or a -SO₂- group, Q is an oxygen atom or a sulfur atom, Z
 is an oxygen atom, a sulfur atom, a -NR⁶- group, a
 -CH₂CH₂- group, a -CH=CH- group, a -C(R⁴)R⁵- group, a
 -C(R⁴)R⁵-Q- group, a -Q-C(R⁴)R⁵- group, a -C(=Q)- group, a
 25 -NR⁶NR^{6a}- group or a -NR⁶C(R⁴)R⁵- group, each of R⁴ and R⁵
 is a hydrogen atom, a C₁-C₆ alkyl group, a halogen atom,
 a C₁-C₆ alkoxy group or a C₁-C₆ alkylthio group, each of

R^6 and R^{6a} is a hydrogen atom, a C_1 - C_6 alkyl group, a C_2 - C_6 alkenyl group or a C_2 - C_6 alkynyl group, here R^3 and R^6 may, together with the carbon atom to which they are bonded, form a 5- to 7-membered cyclic urea, Ar is a group
 5 represented by any one of the formulae Ar-1 to Ar-17:



(wherein X' is a hydrogen atom, a halogen atom, a C_1 - C_6 alkyl group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_1 - C_6 alkoxy group, a C_1 - C_6 alkoxy C_1 - C_6 alkyl group, a
 10 NR^9R^{10} group, a $CONR^9R^{10}$ group, a C_1 - C_4 haloalkoxy group, a C_2 - C_6 alkenyloxy group, a C_3 - C_6 cycloalkyloxy group, a C_2 - C_7 acyl group, a C_1 - C_6 alkoxycarbonyl group, a C_1 - C_6 alkylthio group, a C_1 - C_6 alkylsulfinyl group, a C_1 - C_6 alkylsulfonyl group, a cyano group, a nitro group or a
 15 C_1 - C_4 haloalkyl group, n' is an integer of from 1 to 3, m is an integer of from 0 to 3, when n' is an integer of 2

or 3, the plurality of X' may be the same or different,
and two adjacent lower alkoxy groups may be bonded to
each other to form a C₁-C₃ alkylenedioxy group), R⁷ is a
hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a
5 C₁-C₆ alkoxy group, a C₁-C₆ alkylthio group, a C₁-C₄
haloalkyl group or a C₃-C₆ cycloalkyl group, and R⁸ is a
hydrogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylthio
group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl
group; and a herbicide containing it as an active
10 ingredient.

Now, definitions of terms used in this specification
will be shown below.

The halogen atom represents a fluorine atom, a
chlorine atom, a bromine atom or an iodine atom.

15 The C₁-C₆ alkyl group means a straight chain or
branched chain alkyl group having a carbon number of from
1 to 6, unless otherwise specified, and it may, for
example, be a methyl group, an ethyl group, a n-propyl
group, an isopropyl group, a n-butyl group, an isobutyl
20 group, a sec-butyl group or a tert-butyl group.

The C₃-C₆ cycloalkyl group represents a cycloalkyl
group having a carbon number of from 3 to 6, and it may,
for example, be a cyclopropyl group, a cyclopentyl group
or a cyclohexyl group.

25 The C₂-C₆ alkenyl group represents a straight chain
or branched chain alkenyl group having a carbon number of
from 2 to 6, and it may, for example, be an ethenyl group

10070804 "031106"

or a 2-propenyl group.

The C₂-C₆ alkynyl group represents a straight chain or branched chain alkynyl group having a carbon number of from 2 to 6, and it may, for example, be an ethynyl group
5 or a 2-propynyl group.

The C₁-C₄ haloalkyl group represents a straight chain or branched chain alkyl group having a carbon number of from 1 to 4, which is substituted by from 1 to 9 same or different halogen atoms, unless otherwise specified, and
10 it may, for example, be a chloromethyl group, a trifluoromethyl group or a tetrafluoroethyl group.

The C₁-C₆ alkoxy group represents an (alkyl)-O- group wherein the alkyl moiety has the above meaning, and it may, for example, be a methoxy group, an ethoxy group or
15 a propoxy group.

The C₂-C₆ alkenyloxy group represents an (alkenyl)-O-group wherein the alkenyl moiety has the above meaning, and it may, for example, be an ethenyloxy group or a 2-propenyloxy group.

20 The C₂-C₆ alkynyloxy group represents an (alkynyl)-O-group wherein the alkynyl moiety has the above meaning, and it may, for example, be an ethynyloxy group or a 2-propynyloxy group.

The C₃-C₆ cycloalkyloxy group represents a
25 (cycloalkyl)-O- group wherein the cycloalkyl moiety has the above meaning, and it may, for example, be a cyclopropyloxy group, a cyclopentyloxy group or a

20070804 0910

cyclohexyloxy group.

The C₁-C₆ alkoxy C₁-C₆ alkyl group represents an (alkyl)-O-(alkylene)- group, wherein the alkyl moiety has the above meaning, and it may, for example, be a methoxymethyl group or an ethoxymethyl group.

The C₃-C₆ cycloalkyl C₁-C₆ alkyl group represents a (cycloalkyl)-(C₁-C₆ alkylene) group wherein the cycloalkyl moiety has the above meaning, and it may, for example, be a cyclopropylmethyl group, a cyclopentylmethyl group, a cyclohexylmethyl group or a cyclohexylethyl group.

The C₁-C₄ haloalkoxy group represents a (haloalkyl)-O- group wherein the haloalkyl moiety has the above meaning, and it may, for example, be a trifluoromethoxy group or a 2,2,2-trifluoroethoxy group.

The C₁-C₆ alkylthio group, the C₁-C₆ alkylsulfinyl group and the C₁-C₆ alkylsulfonyl group, represent an (alkyl)-S-group, an (alkyl)-SO-group and an (alkyl)-SO₂-group, wherein the alkyl moiety has the above meaning, and they may, for example, be a methylthio group, an ethylthio group, a methylsulfinyl group, an ethylsulfinyl group, a methylsulfonyl group or an ethylsulfonyl group.

The C₂-C₆ alkenylthio group, the C₂-C₆ alkenylsulfinyl group and the C₂-C₆ alkenylsulfonyl group, represent an (alkenyl)-S-group, an (alkenyl)-SO-group and an (alkenyl)-SO₂-group, wherein the alkenyl moiety has the above meaning, and they may, for example, be a

10070804-031102

propenylthio group, a butenylthio group, a propenylsulfinyl group, a butenylsulfinyl group, a propenylsulfonyl group or a butenylsulfonyl group.

The C₂-C₆ alkynylthio group, the C₂-C₆ alkynylsulfinyl group and the C₂-C₆ alkynylsulfonyl group, represent an (alkynyl)-S-group, an (alkynyl)-SO-group and an (alkynyl)-SO₂-group, wherein the alkynyl moiety has the above meaning, and they may, for example, be an ethynylthio group, a 2-propynylthio group, an ethynylsulfinyl group, a 2-propynylsulfinyl group, an ethynylsulfonyl group or a 2-propynylsulfonyl group.

The C₃-C₆ cycloalkylthio group, the C₃-C₆ cycloalkylsulfinyl group and the C₃-C₆ cycloalkylsulfonyl group, represent a (cycloalkyl)-S-group, a (cycloalkyl)-SO-group, and a (cycloalkyl)-SO₂-group, wherein the cycloalkyl moiety has the above meaning, and they may, for example, be a cyclopropylthio group, a cyclobutylthio group, a cyclopentylthio group, a cyclohexylthio group, a cyclopropylsulfinyl group, a cyclobutylsulfinyl group, a cyclopentylsulfinyl group, a cyclohexylsulfinyl group, a cyclopropylsulfonyl group, a cyclobutylsulfonyl group, a cyclopentylsulfonyl group or a cyclohexylsulfonyl group.

The C₁-C₆ alkylthio C₁-C₆ alkyl group represents an (alkyl)-S-(alkylene) group wherein the alkyl moiety has the above meaning, and it may, for example, be a methylthiomethyl group, an ethylthiomethyl group, a propylthiomethyl group or a methylthioethyl group.

The C₂-C₇ acyl group represents a C₁-C₆ alkylcarbonyl group, a C₂-C₆ alkenylcarbonyl group, a C₂-C₆ alkynylcarbonyl group, a C₃-C₆ cycloalkylcarbonyl group or a benzoyl group, and it may, for example, be an acetyl group, a propionyl group, a n-butyryl group, an isobutyryl group, a cyclopropylcarbonyl group or a benzoyl group.

The C₁-C₆ alkylcarbonyl C₁-C₆ alkyl group may, for example, be a methylcarbonylmethyl group, an ethylcarbonylmethyl group or a propylcarbonylmethyl group.

The diC₁-C₆ alkoxy C₁-C₆ alkyl group may, for example, be a dimethoxymethyl group or a diethoxymethyl group.

The C₁-C₆ alkoxyimino C₁-C₆ alkyl group may, for example, be a methoxyiminomethyl group or an ethoxyiminomethyl group.

The hydroxyimino C₁-C₆ alkyl group may, for example, be a hydroxyiminomethyl group or a hydroxyiminoethyl group.

The cyano C₁-C₆ alkyl group may, for example, be a cyanomethyl group or a cyanoethyl group.

The C₁-C₆ hydroxyalkyl group may, for example, be a hydroxymethyl group or a hydroxyethyl group.

The C₁-C₆ alkoxycarbonyl group may, for example, be a methoxycarbonyl group or an ethoxycarbonyl group.

The C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group may, for example, be a methoxycarbonyl methyl group or an

ethoxycarbonyl methyl group.

The carboxyl C₁-C₆ alkyl group may, for example, be a carboxymethyl group or a carboxyethyl group.

The diC₁-C₆ alkoxy C₁-C₆ alkyl group may, for example,
5 be a diethoxymethyl group or a 2-dimethoxyethyl group.

The diC₁-C₆ alkylamino group is a dialkylamino group wherein the alkylalkyl moiety has the above meaning, and it may, for example, be a dimethylamino group or a diethylamino group.

10 BEST MODE FOR CARRYING OUT THE INVENTION

Now, typical specific examples of the compound of the present invention represented by the formula (I) will be exemplified in Tables 1 to 39. However, the compound of the present invention is not limited to such
15 compounds. The compound numbers will be referred to in the subsequent description. Further, in a case where the compound of the present invention or the disclosed compound has at least one asymmetric carbon, its all steric isomers are included in the compound of the
20 present invention.

In the tables in this specification, S-isomer and R-isomer represent S-isomer and R-isomer of optical isomers, respectively, and in a case where there is no specific representation even when the compound has an
25 asymmetric carbon, such represents a racemate. Further, in the tables, A-isomer and B-isomer represent diastereomers such that when resolved by silica gel

column chromatography, one eluting first is designated as A-isomer, and one eluting later is designated as B-isomer. In a case where there is no representation even if diastereomers exist, such represents a mixture of


5 diastereomers.

The following representations in the tables in this specification represent the respective corresponding groups as shown below.

	Me: methyl group	Et: ethyl group
10	Pr: n-propyl group	Pr-i: isopropyl group
	Pr-c: cyclopropyl group	Bu: n-butyl group
	Bu-i: isobutyl group	Bu-s: sec-butyl group
	Bu-t: tert-butyl group	Bu-c: cyclobutyl group
	Pen: n-pentyl group	Pen-i: isopentyl group
15	Pen-c: cyclopentyl group	Hex-c: cyclohexyl group

10070804-031102

Table 1

							
Compound No.	R ¹	R ²	R ³	Z	Xn	Q	m. p. (° C) or refractive index (n _D ²⁰)
1-1	CClF ₂	Pr-c	H	CH ₂	H	O	124-127
1-2	CClF ₂	Pr-c	H	CH ₂	4-OMe	O	116-119
1-3	CClF ₂	Pr-c	H	CH ₂	4-Cl	O	125-128
1-4	CClF ₂	Pr-c	H	CH ₂	4-CF ₃	O	111-114
1-5	CF ₃	Pr-i	H	CH ₂	H	O	144-146
1-6	CF ₃	Pr-i	H	CH ₂	4-OMe	O	114-117
1-7	CF ₃	Pr-i	H	CH(Me)	H	O	1.5163
1-8	CF ₃	Pr-i	Me	CH ₂	H	O	106-109
1-9	CF ₃	Pr-i	Me	CH ₂	4-OMe	O	1.5289
1-10	CF ₃	Pr-i	Me	S	H	O	131-133
1-11	CF ₃	Pr-i	Me	S	4-OMe	O	156-159
1-12	CF ₃	Pr-i	Me	CH ₂	4-F	O	109-110
1-13	CF ₃	Pr-i	Me	CH ₂	4-OEt	O	1.5151
1-14	CF ₃	Pr-i	Me	S	4-Cl	O	
1-15	CClF ₂	Pr-i	Me	CH ₂	H	O	109-112
1-16	CClF ₂	Pr-i	Me	CH ₂	4-OMe	O	Not Measurable
1-17	CClF ₂	Pr-i	Me	S	H	O	127-130
1-18	CClF ₂	Pr-i	Me	S	4-OMe	O	136-139
1-19	CClF ₂	Pr-i	Me	O	H	O	115-118
1-20	CF ₃	Pr-i	Me	CH ₂	2-Cl	O	178-181
1-21	CF ₃	Pr-i	Me	CH ₂	3-Cl	O	122-125
1-22	CF ₃	Pr-i	Me	CH ₂	4-Cl	O	98-101
1-23	CF ₃	Pr-i	Me	CH ₂	4-Me	O	76-79
1-24	CF ₃	Pr-i	Me	CH ₂	4-CF ₃	O	105-108
1-25	CClF ₂	Pr-i	Me	CH ₂	4-F	O	126-129
1-26	CF ₃	Pr-i	Et	CH ₂	H	O	87-90
1-27	CF ₃	Pr-i	Et	CH ₂	4-F	O	130-132
1-28	CF ₃	Pr-i	Me	NH	H	O	149-150
1-29	CF ₃	Pr-i	Me	NH	4-Cl	O	

20170404-031101

Table 2

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m.p. (°C) or refrac- tive index (n _D ²⁰)
1-30	CF ₃	Me	Me	CH ₂	H	O		15258
1-31	CF ₃	Me	Me	CH ₂	4-F	O		15202
1-32	CF ₃	Et	Me	CH ₂	H	O		40-41
1-33	CF ₃	Et	Me	CH ₂	4-F	O		72-73
1-34	CF ₃	Pr-c	Me	CH ₂	H	O		Not Measurable
1-35	CF ₃	Pr-c	Me	CH ₂	4-F	O		97-99
1-36	CF ₃	Ph	Me	CH ₂	4-F	O		93-94
1-37	CClF ₂	Pr-i	Me	NH	4-Me	O		135-137
1-38	CClF ₂	Pr-i	Me	NH	H	O		146-147
1-39	CF ₃	Pr-i	Me	CH ₂	3-CF ₃	O		119-120
1-40	CF ₃	Pr-i	Me	CH ₂	2,5-F ₂	O		145-146
1-41	CF ₃	Pr-i	Me	CH ₂	4-Br	O		93-95
1-42	CF ₃	Pr-i	Me	CH ₂	4-I	O		102-104
1-43	CF ₃	Pr-i	Me	CH ₂	4-Bu-t	O		101-102
1-44	CF ₃	Pr-i	Me	CH ₂	4-SMe	O		69-71
1-45	CF ₃	Pr-i	Me	CH ₂	3,4-Cl ₂	O		145-146
1-46	CF ₃	Pr-i	Me	CH ₂	2-F,4-Cl	O		115-116
1-47	CF ₃	Pr-i	Me	CH ₂	3-OMe,4-Cl	O		129-131
1-48	CF ₃	Pr-i	Et	CH ₂	4-Cl	O		120-123
1-49	CF ₃	Pr-i	Pr	CH ₂	4-Cl	O		140-141
1-50	CF ₃	Pr-i	Me	CH ₂	2-Me	O		154-155
1-51	CF ₃	Pr-i	Me	CH ₂	3-Me	O		93-94
1-52	CF ₃	Pr-i	Me	CH ₂	4-NO ₂	O		146-149
1-53	CF ₃	Bu-t	Me	CH ₂	4-F	O		91-92
1-54	CF ₃	Bu-t	Me	CH ₂	4-Cl	O		111-112
1-55	CF ₃	Bu-t	Me	CH ₂	4-Me	O		84-87
1-56	CH ₃	Pr-i	Me	CH ₂	4-Cl	O		118-119
1-57	CF ₃	Bu-s	Me	CH ₂	H	O		70-71
1-58	CF ₃	Bu-s	Me	CH ₂	4-F	O		84-85
1-59	CF ₃	Bu-s	Me	CH ₂	4-Cl	O		73-75
1-60	CF ₃	Bu-s	Me	CH ₂	4-Me	O		61-64
1-61	CF ₃	Pr-i	Et	CH ₂	4-Me	O		92-94
1-62	CF ₃	Pr-i	Pr	CH ₂	4-Me	O		83-86
1-63	CF ₃	Pr-i	Pr	CH ₂	H	O		146-147
1-64	CF ₃	Pr-i	Me	CH ₂ O	H	O		117-119
1-65	CF ₃	Pr-i	Me	CH ₂ O	4-Cl	O		141-142

10070804 "031102"

Table 3

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m.p. (°C) or refrac- tive index (n _D ²⁰)
1-66	CF ₃	Pr-i	Me	CH ₂	3-F	O		120-123
1-67	CF ₃	Pr-i	Me	CH ₂	4-Et	O		56-58
1-68	CF ₃	Pr-i	Me	CH ₂	4-Pr-i	O		86-87
1-69	Pr-i	Pr-i	Me	CH ₂ S	H	O		
1-70	CF ₃	Pr-i	Me	CH ₂	3-Br	O		120-121
1-71	CF ₃	Pr-i	Me	CH(Me)	4-Cl	O		1.5232
1-72	CF ₃	Pr-i	Me	CH ₂	3,4-(Me) ₂	O		83-85
1-73	Pr-i	Pr-i	Me	CH ₂ S	4-Cl	O		
1-74	CF ₃	Pr-i	Me	CH ₂	3-NO ₂	O		118-121
1-75	CF ₃	Pr-i	Me	CH ₂	4-CN	O		141-142
1-76	CF ₃	Pr-i	Me	CH ₂	4-CH ₂ OMe	O		58-60
1-77	CF ₃	Pr-i	Me	CH ₂ CH ₂	H	O		79-82
1-78	Pr-c	Pr-i	Me	CH ₂	4-Cl	O		110-113
1-79	Pr-i	Me	Me	CH ₂	H	O		69-70
1-80	CF ₃	Pr-i	Pr-c	CH ₂	H	O		83-86
1-81	CF ₃	Pr-i	Pr-c	CH ₂	4-Cl	O		1.5297
1-82	CF ₃	Pr-i	Pr-c	CH ₂	4-Me	O		1.5219
1-83	CF ₃	Pr-i	Pr-c	CH ₂	4-F	O		81-84
1-84	CF ₃	Pr-i	Me	CH ₂	4-C≡CMe	O		128-132
1-85	CF ₃	Pr-i	Me	CH=CH	H	O		1.5375
1-86	CF ₃	Pr-i	Me	CH=CH	4-Cl	O		1.5565
1-87	Me	Pr-i	Me	CH ₂	H	O		80-83
1-88	Me	Pr-i	Me	CH ₂	4-F	O		102-104
1-89	Me	Pr-i	Me	CH ₂	4-Me	O		106-107
1-90	H	Pr-i	Me	CH ₂	4-Cl	O		1.5503
1-91	CClF ₂	Pr-c	Me	CH ₂	H	O		111-113
1-92	CClF ₂	Pr-c	Me	CH ₂	4-F	O		91-92
1-93	CClF ₂	Pr-c	Me	CH ₂	4-Me	O		87-88
1-94	CClF ₂	Pr-c	Me	CH ₂	4-Cl	O		112-114
1-95	CF ₃	Pr-i	Me	CH ₂	4-OCF ₃	O		80-81
1-96	CF ₃	Pr-i	Me	CH ₂	4-OCHF ₂	O		54-57
1-97	CF ₃	Pr-i	Me	CH ₂	4-OPr-i	O		74-75
1-98	CF ₃	Pr-i	Et	CH ₂	4-CN	O		139-142
1-99	CF ₃	Pr-i	Pr	CH ₂	4-CN	O		162-163
1-100	CF ₃	Pr-i	Me	CH ₂	2-F	O		163-164
1-101	Pr-c	Pr-i	Me	CH ₂	4-F	O		111-112

10070804, 031103

Table 4

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-102	Pr-c	Pr-i	Me	CH ₂	4-Me	O		81-83
1-103	CF ₃	Pr-i	Pr-i	CH ₂	H	O		1.5131
1-104	CF ₃	Pr-i	Me	CH ₂	4-SO ₂ Me	O		137-139
1-105	CF ₃	Pr-i	CH ₂ OMe	CH ₂	4-Cl	O		142-145
1-106	CF ₃	Pr-i	CH ₂ OMe	CH ₂	4-Me	O		104-106
1-107	CF ₃	Pr-i	CH ₂ OEt	CH ₂	4-Me	O		91-94
1-108	CF ₃	Pr-i	Me	O	4-F	O		
1-109	CF ₃	Pr-i	Me	O	4-Me	O		
1-110	CF ₃	Pr-i	Me	O	4-Cl	O		
1-111	CF ₃	Pr	Me	CH ₂	H	O		54-55
1-112	CF ₃	Pr	Me	CH ₂	4-F	O		67-70
1-113	CF ₃	Pr	Me	CH ₂	4-Me	O		63-64
1-114	CF ₃	Pr	Me	CH ₂	4-Cl	O		91-92
1-115	CF ₃	Pr-i	Me	CH(Me)O	H	O		127-130
1-116	CF ₃	Pr-i	Me	CH(Me)O	4-Cl	O		104-105
1-117	CF ₃	Pr-i	Me	CH(Me)O	4-Me	O		
1-118	CF ₃	Pr-i	Me	OCH ₂	H	O		1.5028
1-119	CF ₃	Pr-i	Me	CH ₂	3-OMe,4-Me	O		1.5109
1-120	CF ₃	Pr-i	Me	CH ₂	3-Me,4-Cl	O		92-94
1-121	CF ₃	Pr-i	Me	CH ₂	3-Cl,4-Me	O		121-122
1-122	CF ₃	Pr-i	Me	CH ₂	3,4-F ₂	O		135-136
1-123	CF ₃	Pr-i	Me	CH ₂	2,6-F ₂	O		176-177
1-124	CF ₃	Pr-i	Me	CH ₂	2,4-Cl ₂	O		147-149
1-125	CF ₃	Pr-i	Me	CH ₂ O	2-F	O		157-158
1-126	CF ₃	Pr-i	Me	CH ₂ O	3-F	O		127-128
1-127	CF ₃	Pr-i	Me	CH ₂ O	4-F	O		119-121
1-128	Pr-i	Pr-i	Me	CH ₂	H	O		118-119
1-129	Pr-i	Pr-i	Me	CH ₂	4-F	O		125-126
1-130	Pr-i	Pr-i	Me	CH ₂	4-Cl	O		123-126
1-131	Pr-i	Pr-i	Me	CH ₂	4-Me	O		110-113
1-132	CF ₃	Pr-i	Me	CH ₂ O	2-Cl	O		162-163
1-133	CF ₃	Pr-i	Me	CH ₂ O	3-Cl	O		122-124
1-134	CF ₃	Pr-i	Me	CH ₂ O	2-Me	O		136-138
1-135	CF ₃	Pr-i	Me	CH ₂ O	3-Me	O		117-119
1-136	CF ₃	Pr-i	Me	CH ₂ O	4-Me	O		140-141
1-137	CF ₃	Pen-c	Me	CH ₂	H	O		72-74

202504 10804001

Table 5

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (°C) or refrac- tive index (n _D ²⁰)
1-138	CF ₃	Pen-c	Me	CH ₂	4-F	O		97-99
1-139	CF ₃	Pen-c	Me	CH ₂	4-Cl	O		55-57
1-140	CF ₃	Pen-c	Me	CH ₂	4-Br	O		69-71
1-141	CF ₃	Pen-c	Me	CH ₂	4-Me	O		76-78
1-142	CF ₃	Pr-i	Me	CH ₂	H	S		93-94
1-143	CF ₃	Pr-i	Me	CH ₂	4-F	S		103-104
1-144	CF ₃	Pr-i	Me	CH ₂	4-Cl	S		92-93
1-145	CF ₃	Pr-i	Me	CH ₂	4-Me	S		1.5541
1-146	CF ₃	Pr-i	Me	CH ₂	3,4-(OCH ₂ O-)	O		82-85
1-147	CF ₃	Pr-i	Me	CH ₂	2,4-F ₂	O		137-139
1-148	CF ₃	Pr-i	Me	CH ₂	2,3-F ₂	O		183-184
1-149	CF ₃	Pr-i	Me	CH ₂	2,3,4-F ₃	O		
1-150	SMe	Pr-i	Me	CH ₂	H	O		88-89
1-151	SMe	Pr-i	Me	CH ₂	4-Cl	O		125-127
1-152	SMe	Pr-i	Me	CH ₂	4-F	O		121-124
1-153	SMe	Pr-i	Me	CH ₂	4-Me	O		78-79
1-154	CF ₃	Pr-i	Me	CH(SMe)	4-Cl	O		148-149
1-155	CF ₃	Pr-i	Me	CH(OMe)	4-Cl	O		107-108
1-156	CF ₃	Pen-c	Me	CH ₂	2-F	O		111-112
1-157	CF ₃	Pr-i	Me	CH ₂	4-N(Me) ₂	O		109-111
1-158	CF ₃	Ph(4-F)	Me	CH ₂	3-F	O		85-86
1-159	CH ₃	Bu-t	Me	CH ₂	H	O		93-95
1-160	CH ₃	Bu-t	Me	CH ₂	4-F	O		96-98
1-161	CH ₃	Bu-t	Me	CH ₂	4-Cl	O		107-109
1-162	CH ₃	Bu-t	Me	CH ₂	4-Me	O		84-85
1-163	CHF ₂	Pr-i	Me	CH ₂	H	O		62-65
1-164	CHF ₂	Pr-i	Me	CH ₂	4-F	O		82-84
1-165	CHF ₂	Pr-i	Me	CH ₂	4-Cl	O		85-87
1-166	CHF ₂	Pr-i	Me	CH ₂	4-Me	O		83-84
1-167	CF ₃	Pr-i	Me	CH ₂	3,5-F ₂	O		156-157
1-168	CHF ₂	Pr-i	Et	CH ₂	H	O		85-86
1-169	CHF ₂	Pr-i	Et	CH ₂	4-F	O		100-103
1-170	CHF ₂	Pr-i	Et	CH ₂	4-Cl	O		114-117
1-171	CHF ₂	Pr-i	Et	CH ₂	4-Me	O		91-92
1-172	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	4-F	O		124-128

10070804, 0110

Table 6

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index
1-173	CF ₃	Pr-i	Et	CH ₂	3-F	O		119-121
1-174	CF ₃	Pr-i	Et	CH ₂	4-CF ₃	O		100-101
1-175	CF ₃	Pr-i	Me	C(Me) ₂	4-Me	O		108-110
1-176	CF ₃	Pr-i	Me	O	H	O		80-81
1-177	CF ₃	Pr-i	Me	O	4-F	O		110-112
1-178	CF ₃	Pr-i	Me	O	4-Cl	O		112-115
1-179	CF ₃	Pr-i	Me	O	4-Me	O		94-97
1-180	CF ₃	Pr-i	Me	CH ₂	3-F,4-Cl	O		120-124
1-181	CF ₃	Pr-i	Pr	CH ₂	4-F	O		126-127
1-182	CF ₃	Pr-i	Me	CH ₂ S	H	O		105-108
1-183	CF ₃	Pr-i	Me	CH ₂ S	4-Cl	O		111-113
1-184	CClF ₂	Pr-i	Me	O	4-F	O		119-123
1-185	CClF ₂	Pr-i	Me	O	4-Cl	O		99-103
1-186	CF ₃	Ph	Me	CH ₂	H	O		86-87
1-187	CF ₃	Ph	Me	CH ₂	4-Cl	O		146-147
1-188	Bu-t	Me	Me	CH ₂	H	O		1.5511
1-189	Bu-t	Me	Me	CH ₂	4-F	O		88-89
1-190	Bu-t	Me	Me	CH ₂	4-Cl	O		1.5532
1-191	Bu-t	Me	Me	CH ₂	4-Me	O		1.5471
1-192	CF ₃	Pr-i	Me	CH(Me)	4-OMe	O		1.5135
1-193	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	H	O		117-121
1-194	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	4-Cl	O		119-121
1-195	CF ₃	Pr-i	Me	CH(Me)	H	O		Not Measurable
1-196	CF ₃	Bu-t	Me	CH ₂	H	O		107-109
1-197	CF ₃	Ph	Me	CH ₂	4-Me	O		151-154
1-198	CF ₃	Pr-i	Me	CH(Me)	4-F	O		1.4992
1-199	CF ₃	Pr-i	Me	CH(Me)	4-Me	O		
1-200	CF ₃	2-thienyl	Me	CH ₂	4-Cl	O		120-121
1-201	SMe	Bu-t	Me	CH ₂	H	O		
1-202	SMe	Bu-t	Me	CH ₂	4-F	O		
1-203	SMe	Bu-t	Me	CH ₂	4-Cl	O		
1-204	SMe	Bu-t	Me	CH ₂	4-Me	O		
1-205	SMe	Ph	Me	CH ₂	H	O		
1-206	SMe	Ph	Me	CH ₂	4-F	O		
1-207	SMe	Ph	Me	CH ₂	4-Cl	O		
1-208	SMe	Ph	Me	CH ₂	4-Me	O		

10070804, 034102

Table 7

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-209	Pr-i	Bu-t	Me	CH ₂	H	O		
1-210	Pr-i	Bu-t	Me	CH ₂	4-F	O		
1-211	Pr-i	Bu-t	Me	CH ₂	4-Cl	O		
1-212	Pr-i	Bu-t	Me	CH ₂	4-Me	O		
1-213	Pr-i	Ph	Me	CH ₂	H	O		
1-214	Pr-i	Ph	Me	CH ₂	4-F	O		90-91
1-215	Pr-i	Ph	Me	CH ₂	4-Cl	O		
1-216	Pr-i	Ph	Me	CH ₂	4-Me	O		
1-217	CF ₃	Ph(4-F)	Me	CH ₂	H	O		111-112
1-218	CF ₃	Ph(4-F)	Me	CH ₂	4-F	O		99-101
1-219	CF ₃	Ph(4-F)	Me	CH ₂	4-Cl	O		137-139
1-220	CF ₃	Ph(4-F)	Me	CH ₂	4-Me	O		132-134
1-221	CF ₃	Ph(4-Cl)	Me	CH ₂	H	O		136-137
1-222	CF ₃	Ph(4-Cl)	Me	CH ₂	4-F	O		114-115
1-223	CF ₃	Ph(4-Cl)	Me	CH ₂	4-Cl	O		
1-224	CF ₃	Ph(4-Cl)	Me	CH ₂	4-Me	O		
1-225	CF ₃	Ph(4-Me)	Me	CH ₂	H	O		1.5566
1-226	CF ₃	Ph(4-Me)	Me	CH ₂	4-F	O		1.5549
1-227	CF ₃	Ph(4-Me)	Me	CH ₂	4-Cl	O		
1-228	CF ₃	Ph(4-Me)	Me	CH ₂	4-Me	O		1.5531
1-229	CF ₃	3-thienyl	Me	CH ₂	H	O		
1-230	CF ₃	3-thienyl	Me	CH ₂	4-F	O		
1-231	CF ₃	3-thienyl	Me	CH ₂	4-Cl	O		
1-232	CF ₃	3-thienyl	Me	CH ₂	4-Me	O		
1-233	CF ₃	2-thienyl	Me	CH ₂	H	O		
1-234	CF ₃	2-thienyl	Me	CH ₂	4-F	O		99-103
1-235	CF ₃	2-thienyl	Me	CH ₂	4-Cl	O		
1-236	CF ₃	2-thienyl	Me	CH ₂	4-Me	O		
1-237	CF ₃	Ph(3-Cl)	Me	CH ₂	H	O		
1-238	CF ₃	Ph(3-Cl)	Me	CH ₂	4-F	O		
1-239	CF ₃	Ph(3-Cl)	Me	CH ₂	4-Cl	O		
1-240	CF ₃	Ph(3-Cl)	Me	CH ₂	4-Me	O		
1-241	CF ₃	Bu-t	Me	CH ₂	4-Br	O		
1-242	CF ₃	Ph	Me	CH ₂	4-Br	O		
1-243	CF ₃	Bu-s	Me	CH ₂	4-Br	O		
1-244	CHF ₂	Pr-i	Me	CH ₂	4-Br	O		

20750-4080/001

Table 8

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-245	SMe	Pr-i	Me	CH ₂	4-Br	O		
1-246	Pr-i	Pr-i	Me	CH ₂	4-Br	O		
1-247	Pr-c	Pr-i	Me	CH ₂	4-Br	O		
1-248	Me	Bu-t	Me	CH ₂	4-Br	O		
1-249	CF ₃	Bu-t	Me	CH ₂	2-F,4-Cl	O		101-103
1-250	CF ₃	Ph	Me	CH ₂	2-F,4-Cl	O		170-173
1-251	CF ₃	Bu-s	Me	CH ₂	2-F,4-Cl	O		84-85
1-252	CHF ₂	Pr-i	Me	CH ₂	2-F,4-Cl	O		
1-253	SMe	Pr-i	Me	CH ₂	2-F,4-Cl	O		
1-254	Pr-i	Pr-i	Me	CH ₂	2-F,4-Cl	O		141-142
1-255	Pr-c	Pr-i	Me	CH ₂	2-F,4-Cl	O		
1-256	Me	Bu-t	Me	CH ₂	2-F,4-Cl	O		
1-257	CF ₃	Bu-t	Me	CH ₂	3,4-(Me) ₂	O		
1-258	CF ₃	Ph	Me	CH ₂	3,4-(Me) ₂	O		
1-259	CF ₃	Bu-s	Me	CH ₂	3,4-(Me) ₂	O		
1-260	CHF ₂	Pr-i	Me	CH ₂	3,4-(Me) ₂	O		
1-261	SMe	Pr-i	Me	CH ₂	3,4-(Me) ₂	O		
1-262	Pr-i	Pr-i	Me	CH ₂	3,4-(Me) ₂	O		
1-263	Pr-c	Pr-i	Me	CH ₂	3,4-(Me) ₂	O		
1-264	Me	Bu-t	Me	CH ₂	3,4-(Me) ₂	O		
1-265	CF ₃	Bu-t	Me	CH ₂	3-F	O		103-104
1-266	CF ₃	Ph	Me	CH ₂	3-F	O		88-90
1-267	CF ₃	Bu-s	Me	CH ₂	3-F	O		85-87
1-268	CHF ₂	Pr-i	Me	CH ₂	3-F	O		
1-269	SMe	Pr-i	Me	CH ₂	3-F	O		
1-270	Pr-i	Pr-i	Me	CH ₂	3-F	O		151-153
1-271	Pr-c	Pr-i	Me	CH ₂	3-F	O		
1-272	Me	Bu-t	Me	CH ₂	3-F	O		
1-273	CF ₃	Bu-t	Me	CH ₂	2,4-F ₂	O		137-140
1-274	CF ₃	Ph	Me	CH ₂	2,4-F ₂	O		107-110
1-275	CF ₃	Bu-s	Me	CH ₂	2,4-F ₂	O		
1-276	CHF ₂	Pr-i	Me	CH ₂	2,4-F ₂	O		
1-277	SMe	Pr-i	Me	CH ₂	2,4-F ₂	O		
1-278	Pr-i	Pr-i	Me	CH ₂	2,4-F ₂	O		
1-279	Pr-c	Pr-i	Me	CH ₂	2,4-F ₂	O		
1-280	Me	Bu-t	Me	CH ₂	2,4-F ₂	O		

10070804, 03-11-02

Table 9

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m.p. (°C) or refrac- tive index (n _D ²⁰)
1-281	CF ₃	Bu-t	Me	CH ₂	3-F,4-Cl	O		
1-282	CF ₃	Ph	Me	CH ₂	3-F,4-Cl	O		
1-283	CF ₃	Bu-s	Me	CH ₂	3-F,4-Cl	O		
1-284	CHF ₂	Pr-i	Me	CH ₂	3-F,4-Cl	O		
1-285	SMe	Pr-i	Me	CH ₂	3-F,4-Cl	O		
1-286	Pr-i	Pr-i	Me	CH ₂	3-F,4-Cl	O		
1-287	Pr-c	Pr-i	Me	CH ₂	3-F,4-Cl	O		
1-288	Me	Bu-t	Me	CH ₂	3-F,4-Cl	O		
1-289	CF ₃	Bu-t	Me	CH ₂	3,4-F ₂	O		
1-290	CF ₃	Ph	Me	CH ₂	3,4-F ₂	O		
1-291	CF ₃	Bu-s	Me	CH ₂	3,4-F ₂	O		
1-292	CHF ₂	Pr-i	Me	CH ₂	3,4-F ₂	O		
1-293	SMe	Pr-i	Me	CH ₂	3,4-F ₂	O		
1-294	Pr-i	Pr-i	Me	CH ₂	3,4-F ₂	O		
1-295	Pr-c	Pr-i	Me	CH ₂	3,4-F ₂	O		
1-296	Me	Bu-t	Me	CH ₂	3,4-F ₂	O		
1-297	CF ₃	Bu-t	Me	CH ₂	3,5-F ₂	O		
1-298	CF ₃	Ph	Me	CH ₂	3,5-F ₂	O		
1-299	CF ₃	Bu-s	Me	CH ₂	3,5-F ₂	O		
1-300	CHF ₂	Pr-i	Me	CH ₂	3,5-F ₂	O		
1-301	SMe	Pr-i	Me	CH ₂	3,5-F ₂	O		
1-302	Pr-i	Pr-i	Me	CH ₂	3,5-F ₂	O		
1-303	Pr-c	Pr-i	Me	CH ₂	3,5-F ₂	O		
1-304	Me	Bu-t	Me	CH ₂	3,5-F ₂	O		
1-305	CF ₃	Bu-t	Me	CH ₂	4-CF ₃	O		85-87
1-306	CF ₃	Ph	Me	CH ₂	4-CF ₃	O		92-93
1-307	CF ₃	Bu-s	Me	CH ₂	4-CF ₃	O		123-125
1-308	CHF ₂	Pr-i	Me	CH ₂	4-CF ₃	O		
1-309	SMe	Pr-i	Me	CH ₂	4-CF ₃	O		
1-310	Pr-i	Pr-i	Me	CH ₂	4-CF ₃	O		139-140
1-311	Pr-c	Pr-i	Me	CH ₂	4-CF ₃	O		
1-312	Me	Bu-t	Me	CH ₂	4-CF ₃	O		
1-313	CF ₃	Bu-t	Me	CH ₂	3-CF ₃	O		
1-314	CF ₃	Ph	Me	CH ₂	3-CF ₃	O		
1-315	CF ₃	Bu-s	Me	CH ₂	3-CF ₃	O		
1-316	CHF ₂	Pr-i	Me	CH ₂	3-CF ₃	O		

20170404 10070804

Table 10

Compound No.	R ¹	R ²	R ³	Z	Xn.	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-317	SMe	Pr-i	Me	CH ₂	3-CF ₃	O		
1-318	Pr-i	Pr-i	Me	CH ₂	3-CF ₃	O		
1-319	Pr-c	Pr-i	Me	CH ₂	3-CF ₃	O		
1-320	Me	Bu-t	Me	CH ₂	3-CF ₃	O		
1-321	CF ₃	Pr-i	Et	CH ₂	2-F, 4-Cl	O		144-146
1-322	Ph	Pr-i	Me	CH ₂	H	O		82-84
1-323	Ph	Pr-i	Me	CH ₂	4-F	O		104-105
1-324	Ph	Pr-i	Me	CH ₂	4-Cl	O		88-90
1-325	Ph	Pr-i	Me	CH ₂	4-Me	O		79-80
1-326	Pr-i	Pr-i	Me	NH	H	O		199-200
1-327	Pr-i	Pr-i	Me	N(Me)	H	O		1.5384
1-328	CF ₃	Pr-i	Me	C(=O)	H	O		101-102
1-329	CF ₃	Pr-i	Me	C(Me) ₂	4-Cl	O		Not Measurable
1-330	CF ₃	Bu-i	Me	CH ₂	H	O		86-87
1-331	CF ₃	Bu-i	Me	CH ₂	4-F	O		97-98
1-332	CF ₃	Pr-i	OMe	CH ₂	H	O		1.5071
1-333	CF ₃	Pr-i	OMe	CH ₂	4-F	O		59-62
1-334	CF ₃	Bu-i	Me	CH ₂	3-F	O		93-94
1-335	CF ₃	Pr-i	Me	C(=O)	4-Cl	O		116-119
1-336	Pr-i	Ph	Et	CH ₂	4-Me	O		
1-337	CF ₃	Ph(4-F)	Et	CH ₂	H	O		
1-338	CF ₃	Ph(4-F)	Et	CH ₂	4-F	O		
1-339	CF ₃	Ph(4-F)	Et	CH ₂	4-Cl	O		
1-340	CF ₃	Ph(4-F)	Et	CH ₂	4-Me	O		
1-341	CF ₃	Ph(4-Cl)	Et	CH ₂	H	O		
1-342	CF ₃	Ph(4-Cl)	Et	CH ₂	4-F	O		
1-343	CF ₃	Ph(4-Cl)	Et	CH ₂	4-Cl	O		
1-344	CF ₃	Ph(4-Cl)	Et	CH ₂	4-Me	O		
1-345	CF ₃	Ph(4-Me)	Et	CH ₂	H	O		
1-346	CF ₃	Ph(4-Me)	Et	CH ₂	4-F	O		
1-347	CF ₃	Ph(4-Me)	Et	CH ₂	4-Cl	O		
1-348	CF ₃	Ph(4-Me)	Et	CH ₂	4-Me	O		
1-349	CF ₃	3-thienyl	Et	CH ₂	H	O		
1-350	CF ₃	3-thienyl	Et	CH ₂	4-F	O		
1-351	CF ₃	3-thienyl	Et	CH ₂	4-Cl	O		
1-352	CF ₃	3-thienyl	Et	CH ₂	4-Me	O		




2017-07-10 10:00:00

Table 11

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-353	CF ₃	2-thienyl	Et	CH ₂	H	O		
1-354	CF ₃	2-thienyl	Et	CH ₂	4-F	O		
1-355	CF ₃	2-thienyl	Et	CH ₂	4-Cl	O		
1-356	CF ₃	2-thienyl	Et	CH ₂	4-Me	O		
1-357	CF ₃	Ph(3-Cl)	Et	CH ₂	H	O		
1-358	CF ₃	Ph(3-Cl)	Et	CH ₂	4-F	O		
1-359	CF ₃	Ph(3-Cl)	Et	CH ₂	4-Cl	O		
1-360	CF ₃	Ph(3-Cl)	Et	CH ₂	4-Me	O		
1-361	CF ₃	Ph	Me	CH(Me)	H	O		
1-362	CF ₃	Ph	Me	CH(Me)	4-F	O		
1-363	CF ₃	Ph	Me	CH(Me)	4-Cl	O		
1-364	CF ₃	Ph	Me	CH(Me)	4-Me	O		
1-365	CF ₃	Ph(4-F)	Me	CH(Me)	H	O		
1-366	CF ₃	Ph(4-F)	Me	CH(Me)	4-F	O		
1-367	CF ₃	Ph(4-F)	Me	CH(Me)	4-Cl	O		
1-368	CF ₃	Ph(4-F)	Me	CH(Me)	4-Me	O		
1-369	CF ₃	Ph(4-Cl)	Me	CH(Me)	H	O		
1-370	CF ₃	Ph(4-Cl)	Me	CH(Me)	4-F	O		
1-371	CF ₃	Ph(4-Cl)	Me	CH(Me)	4-Cl	O		
1-372	CF ₃	Ph(4-Cl)	Me	CH(Me)	4-Me	O		
1-373	Pr-i	Pr-i	Me	CH(Me)	H	O		
1-374	Pr-i	Pr-i	Me	CH(Me)	4-F	O		
1-375	Pr-i	Pr-i	Me	CH(Me)	4-Cl	O		
1-376	Pr-i	Pr-i	Me	CH(Me)	4-Me	O		
1-377	SMe	Pr-i	Me	CH(Me)	H	O		
1-378	SMe	Pr-i	Me	CH(Me)	4-F	O		
1-379	SMe	Pr-i	Me	CH(Me)	4-Cl	O		
1-380	SMe	Pr-i	Me	CH(Me)	4-Me	O		
1-381	CF ₃	3-thienyl	Me	CH(Me)	H	O		
1-382	CF ₃	3-thienyl	Me	CH(Me)	4-F	O		
1-383	CF ₃	3-thienyl	Me	CH(Me)	4-Cl	O		
1-384	CF ₃	3-thienyl	Me	CH(Me)	4-Me	O		
1-385	CF ₃	Ph(3-Cl)	Me	CH(Me)	H	O		
1-386	CF ₃	Ph(3-Cl)	Me	CH(Me)	4-F	O		
1-387	CF ₃	Ph(3-Cl)	Me	CH(Me)	4-Cl	O		
1-388	CF ₃	Ph(3-Cl)	Me	CH(Me)	4-Me	O		
1-389	Me	Bu-t	Me	CH(Me)	H	O		

10070804-03110

Table 12

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-390	Me	Bu-t	Me	CH(Me)	4-F	O		
1-391	Me	Bu-t	Me	CH(Me)	4-Cl	O		
1-392	Me	Bu-t	Me	CH(Me)	4-Me	O		
1-393	CF ₃	Bu-t	Me	CH(Me)	H	O		
1-394	CF ₃	Bu-t	Me	CH(Me)	4-F	O		
1-395	CF ₃	Bu-t	Me	CH(Me)	4-Cl	O		
1-396	CF ₃	Bu-t	Me	CH(Me)	4-Me	O		
1-397	CF ₃	2-thienyl	Me	CH(Me)	H	O		
1-398	CF ₃	2-thienyl	Me	CH(Me)	4-F	O		
1-399	CF ₃	2-thienyl	Me	CH(Me)	4-Cl	O		
1-400	CF ₃	2-thienyl	Me	CH(Me)	4-Me	O		
1-401	OMe	Pr-i	Me	CH ₂	H	O		1.5439
1-402	OMe	Pr-i	Me	CH ₂	4-F	O		1.5332
1-403	OMe	Pr-i	Me	CH ₂	4-Cl	O		79-82
1-404	OMe	Pr-i	Me	CH ₂	4-Me	O		88-90
1-405	CF ₃	Pr-i	OMe	CH ₂	H	O		
1-406	CF ₃	Pr-i	OMe	CH ₂	4-F	O		
1-407	CF ₃	Pr-i	OMe	CH ₂	4-Cl	O		1.5159
1-408	CF ₃	Pr-i	OMe	CH ₂	4-Me	O		
1-409	CF ₃	1-MePr-c	Me	CH ₂	H	O		78-79
1-410	CF ₃	 Me	Me	CH ₂	4-F	O		85-87
1-411	CF ₃	 Me	Me	CH ₂	4-Cl	O		110-111
1-412	CF ₃	 Me	Me	CH ₂	4-Me	O		88-89
1-413	CF ₃	CH ₂ SMe	Me	CH ₂	4-F	O		65-66
1-414	CF ₃	CH ₂ SMe	Me	CH ₂	4-Cl	O		94-95
1-415	CF ₃	CH ₂ SMe	Me	CH ₂	4-Br	O		109-110
1-416	CF ₃	CH(Me)SMe	Me	CH ₂	4-F	O		118-119
1-417	CF ₃	Pr-i	Me	CH ₂	2,3,4-F ₃	O		167-169
1-418	CF ₃	Pr-i	Me	CH ₂	3,4,5-F ₃	O		181-183
1-419	CF ₃	1-MePr-c	Me	CH ₂	3-F	O		100-101
1-420	CF ₃	CH ₂ SMe	Me	CH ₂	3-F	O		66-67
1-421	CF ₃	CH ₂ SMe	Me	CH ₂	4-Me	O		87-89
1-422	CF ₃	CH ₂ SMe	Me	CH ₂	2-F-4-Cl	O		102-103









20170804, 09:11:07

Table 13

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m.p. (°C) or refrac- tive index (n _D ²⁰)
1-423	CF ₃	Et	Pr-i	CH ₂	4-Cl	O		1.5207
1-424	CF ₃	Pr-i	Me	N-Me	H	O		104-105
1-425	CF ₃	Pr-i	Me	N-Et	H	O		63-65
1-426	CF ₃	Pr-i	Me	N-Me	4-F	O		84-85
1-427	CF ₃	Pr-i	Me	N-Me	4-Cl	O		106-108
1-428	CF ₃	Pr-i	Me	N-Me	4-Me	O		94-96
1-429	Pr-i	Pr-i	Me	N-Me	4-F	O		1.5216
1-430	Pr-i	Pr-i	Me	N-Me	4-Cl	O		120-123
1-431	Pr-i	Pr-i	Me	N-Me	4-Me	O		93-94
1-432	Et	Pr-i	Me	CH ₂	H	O		97-98
1-433	Et	Pr-i	Me	CH ₂	4-F	O		93-95
1-434	Et	Pr-i	Me	CH ₂	4-Cl	O		110-111
1-435	Et	Pr-i	Me	CH ₂	4-Me	O		79-81
1-436	Pr-i	Et	Me	CH ₂	H	O		1.5455
1-437	Pr-i	Et	Me	CH ₂	4-F	O		66-67
1-438	Pr-i	Et	Me	CH ₂	4-Cl	O		110-111
1-439	Pr-i	Et	Me	CH ₂	4-Me	O		98-99
1-440	CF ₃	3-thienyl	Me	CH ₂	H	O		
1-441	CF ₃	3-thienyl	Me	CH ₂	4-F	O		109-110
1-442	CF ₃	3-thienyl	Me	CH ₂	4-Cl	O		135-138
1-443	CF ₃	3-thienyl	Me	CH ₂	4-Me	O		125-128
1-444	CF ₃	Pr-i	Me	CH ₂	2,3,5-F ₃	O		167-169
1-445	Pr-n	Pr-i	Me	CH ₂	H	O		67-69
1-446	Pr-n	Pr-i	Me	CH ₂	4-F	O		117-118
1-447	Pr-n	Pr-i	Me	CH ₂	4-Cl	O		122-123
1-448	Pr-n	Pr-i	Me	CH ₂	4-Me	O		89-90
1-449	Pr-i	Pr-n	Me	CH ₂	H	O		1.5402
1-450	Pr-i	Pr-n	Me	CH ₂	4-F	O		83-84
1-451	Pr-i	Pr-n	Me	CH ₂	4-Cl	O		78-79
1-452	Pr-i	Pr-n	Me	CH ₂	4-Me	O		94-95
1-453	CH(OEt) ₂	Pr-i	Me	CH ₂	H	O		1.5253
1-454	Pr-i	CH(OEt) ₂	Me	CH ₂	H	O		1.5221
1-455	Pr-i	CH(OEt) ₂	Me	CH ₂	4-F	O		1.5101
1-456	Pr-i	CH(OEt) ₂	Me	CH ₂	4-Cl	O		
1-457	Pr-i	CH(OEt) ₂	Me	CH ₂	4-Me	O		
1-458	Pr-i	CH(OEt) ₂	Me	OCH ₂	H	O		1.5191

20170404 10070804 40804001

Table 14

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia- stereo- mer	n _D ²⁰ or refrac- tive index (n _D ²⁰)
1-459	CF ₃	Pr-i	Me	N-Me	4-CN	O		144-145
1-460	CF ₃	Pr-i	Me	N-Me	4-OMe	O		1.5081
1-461	CF ₃	Pr-i	Me	NHCH ₂	H	O		92-95
1-462	Pr-i	CH=NOMe	Me	CH ₂	H	O		
1-463	Pr-i	CH=NOMe	Me	CH ₂	4-F	O		1.5309
1-464	Pr-i	CH=NOMe	Me	CH ₂	4-Cl	O		1.5459
1-465	Pr-i	CH=NOMe	Me	CH ₂	4-Me	O		1.5412
1-466	Pr-i	CH=NOMe	Me	OCH ₂	H	O		1.5352
1-467	CH(OEt) ₂	Pr-i	Me	OCH ₂	H	O		1.5236
1-468	CH(OEt) ₂	Pr-i	Me	CH ₂	4-F	O		1.5135
1-469	CH(OEt) ₂	Pr-i	Me	CH ₂	4-Cl	O		1.5282
1-470	CH(OEt) ₂	Pr-i	Me	CH ₂	4-Me	O		116-117
1-471	CH=NOMe	Pr-i	Me	OCH ₂	H	O		1.5481
1-472	 Me	 Me	Me	CH ₂	H	O		
1-473	 Me	 Me	Me	CH ₂	4-F	O		110-112
1-474	 Me	 Me	Me	CH ₂	4-Cl	O		
1-475	 Me	 Me	Me	CH ₂	4-Me	O		
1-476	CF ₃	Pr-i	CH ₂ CO ₂ Et	CH ₂	H	O		158-159
1-477	CF ₃	Pr-i	CH ₂ CO ₂ Et	CH ₂	4-F	O		
1-478	CF ₃	Pr-i	CH ₂ CO ₂ Et	CH ₂	4-Cl	O		
1-479	CF ₃	Pr-i	CH ₂ CO ₂ Et	CH ₂	4-Me	O		
1-480	CF ₃	Pr-i	CH ₂ CN	CH ₂	H	O		
1-481	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-F	O		
1-482	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-Cl	O		164-166
1-483	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-Me	O		159-161
1-484	CF ₃	Ph(4-OMe)	Me	CH ₂	H	O		97-98
1-485	CF ₃	Ph(4-OMe)	Me	CH ₂	4-F	O		103-105
1-486	CF ₃	Ph(4-OMe)	Me	CH ₂	4-Cl	O		131-133
1-487	CF ₃	Ph(4-OMe)	Me	CH ₂	4-Me	O		147-150
1-488	CF ₃	Ph(2-OMe)	Me	CH ₂	H	O		Not Measurable





2014-08-04 10:00:00

Table 15

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m.p. (° C) or refrac- tive index (n _D ²⁰)
1-489	CF ₃	Ph(2-OMe)	Me	CH ₂	4-F	O		1.5474
1-490	CF ₃	Ph(2-OMe)	Me	CH ₂	4-Cl	O		Not Measurable
1-491	CF ₃	Ph(2-OMe)	Me	CH ₂	4-Me	O		1.5432
1-492	Pr-n	Pr-n	Me	CH ₂	H	O		65-66
1-493	Pr-n	Pr-n	Me	CH ₂	4-F	O		83-84
1-494	Pr-n	Pr-n	Me	CH ₂	4-Cl	O		91-92
1-495	Pr-n	Pr-n	Me	CH ₂	4-Me	O		55-56
1-496	CH=NOMe	Pr-i	Me	CH ₂	H	O		113-115
1-497	CH=NOMe	Pr-i	Me	CH ₂	4-F	O		155-156
1-498	CH=NOMe	Pr-i	Me	CH ₂	4-Cl	O		122-123
1-499	CH=NOMe	Pr-i	Me	CH ₂	4-Me	O		1.5468
1-500	CH=NOH	Pr-i	Me	CH ₂	H	O		171-172
1-501	CH=NOH	Pr-i	Me	CH ₂	4-F	O		197-198
1-502	CH=NOH	Pr-i	Me	CH ₂	4-Cl	O		183-184
1-503	CH=NOH	Pr-i	Me	CH ₂	4-Me	O		155-157
1-504	CN	Pr-i	Me	CH ₂	H	O		80-81
1-505	CN	Pr-i	Me	CH ₂	4-F	O		105-106
1-506	CN	Pr-i	Me	CH ₂	4-Cl	O		99-100
1-507	CN	Pr-i	Me	CH ₂	4-Me	O		75-76
1-508	CN	Pr-i	Me	CH(Me)	4-Cl	O		1.5569
1-509	Pr-i	CMe(OMe) ₂	Me	CH ₂	H	O		1.5352
1-510	Pr-i	CMe(OMe) ₂	Me	CH ₂	4-F	O		112-113
1-511	Pr-i	CMe(OMe) ₂	Me	CH ₂	4-Cl	O		106-107
1-512	Pr-i	CMe(OMe) ₂	Me	CH ₂	4-Me	O		104-105
1-513	Pr-i	COMe	Me	CH ₂	H	O		99-100
1-514	Pr-i	COMe	Me	CH ₂	4-F	O		114-115
1-515	Pr-i	COMe	Me	CH ₂	4-Cl	O		108-109
1-516	Pr-i	COMe	Me	CH ₂	4-Me	O		119-120
1-517	CMe(OMe) ₂	Pr-i	Me	CH ₂	4-Cl	O		78-79
1-518	CF ₃	Pr-i	CH ₂ CH=CH ₂	CH ₂	H	O		121-122
1-519	CF ₃	Pr-i	CH ₂ CH=CH ₂	CH ₂	4-F	O		129-130
1-520	CF ₃	Pr-i	CH ₂ CH=CH ₂	CH ₂	4-Cl	O		124-127
1-521	CF ₃	Pr-i	CH ₂ CH=CH ₂	CH ₂	4-Me	O		98-99
1-522	CHO	Pr-i	Me	CH ₂	H	O		
1-523	CHO	Pr-i	Me	CH ₂	4-F	O		1.5466
1-524	CHO	Pr-i	Me	CH ₂	4-Cl	O		1.5609

200704040802001

Table 16

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-525	CHO	Pr-i	Me	CH ₂	4-Me	O		1.5558
1-526	COMe	Pr-i	Me	CH ₂	H	O		Not Measurable
1-527	COMe	Pr-i	Me	CH ₂	4-F	O		1.5341
1-528	COMe	Pr-i	Me	CH ₂	4-Cl	O		1.5501
1-529	COMe	Pr-i	Me	CH ₂	4-Me	O		1.5423
1-530	COMe	Pr-i	Me	CH(Me)	4-Cl	O		1.5395
1-531	Pr-i	CH=NOH	Me	OCH ₂	H	O		1.5365
1-532	CF ₃	Pr-i	Me	N(Me)CH ₂	4-Cl	O		95-98
1-533	CF ₃	Pr-i	Me	N(CH ₂ C≡CH)	4-F	O		1.5121
1-534	CF ₃	Pr-i	Me	NHCH(Me) (R-isomer)	H	O		69-70
1-535	CF ₃	Pr-i	Me	NHCH(Me) (S-isomer)	H	O		1.5134
1-536	CF ₃	Pr-i	Me	N(Me)	2-F	O		1.5043
1-537	CF ₃	Pr-i	Me	N(Me)	2,4-F ₂	O		1.4936
1-538	Et	Pr-i	Me	N(Me)	H	O		1.5451
1-539	Et	Pr-i	Me	N(Me)	4-F	O		1.5349
1-540	Et	Pr-i	Me	N(Me)	4-Cl	O		115-117
1-541	Et	Pr-i	Me	N(Me)	4-Me	O		1.5342
1-542	CF ₃	Pr-i	CH ₂ 	CH ₂	H	O		1.5131
1-543	CF ₃	Pr-i	CH ₂ 	CH ₂	4-F	O		1.5052
1-544	CF ₃	Pr-i	CH ₂ 	CH ₂	4-Cl	O		1.5215
1-545	CF ₃	Pr-i	CH ₂ 	CH ₂	4-Me	O		1.5121
1-546	CF ₃	Ph(2-F)	Me	CH ₂	H	O		109-110
1-547	CF ₃	Ph(2-F)	Me	CH ₂	4-F	O		107-108
1-548	CF ₃	Ph(2-F)	Me	CH ₂	4-Cl	O		139-141
1-549	CF ₃	Ph(2-F)	Me	CH ₂	4-Me	O		107-110
1-550	CF ₃	Ph(2-Me)	Me	CH ₂	H	O		146-147
1-551	CF ₃	Ph(2-Me)	Me	CH ₂	4-F	O		149-150
1-552	CF ₃	Ph(2-Me)	Me	CH ₂	4-Cl	O		
1-553	CF ₃	Ph(2-Me)	Me	CH ₂	4-Me	O		135-136











"NOTED" 4080/001

Table 17

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m, p. (° C) or refrac- tive index (n _D ²⁰)
1-554	CF ₃	Ph(2,4-F ₂)	Me	CH ₂	H	O		102-104
1-555	CF ₃	Ph(2,4-F ₂)	Me	CH ₂	4-F	O		
1-556	CF ₃	Ph(2,4-F ₂)	Me	CH ₂	4-Cl	O		
1-557	CF ₃	Ph(2,4-F ₂)	Me	CH ₂	4-Me	O		
1-558	Et	Pr-i	CH ₂ C≡CH	CH ₂	H	O		131-132
1-559	Et	Pr-i	CH ₂ C≡CH	CH ₂	4-F	O		93-96
1-560	Et	Pr-i	CH ₂ C≡CH	CH ₂	4-Cl	O		124-125
1-561	Et	Pr-i	CH ₂ C≡CH	CH ₂	4-Me	O		110-111
1-562	Et	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		Not Measurable
1-563	Pr-i	C(Me)=NOMe	Me	CH ₂	4-F	O		73-74
1-564	Et	Bu-t	Me	CH ₂	H	O		
1-565	Et	Bu-t	Me	CH ₂	4-F	O		82-83
1-566	Et	Bu-t	Me	CH ₂	4-Cl	O		98-99
1-567	Et	Bu-t	Me	CH ₂	4-Me	O		78-80
1-568	Pr-i	CN	Me	OCH ₂	H	O		1.5399
1-569	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	3-F	O		131-133
1-570	Bu-t	Et	Me	CH ₂	H	O		
1-571	Bu-t	Et	Me	CH ₂	4-F	O		88-90
1-572	Bu-t	Et	Me	CH ₂	4-Cl	O		96-97
1-573	Bu-t	Et	Me	CH ₂	4-Me	O		101-102
1-574	CF ₃	Pr-i	CH ₂ -Pr-c	CH ₂	H	O		
1-575	CF ₃	Pr-i	CH ₂ -Pr-c	CH ₂	4-F	O		108-109
1-576	CF ₃	Pr-i	CH ₂ -Pr-c	CH ₂	4-Cl	O		
1-577	CF ₃	Pr-i	CH ₂ -Pr-c	CH ₂	4-Me	O		
1-578	CF ₃	Pr-i	CH ₂ CN	CH ₂	H	O		
1-579	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-F	O		162-163
1-580	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-Cl	O		
1-581	CF ₃	Pr-i	CH ₂ CN	CH ₂	4-Me	O		
1-582	Pr-i	CH ₂ OMe	Me	CH ₂	H	O		
1-583	Pr-i	CH ₂ OMe	Me	CH ₂	4-F	O		
1-584	Pr-i	CH ₂ OMe	Me	CH ₂	4-Cl	O		1.5391
1-585	Pr-i	CH ₂ OMe	Me	CH ₂	4-Me	O		
1-586	Pr-i	CH ₂ OMe	Me	CH(Me)	4-Cl	O		1.5358
1-587	CH ₂ OMe	Pr-i	Me	CH ₂	H	O		
1-588	CH ₂ OMe	Pr-i	Me	CH ₂	4-F	O		
1-589	CH ₂ OMe	Pr-i	Me	CH ₂	4-Cl	O		1.5485

2017E040802001

Table 18

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-590	CH ₂ OMe	Pr-i	Me	CH ₂	4-Me	O		
1-591	CH ₂ OMe	Pr-i	Me	CH(Me)	4-Cl	O		1.5382
1-592	CO ₂ Me	Pr-i	Me	CH(Me)	4-Cl	O	A- isomer	Not Measurable
1-593	CO ₂ Me	Pr-i	Me	CH(Me)	4-Cl	O	B- isomer	Not Measurable
1-594	CO ₂ Et	Pr-i	Me	CH(Me)	4-Cl	O	A- isomer	1.5406
1-595	CO ₂ Et	Pr-i	Me	CH(Me)	4-Cl	O	B- isomer	Not Measurable
1-596		Pr-i	Me	CH ₂	H	O		
1-597		Pr-i	Me	CH ₂	4-F	O		171-173
1-598		Pr-i	Me	CH ₂	4-Cl	O		167-168
1-599		Pr-i	Me	CH ₂	4-Me	O		141-142
1-600		Pr-i	Me	CH(Me)	4-Cl	O		95-98
1-601	Pr-i		Me	CH ₂	H	O		
1-602	Pr-i		Me	CH ₂	4-F	O		123-124
1-603	Pr-i		Me	CH ₂	4-Cl	O		133-134
1-604	Pr-i		Me	CH ₂	4-Me	O		103-104
1-605	Pr-i		Me	CH(Me)	4-Cl	O		
1-606	Et	Pr-n	CH ₂ C≡CH	CH ₂	H	O		58-59
1-607	Et	Pr-n	CH ₂ C≡CH	CH ₂	4-F	O		76-77
1-608	Et	Pr-n	CH ₂ C≡CH	CH ₂	4-Cl	O		111-113
1-609	Et	Pr-n	CH ₂ C≡CH	CH ₂	4-Me	O		90-91
1-610	Pr-i	Pr-n	CH ₂ C≡CH	CH ₂	H	O		
1-611	Pr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-F	O		70-71
1-612	Pr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-Cl	O		

10070804-031103

Table 19

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (°C) or refrac- tive index (n _D ²⁰)
1-613	Pr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-Me	O		
1-614	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	3,4-F ₂	O		133-134
1-615	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	2-F-4-Cl	O		122-124
1-616	Pr-n	Pr-i	CH ₂ C≡CH	CH ₂	H	O		118-119
1-617	Pr-n	Pr-i	CH ₂ C≡CH	CH ₂	4-F	O		106-107
1-618	Pr-n	Pr-i	CH ₂ C≡CH	CH ₂	4-Cl	O		111-112
1-619	Pr-n	Pr-i	CH ₂ C≡CH	CH ₂	4-Me	O		98-99
1-620	CF ₃	Bu-t	CH ₂ C≡CH	CH ₂	4-F	O		93-96
1-621	Pr-i	Pr-i	CH ₂ C≡CH	CH ₂	H	O		137-138
1-622	Pr-i	Pr-i	CH ₂ C≡CH	CH ₂	4-F	O		159-161
1-623	Pr-i	Pr-i	CH ₂ C≡CH	CH ₂	4-Cl	O		131-134
1-624	Pr-i	Pr-i	CH ₂ C≡CH	CH ₂	4-Me	O		153-154
1-625	CH(OMe) ₂	Pr-i	Me	CH(Me)	4-Cl	O		1.5371
1-626	Et	Bu-t	CH ₂ C≡CH	CH ₂	H	O		84-88
1-627	Et	Bu-t	CH ₂ C≡CH	CH ₂	4-F	O		127-130
1-628	Et	Bu-t	CH ₂ C≡CH	CH ₂	4-Cl	O		
1-629	Et	Bu-t	CH ₂ C≡CH	CH ₂	4-Me	O		
1-630	COPr-i	Pr-i	Me	CH(Me)	4-Cl	O		116-117
1-631	C(Me)=NOMe	Pr-i	Me	CH(Me)	4-Cl	O		1.5423
1-632	CN	Bu-t	Me	CH(Me)	4-Cl	O	A- isomer	130-132
1-633	COMe	Bu-t	Me	CH(Me)	4-Cl	O		1.5439
1-634	CF ₃	Pr-i	Me	CH(Me) (S-isomer)	H	O	A- isomer	128-131
1-635	CF ₃	Pr-i	Me	CH(Me) (S-isomer)	H	O	B- isomer	1.5091
1-636	CF ₂ Cl	Pr-i	Me	O	4-Me	O		112-115
1-637	CF ₂ Cl	Pr-i	Me	O	4-OMe	O		123-126
1-638	CF ₂ Cl	Pr-i	Me	O	4-Br	O		108-111
1-639	CF ₂ Cl	Pr-i	Me	OCH ₂	H	O		1.5251
1-640	CF ₂ Cl	Pr-i	Me	O	4-NO ₂	O		1.5301
1-641	CF ₂ Cl	Pr-i	Me	O	H	S		132-135
1-642	Et	Pr-i	Me	O	4-Cl	O		80-83
1-643	Pr-n	Pr-n	Me	O	4-Cl	O		1.5379
1-644	Pr-n	Pr-i	Me	O	4-Cl	O		1.5367
1-645	Me	Me	Me	O	4-Cl	O		90-93
1-646	Et	Et	Me	O	4-Cl	O		1.5468

20170304 10:00:00

Table 20

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-647	Pr-i	Pr-i	Me	O	H	O		1.5331
1-648	Pr-i	Pr-i	Me	O	4-Me	O		1.5346
1-649	Pr-i	Pr-i	Me	O	4-OMe	O		1.5282
1-650	Pr-i	Pr-i	Me	O	4-F	O		1.5169
1-651	Et	CH(Me)SMe	Me	CH ₂	H	O		Not Measurable
1-652	Et	CH(Me)SMe	Me	CH ₂	4-F	O		Not Measurable
1-653	Et	CH(Me)SMe	Me	CH ₂	4-Cl	O		88-91
1-654	Et	CH(Me)SMe	Me	CH ₂	4-Me	O		1.5676
1-655	NHCO ₂ CH ₂ Ph	Pr-i	Me	CH(Me)	4-Cl	O		161-163
1-656	Et	C(Me) ₂ CO ₂ Me	Me	CH ₂	4-Cl	O		1.5502
1-657	SOMe	Pr-i	Me	CH ₂	4-Cl	O		
1-658	SO ₂ Me	Pr-i	Me	CH ₂	4-Cl	O		
1-659	OE _t	Pr-i	Me	CH ₂	H	O		
1-660	OE _t	Pr-i	Me	CH ₂	4-F	O		
1-661	OE _t	Pr-i	Me	CH ₂	4-Cl	O		
1-662	OE _t	Pr-i	Me	CH ₂	4-Me	O		
1-663	OCHF ₂	Pr-i	Me	CH ₂	H	O		
1-664	OCHF ₂	Pr-i	Me	CH ₂	4-F	O		
1-665	OCHF ₂	Pr-i	Me	CH ₂	4-Cl	O		
1-666	OCHF ₂	Pr-i	Me	CH ₂	4-Me	O		
1-667	SOCH ₂ CH=CH ₂	Pr-i	Me	CH ₂	4-Cl	O		
1-668	SOCH ₂ C≡CH	Pr-i	Me	CH ₂	4-Cl	O		
1-669	OCH ₂ CH=CH ₂	Pr-i	Me	CH ₂	H	O		
1-670	OCH ₂ CH=CH ₂	Pr-i	Me	CH ₂	4-F	O		
1-671	OCH ₂ CH=CH ₂	Pr-i	Me	CH ₂	4-Cl	O		
1-672	OCH ₂ CH=CH ₂	Pr-i	Me	CH ₂	4-Me	O		
1-673	OCH ₂ C≡CH	Pr-i	Me	CH ₂	H	O		
1-674	OCH ₂ C≡CH	Pr-i	Me	CH ₂	4-F	O		
1-675	OCH ₂ C≡CH	Pr-i	Me	CH ₂	4-Cl	O		
1-676	OCH ₂ C≡CH	Pr-i	Me	CH ₂	4-Me	O		
1-677	OPr-c	Pr-i	Me	CH ₂	H	O		
1-678	OPr-c	Pr-i	Me	CH ₂	4-F	O		
1-679	OPr-c	Pr-i	Me	CH ₂	4-Cl	O		
1-680	OPr-c	Pr-i	Me	CH ₂	4-Me	O		
1-681	SPr-c	Pr-i	Me	CH ₂	4-Cl	O		

20170404 10:00:00

Table 21

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia-stereo-mer	m.p. (°C) or refractive index (n _D ²⁰)
1-682	SOPr-c	Pr-i	Me	CH ₂	4-Cl	O		
1-683	SO ₂ Pr-c	Pr-i	Me	CH ₂	4-Cl	O		
1-684	N(Me) ₂	Pr-i	Me	CH ₂	4-Cl	O		
1-685	NHMe	Pr-i	Me	CH ₂	4-Cl	O		
1-686	NH(CHF ₂)	Pr-i	Me	CH ₂	4-Cl	O		
1-687	NH(CH ₂ OMe)	Pr-i	Me	CH ₂	4-Cl	O		
1-688	NH(CH ₂ SMe)	Pr-i	Me	CH ₂	4-Cl	O		
1-689	NHPr-c	Pr-i	Me	CH ₂	4-Cl	O		
1-690	NHCOMe	Pr-i	Me	CH ₂	4-Cl	O		
1-691	NHSO ₂ Me	Pr-i	Me	CH ₂	4-Cl	O		
1-692	NHCO ₂ Me	Pr-i	Me	CH ₂	4-Cl	O		
1-693	NH(CH ₂ CH=CH ₂)	Pr-i	Me	CH ₂	4-Cl	O		
1-694	NH(CH ₂ C≡CH)	Pr-i	Me	CH ₂	4-Cl	O		
1-695	CH(Me)CH=CH ₂	Pr-i	Me	CH ₂	4-Cl	O		
1-696	CH ₂ C≡CH	Pr-i	Me	CH ₂	4-Cl	O		
1-697	OH	Pr-i	Me	CH ₂	4-Cl	O		
1-698	CO ₂ H	Pr-i	Me	CH ₂	4-Cl	O		
1-699	CON(C ₄ H ₉)	Pr-i	Me	CH ₂	4-Cl	O		
1-700	CONH(CH ₂ CH=CH ₂)	Pr-i	Me	CH ₂	4-Cl	O		
1-701	Pr-i	CH(Me)CH=CH ₂	Me	CH ₂	4-Cl	O		
1-702	Pr-i	CH ₂ C≡CH	Me	CH ₂	4-Cl	O		
1-703	Et	CHClMe	Me	CH ₂	4-Cl	O		
1-704	Et	OEt	Me	CH ₂	4-Cl	O		
1-705	Et	CH(Me)CN	Me	CH ₂	4-Cl	O		
1-706	Et	CO ₂ Me	Me	CH ₂	4-Cl	O		
1-707	Et	CHMeN(Me) ₂	Me	CH ₂	4-Cl	O		
1-708	Et	CON(Me) ₂	Me	CH ₂	4-Cl	O		
1-709	Et	CHMeCONMe ₂	Me	CH ₂	4-Cl	O		
1-710	Et	Pr-i	Me	CH ₂	4-OCH ₂ CH=CH ₂	O		
1-711	Et	Pr-i	Me	CH ₂	4-OPr-c	O		
1-712	Et	Pr-i	Me	CH ₂	4-COMe	O		

2017-04-08 10:00:00

Table 22

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (°C) or refrac- tive index (n _D ²⁰)
1-713	Et	Pr-i	Me	CH ₂	4-CO ₂ Me	O		
1-714	Et	Pr-i	Me	CH ₂	4-SOMe	O		
1-715	Et	Pr-i	N(NMe ₂)	CH ₂	4-Cl	O		
1-716	Et	Pr-i	Me	CH ₂	4-CH ₂ CH=CH ₂	O		
1-717	Et	Pr-i	Me	CH ₂	4-CH ₂ C≡CH	O		
1-718	CO ₂ H	Pr-i	N(Me)	CH(Me)	4-Cl	O		168-170
1-719	CH=CHCO ₂ Et	Pr-i	Me	CH(Me)	4-Cl	O		57-59
1-720	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	4-Me	O		111-113
1-721	COEt	Pr-i	Me	CH(Me)	H	O		
1-722	COEt	Pr-i	Me	CH(Me)	4-F	O		
1-723	COEt	Pr-i	Me	CH(Me)	4-Cl	O		
1-724	COEt	Pr-i	Me	CH(Me)	4-Me	O		
1-725	COEt	Pr-n	Me	CH ₂	H	O		
1-726	COEt	Pr-n	Me	CH ₂	4-F	O		
1-727	COEt	Pr-n	Me	CH ₂	4-Cl	O		
1-728	COEt	Pr-n	Me	CH ₂	4-Me	O		
1-729	COEt	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		
1-730	COEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-F	O		
1-731	COEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-Cl	O		
1-732	COEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-Me	O		
1-733	COEt	Pr-n	CH ₂ C≡CH	CH ₂	H	O		
1-734	COEt	Pr-n	CH ₂ C≡CH	CH ₂	4-F	O		
1-735	COEt	Pr-n	CH ₂ C≡CH	CH ₂	4-Cl	O		
1-736	COEt	Pr-n	CH ₂ C≡CH	CH ₂	4-Me	O		
1-737	COMe	Pr-n	Me	CH ₂	H	O		
1-738	COMe	Pr-n	Me	CH ₂	4-F	O		
1-739	COMe	Pr-n	Me	CH ₂	4-Cl	O		
1-740	COMe	Pr-n	Me	CH ₂	4-Me	O		
1-741	COMe	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		
1-742	COMe	Pr-i	CH ₂ C≡CH	CH(Me)	4-F	O		
1-743	COMe	Pr-i	CH ₂ C≡CH	CH(Me)	4-Cl	O		
1-744	COMe	Pr-i	CH ₂ C≡CH	CH(Me)	4-Me	O		
1-745	COMe	Pr-n	CH ₂ C≡CH	CH ₂	H	O		
1-746	COMe	Pr-n	CH ₂ C≡CH	CH ₂	4-F	O		
1-747	COMe	Pr-n	CH ₂ C≡CH	CH ₂	4-Cl	O		
1-748	COMe	Pr-n	CH ₂ C≡CH	CH ₂	4-Me	O		

10070804-0310
20750-4080/007

Table 23

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-749	COPr-i	Pr-i	Me	CH(Me)	H	O		
1-750	COPr-i	Pr-i	Me	CH(Me)	4-F	O		
1-751	COPr-i	Pr-i	Me	CH(Me)	4-Me	O		
1-752	COPr-i	Pr-n	Me	CH ₂	H	O		
1-753	COPr-i	Pr-n	Me	CH ₂	4-F	O		
1-754	COPr-i	Pr-n	Me	CH ₂	4-Cl	O		
1-755	COPr-i	Pr-n	Me	CH ₂	4-Me	O		
1-756	COPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		
1-757	COPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-F	O		
1-758	COPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-Cl	O		
1-759	COPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-Me	O		
1-760	COPr-i	Pr-n	CH ₂ C≡CH	CH ₂	H	O		
1-761	COPr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-F	O		
1-762	COPr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-Cl	O		
1-763	COPr-i	Pr-n	CH ₂ C≡CH	CH ₂	4-Me	O		
1-764	OEt	Pr-n	Me	CH ₂	H	O		
1-765	OEt	Pr-n	Me	CH ₂	4-F	O		
1-766	OEt	Pr-n	Me	CH ₂	4-Cl	O		
1-767	OEt	Pr-n	Me	CH ₂	4-Me	O		
1-768	OEt	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		
1-769	OEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-F	O		
1-770	OEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-Cl	O		
1-771	OEt	Pr-i	CH ₂ C≡CH	CH(Me)	4-Me	O		
1-772	OPr-i	Pr-i	Me	CH(Me)	H	O		
1-773	OPr-i	Pr-i	Me	CH(Me)	4-F	O		
1-774	OPr-i	Pr-i	Me	CH(Me)	4-Cl	O		
1-775	OPr-i	Pr-i	Me	CH(Me)	4-Me	O		
1-776	OPr-i	Pr-n	Me	CH ₂	H	O		
1-777	OPr-i	Pr-n	Me	CH ₂	4-F	O		
1-778	OPr-i	Pr-n	Me	CH ₂	4-Cl	O		
1-779	OPr-i	Pr-n	Me	CH ₂	4-Me	O		
1-780	OPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	H	O		
1-781	OPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-F	O		
1-782	OPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-Cl	O		
1-783	OPr-i	Pr-i	CH ₂ C≡CH	CH(Me)	4-Me	O		
1-784	Et	Ph	Me	CH ₂	H	O		
1-785	Et	Ph	Me	CH ₂	4-F	O		

2070804-034102

Table 24

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-786	Et	Ph	Me	CH ₂	4-Cl	O		63-66
1-787	Et	Ph	Me	CH ₂	4-Me	O		
1-788	N(Me) ₂	Pr-i	Me	CH ₂	H	O		
1-789	N(Me) ₂	Pr-i	Me	CH ₂	4-F	O		
1-790	N(Me) ₂	Pr-i	Me	CH ₂	4-Me	O		
1-791	N(Me) ₂	Pr-i	Me	CH(Me)	H	O		
1-792	N(Me) ₂	Pr-i	Me	CH(Me)	4-F	O		
1-793	N(Me) ₂	Pr-i	Me	CH(Me)	4-Cl	O		
1-794	N(Me) ₂	Pr-i	Me	CH(Me)	4-Me	O		
1-795	CF ₃	Pr-i	Me	N(Me)CH ₂	H	O		
1-796	CF ₃	Pr-i	Me	N(Me)CH ₂	4-F	O		
1-797	CF ₃	Pr-i	Me	N(Me)CH ₂	4-Me	O		
1-798	Et	Pr-i	Me	N(Me)CH ₂	H	O		
1-799	Et	Pr-i	Me	N(Me)CH ₂	4-F	O		
1-800	Et	Pr-i	Me	N(Me)CH ₂	4-Cl	O		
1-801	Et	Pr-i	Me	N(Me)CH ₂	4-Me	O		
1-802	Pr-i	Pr-i	Me	N(Me)CH ₂	H	O		
1-803	Pr-i	Pr-i	Me	N(Me)CH ₂	4-F	O		
1-804	Pr-i	Pr-i	Me	N(Me)CH ₂	4-Cl	O		
1-805	Pr-i	Pr-i	Me	N(Me)CH ₂	4-Me	O		
1-806	C(Me)=CH ₂	Pr-n	Me	CH ₂	H	O		
1-807	C(Me)=CH ₂	Pr-n	Me	CH ₂	4-F	O		
1-808	C(Me)=CH ₂	Pr-n	Me	CH ₂	4-Cl	O		
1-809	C(Me)=CH ₂	Pr-n	Me	CH ₂	4-Me	O		
1-810	Pr-n	C(Me)=CH ₂	Me	CH ₂	H	O		
1-811	Pr-n	C(Me)=CH ₂	Me	CH ₂	4-F	O		
1-812	Pr-n	C(Me)=CH ₂	Me	CH ₂	4-Cl	O		
1-813	Pr-n	C(Me)=CH ₂	Me	CH ₂	4-Me	O		
1-814	Et	C(Me)=CH ₂	Me	CH ₂	H	O		
1-815	Et	C(Me)=CH ₂	Me	CH ₂	4-F	O		
1-816	Et	C(Me)=CH ₂	Me	CH ₂	4-Cl	O		
1-817	Et	C(Me)=CH ₂	Me	CH ₂	4-Me	O		
1-818	Et	OEt	Me	CH(Me)	4-Cl	O		
1-819	Et	CH(Me)CN	Me	CH(Me)	4-Cl	O		
1-820	Et	CO ₂ Me	Me	CH(Me)	4-Cl	O		
1-821	Et	CHMeN(Me) ₂	Me	CH(Me)	4-Cl	O		



10070804-031102

Table 25

Compound No.	R ¹	R ²	R ³	Z	X _n	Q	Dia- stereo- mer	m. p. (° C) or refrac- tive index (n _D ²⁰)
1-822	Et	CON(Me) ₂	Me	CH(Me)	4-Cl	O		
1-823	Et	CHMeCONMe ₂	Me	CH(Me)	4-Cl	O		
1-824	Bu-t	Et	CH ₂ C≡CH	CH ₂	H	O		
1-825	Bu-t	Et	CH ₂ C≡CH	CH ₂	4-F	O		
1-826	Bu-t	Et	CH ₂ C≡CH	CH ₂	4-Cl	O		
1-827	Bu-t	Et	CH ₂ C≡CH	CH ₂	4-Me	O		
1-828	COPr-c	Pr-n	Me	CH ₂	H	O		
1-829	COPr-c	Pr-n	Me	CH ₂	4-F	O		
1-830	COPr-c	Pr-n	Me	CH ₂	4-Cl	O		
1-831	COPr-c	Pr-n	Me	CH ₂	4-Me	O		
1-832	Et	C(Me) ₂ OH	Me	CH ₂	H	O		
1-833	Et	C(Me) ₂ OH	Me	CH ₂	4-F	O		
1-834	Et	C(Me) ₂ OH	Me	CH ₂	4-Cl	O		
1-835	Et	C(Me) ₂ OH	Me	CH ₂	4-Me	O		
1-836	Et	C(Me) ₂ Cl	Me	CH ₂	H	O		
1-837	Et	C(Me) ₂ Cl	Me	CH ₂	4-F	O		
1-838	Et	C(Me) ₂ Cl	Me	CH ₂	4-Cl	O		
1-839	Et	C(Me) ₂ Cl	Me	CH ₂	4-Me	O		
1-840	N(Me)CH ₂ C≡CH	Pr-i	Me	CH ₂	H	O		
1-841	N(Me)CH ₂ C≡CH	Pr-i	Me	CH ₂	4-F	O		
1-842	N(Me)CH ₂ C≡CH	Pr-i	Me	CH ₂	4-Cl	O		
1-843	N(Me)CH ₂ C≡CH	Pr-i	Me	CH ₂	4-Me	O		
1-844	N(Me)CH ₂ C≡CH	Pr-i	Me	CH(Me)	H	O		
1-845	N(Me)CH ₂ C≡CH	Pr-i	Me	CH(Me)	4-F	O		
1-846	N(Me)CH ₂ C≡CH	Pr-i	Me	CH(Me)	4-Cl	O		
1-847	N(Me)CH ₂ C≡CH	Pr-i	Me	CH(Me)	4-Me	O		
1-848	CH ₂ CF ₃	Pr-i	Me	CH ₂	H	O		
1-849	CH ₂ CF ₃	Pr-i	Me	CH ₂	4-F	O		
1-850	CH ₂ CF ₃	Pr-i	Me	CH ₂	4-Cl	O		
1-851	CH ₂ CF ₃	Pr-i	Me	CH ₂	4-Me	O		
1-852	CF ₂ CF ₃	Pr-i	Me	CH ₂	H	O		106-108
1-853	CF ₂ CF ₃	Pr-i	Me	CH ₂	4-F	O		118-119
1-854	CF ₂ CF ₃	Pr-i	Me	CH ₂	4-Cl	O		122-123
1-855	CF ₂ CF ₃	Pr-i	Me	CH ₂	4-Me	O		68-69
1-856	OCF ₃	Pr-i	Me	CH ₂	H	O		
1-857	OCF ₃	Pr-i	Me	CH ₂	4-F	O		


20170404 10:08:00

Table 26

Compound No.	R ¹	R ²	R ³	Z	Xn	Q	Diastereomer	m.p. (°C) or refractive index (n _D ²⁰)
1-858	OCF ₃	Pr-i	Me	CH ₂	4-Cl	O		
1-859	OCF ₃	Pr-i	Me	CH ₂	4-Me	O		
1-860	Et	CH(Me)OMe	Me	CH ₂	H	O		
1-861	Et	CH(Me)OMe	Me	CH ₂	4-F	O		
1-862	Et	CH(Me)OMe	Me	CH ₂	4-Cl	O		
1-863	Et	CH(Me)OMe	Me	CH ₂	4-Me	O		
1-864	Et	CH(Me)CN	Me	CH ₂	H	O		
1-865	Et	CH(Me)CN	Me	CH ₂	4-F	O		
1-866	Et	CH(Me)CN	Me	CH ₂	4-Me	O		
1-867	Et	Pr-i	CH ₂ C≡CH	CH ₂	3,4-F ₂	O		
1-868	Et	Pr-i	CH ₂ C≡CH	CH ₂	2,4-F ₂	O		
1-869	Et	Pr-i	CH ₂ C≡CH	CH ₂	3-F	O		
1-870	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	2,4-F ₂	O		110-113
1-871	CF ₃	Pr-i	Me	CH(Me) (R-isomer)	H	O	A-isomer	144-146
1-872	CF ₃	Pr-i	Me	CH(Me) (R-isomer)	H	O	B-isomer	1.5164
1-873	CClF ₂	Pr-i	Me	N(Me)	H	O		1.5341
1-874	CF ₃	Pr-i	Me	NHN(Me)	H	O		72-75
1-875	CH ₂ CH(OMe) ₂	Pr-i	Me	CH ₂	4-Cl	O		90-91
1-876	CH ₂ CN	Pr-i	Me	CH ₂	4-Cl	O		106-107
1-877		Et	Me	CH ₂	4-Cl	O		1.5552
1-878	COMe	Et	Me	CH ₂	4-Cl	O		1.5612
1-879	CMe=NOMe	Et	Me	CH ₂	4-Cl	O		81-83
1-880	CF ₃	Pr-i	Me	N(Me)CH ₂	H	O		63-66
1-881	CH=NOMe	Pr-n	Me	CH(Me)	4-Cl	O		Not Measurable
1-882	CN	Pr-n	Me	CH(Me)	4-Cl	O		103-106
1-883	Et		Me	CH ₂	4-Cl	O		161-162
1-884	Et	CMe(OMe) ₂	Me	CH ₂	H	O		Not Measurable
1-885	Et	CMe=NOMe	Me	CH ₂	H	O		Not Measurable
1-886	Et	CMe(OMe) ₂	Me	CH ₂	4-F	O		Not Measurable
1-887	Et	COMe	Me	CH ₂	4-F	O		71-73
1-888	Et	CMe=NOMe	Me	CH ₂	4-F	O		1.5443
1-889	COOH	Pr-i	Me	CH ₂	4-Cl	O		139-141
1-890	CN	Bu-t	Me	CHMe	4-Cl	O	B-isomer	106-108



10070804, 031102

Table 27

						
Compound No.	R ¹	R ²	R ³	Z	Ar	Q m. p. (° C) or refractive index (n _D ²⁰)
2-1	CF ₃	Pr-i	Me	CH ₂	2-naphtyl	O 137-138
2-2	CF ₃	Pr-i	Me	CH ₂	3-thienyl	O 37-38
2-3	CF ₃	Pr-i	Me	CH ₂	2-pyridyl	O 99-100
2-4	CF ₃	Pr-i	Me	CH ₂	3-pyridyl	O 93-96
2-5	CF ₃	Pr-i	Me	CH ₂	4-pyridyl	O 115-118
2-6	CF ₃	Pr-i	Me	CH ₂	2-thienyl	O 51-54
2-7	CHF ₂	Pr-i	Et	CH ₂	2-thienyl	O 69-71
2-8	CHF ₂	Pr-i	Et	CH ₂	3-thienyl	O 83-85
2-9	CF ₃	Pr-i	Et	CH ₂	2-thienyl	O 1.5197
2-10	CF ₃	Pr-i	Et	CH ₂	3-thienyl	O 1.5208
2-11	CF ₃	Bu-s	Me	CH ₂	2-thienyl	O 1.5215
2-12	CF ₃	Bu-s	Me	CH ₂	3-thienyl	O 1.5229
2-13	CF ₃	Bu-t	Me	CH ₂	2-thienyl	O 1.5121
2-14	CF ₃	Bu-t	Me	CH ₂	3-thienyl	O 58-62
2-15	CF ₃	Pr-i	Me	CH(Me)	2-thienyl	O
2-16	CF ₃	Pr-i	Me	CH(Me)	3-thienyl	O
2-17	CF ₃	Bu-t	Me	CH(Me)	2-thienyl	O
2-18	CF ₃	Bu-t	Me	CH(Me)	3-thienyl	O
2-19	CF ₃	Ph	Me	CH ₂	2-thienyl	O 139-142
2-20	CF ₃	Ph	Me	CH ₂	3-thienyl	O 142-145
2-21	SMe	Pr-i	Me	CH ₂	2-thienyl	O
2-22	SMe	Pr-i	Me	CH ₂	3-thienyl	O
2-23	Pr-i	Pr-i	Me	CH ₂	2-thienyl	O 79-81
2-24	Pr-i	Pr-i	Me	CH ₂	3-thienyl	O 101-103
2-25	CF ₃	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O 94-95
2-26	CF ₃	Pr-i	Me	CH ₂	5-Me-2-thienyl	O
2-27	SMe	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O
2-28	SMe	Pr-i	Me	CH ₂	5-Me-2-thienyl	O



2011040804001

Table 28

Compound No.	R ¹	R ²	R ³	Z	Ar	Q	m. p. (° C) or refractive index (n _D ²⁰)
2-29	Pr-i	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O	79-81 111-113
2-30	Pr-i	Pr-i	Me	CH ₂	5-Me-2-thienyl	O	
2-31	CF ₃	Ph	Me	CH ₂	5-Cl-2-thienyl	O	
2-32	CF ₃	Ph	Me	CH ₂	5-Me-2-thienyl	O	
2-33	CF ₃	Ph	Me	CH(Me)	2-thienyl	O	
2-34	CF ₃	Ph	Me	CH(Me)	3-thienyl	O	
2-35	CF ₃	Pr-i	Me	CH ₂	5-CF ₃ -2-thienyl	O	
2-36	CF ₃	Pr-i	Me	CH ₂	5-F-2-thienyl	O	
2-37	CF ₃	Pr-i	Me	CH ₂	3-Cl-2-thienyl	O	
2-38	CF ₃	Pr-i	Me	CH ₂	3-F-2-thienyl	O	
2-39	CF ₃	Pr-i	Me	CH ₂	5-Cl-3-thienyl	O	160-161 106-107 145-147 120-122 138-141 108-112 121-122 192-195 164-167 73-75 68-70 81-82 94-98 86-87 92-93 111-112 1.5295
2-40	CF ₃	Pr-i	Me	CH ₂	5-Me-3-thienyl	O	
2-41	CF ₃	Pr-i	Me	CH ₂	4-Br-pyrazol-1-yl	O	
2-42	CF ₃	Bu-t	Me	CH ₂	5-Cl-2-thienyl	O	
2-43	CF ₃	Pr-i	Me	CH ₂ O	5-Cl-2-pyridyl	O	
2-44	CF ₃	Pr-i	Me	CH ₂ O	5-Cl-3-pyridyl	O	
2-45	CF ₃	Pr-i	Me	CH ₂ O	3-Cl-5-CF ₃ -pyridin-2-yl	O	
2-46	CF ₃	Pr-i	Me	CH ₂ O	1-Me-3-CF ₃ -5-Pyrazolyl	O	
2-47	CF ₃	Pr-i	Me	CH ₂ O	5-CF ₃ -1,3,4-thiazazol-2-yl	O	
2-48	CF ₃	Pr-i	Me	CH ₂ O	2-benzothiazolyl	O	
2-49	CF ₃	Pr-i	Me	CH ₂ O	4-CF ₃ -pyridin-2-yl	O	73-75 68-70 81-82 94-98 86-87 92-93 111-112 1.5295
2-50	CF ₃	Pr-i	Me	CH ₂	5-Me-2-thienyl	O	
2-51	CF ₃	Bu-i	Me	CH ₂	2-thienyl	O	
2-52	CF ₃	Bu-i	Me	CH ₂	3-thienyl	O	
2-53	CF ₃	Bu-t	Me	CH ₂	5-Me-2-thienyl	O	
2-54	CF ₃	Pr-i	Me	CH ₂	Pr-c	O	
2-55	CF ₃		Me	CH ₂	2-thienyl	O	
2-56	CF ₃		Me	CH ₂	3-thienyl	O	
2-57	CF ₃	Bu-s	Me	CH ₂	5-Cl-2-thienyl	O	

2025-03-04 10:31:03

Table 29

Compound No.	R ¹	R ²	R ³	Z	Ar	Q	m. p. (° C) or refractive index (n _D ²⁰)
2-58	CF ₃		Me	CH ₂	5-Cl-2-thienyl	O	Not Measurable
2-59	CF ₃		Me	CH ₂	5-Me-2-thienyl	O	71-74
2-60	CF ₃	Pr-i	Me	CH(Me)	5-Me-2-thienyl	O	1.5141
2-61	CF ₃	Pr-i	Me	CH(Me)	5-Br-2-thienyl	O	1.5331
2-62	CF ₃	Pr-i	Me	CH(Me)	2-thienyl	O	Not more than 30° C
2-63	CF ₃	Pr-i	Me	N(Me)	3-thienyl	O	1.5244
2-64	CF ₃	Pr-i	Me	NH	2-benzothiazolyl	O	180-182
2-65	CF ₃	Pr-i	Me	N(Me)	5-Cl-pyridin-2-yl	O	39-40
2-66	CF ₃	Pr-i	Me	NH	cyclohexyl	O	110-112
2-67	CF ₃	Pr-i	Me	N(Me)	3-Me-5-isoxazolyl	O	1.4939
2-68	CF ₃	Pr-i	Me	N(Me)	4-MeO-6-Me-pyrimidin-2-yl	O	107-110
2-69	CF ₃	Pr-i	Me	N(Me)	4,6-(MeO) ₂ -1,3,5-triazinyl	O	112-113
2-70	CF ₃	Pr-i	Me	N(Me)	6-MeO-pyridin-3-yl	O	1.5079
2-71	Pr-i	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O	112-115
2-72	CF ₃	Pr-i	Me	N(Me)	cyclohexyl	O	98-100
2-73	Et	Pr-i	CH ₂ C≡CH	CH ₂	5-Cl-2-thienyl	O	90-91
2-74	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	5-Cl-2-thienyl	O	117-118
2-75	Et	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O	Not Measurable
2-76	Pr-i	CH ₂ OMe	Me	CH ₂	5-Cl-2-thienyl	O	1.5488
2-77	CH ₂ OMe	Pr-i	Me	CH ₂	5-Cl-2-thienyl	O	1.5508
2-78	CF ₃	Pr-i	CH ₂ C≡CH	CH ₂	3-thienyl	O	112-114
2-79	Pr-i	Pr-i	CH ₂ C≡CH	CH ₂	3-thienyl	O	128-131
2-80	CF ₂ Cl	Pr-i	Me	O	1-naphtyl	O	123-126
2-81	CF ₃	Pr-i	Me	CH ₂	5-CF ₃ -1,3,4-thiadizol-2-yl	O	
2-82	CF ₃	Pr-i	Me	CH ₂	4-CF ₃ -1,3,4-imidazol-2-yl	O	
2-83	CF ₃	Pr-i	Me	CH ₂	2-Cl-5-oxazolyl	O	
2-84	CF ₃	Pr-i	Me	CH ₂	2-Cl-5-thiazolyl	O	
2-85	CF ₃	Pr-i	Me	CH ₂	5-Cl-2-furyl	O	

20170404 10:00:00

Table 30

Compound No.	R ¹	R ²	R ³	Z	Ar	Q	m. p. (° C) or refractive index (n _D ²⁰)
2-86	CF ₃	Pr-i	Me	CH ₂	2-benzoxazolyl	O	
2-87	Et	Pr-i	Me	CH ₂	2-thienyl	O	
2-88	Et	Pr-i	Me	CH ₂	3-thienyl	O	
2-89	Et	Pr-i	Me	CH ₂	5-Me-2-thienyl	O	
2-90	Et	Pr-i	Me	CH(Me)	2-thienyl	O	
2-91	Et	Pr-i	Me	CH(Me)	3-thienyl	O	
2-92	Et	Pr-i	Me	CH(Me)	5-Cl-2-thienyl	O	
2-93	Et	Pr-i	Me	CH(Me)	5-Me-2-thienyl	O	
2-94	Et	Pr-i	CH ₂ C≡CH	CH ₂	2-thienyl	O	
2-95	Et	Pr-i	CH ₂ C≡CH	CH ₂	3-thienyl	O	
2-96	Et	Pr-i	CH ₂ C≡CH	CH ₂	5-Me-2-thienyl	O	
2-97	Et	Bu-s	Me	CH ₂	2-thienyl	O	
2-98	Et	Bu-s	Me	CH ₂	3-thienyl	O	
2-99	Et	Bu-t	Me	CH ₂	2-thienyl	O	
2-100	Et	Bu-t	Me	CH ₂	3-thienyl	O	
2-101	Et	Bu-s	CH ₂ C≡CH	CH ₂	2-thienyl	O	
2-102	Et	Bu-s	CH ₂ C≡CH	CH ₂	3-thienyl	O	
2-103	Et	Bu-t	CH ₂ C≡CH	CH ₂	2-thienyl	O	
2-104	Et	Bu-t	CH ₂ C≡CH	CH ₂	3-thienyl	O	
2-105	CF ₃	Pr-i	Me	N(Me)	2-thienyl	O	
2-106	CF ₃	Pr-i	Me	N(Me)	5-Cl-2-thienyl	O	
2-107	CF ₃	Pr-i	Me	N(Me)	5-Me-2-thienyl	O	
2-108	Et	Pr-i	Me	N(Me)	2-thienyl	O	
2-109	Et	Pr-i	Me	N(Me)	3-thienyl	O	
2-110	Et	Pr-i	Me	N(Me)	5-Cl-2-thienyl	O	
2-111	Et	Pr-i	Me	N(Me)	5-Me-2-thienyl	O	
2-112	CF ₃	Pr-i	Me	NHCH ₂	2-thienyl	O	110-112

10070804.03110

Table 31

Compound No.	R ₁	R ₂	R ₃	Z	Xn	R ₇	R ₈	m. p. (°C) or refractive index (n _D ²⁰)
3-1	CF ₃	Pr-i	Me	CH ₂	H	H	Me	99-101
3-2	CF ₃	Pr-i	Me	CH ₂	4-F	H	Me	74-75
3-3	CF ₃	Pr-i	Me	CH ₂	4-Cl	H	Me	67-68
3-4	CF ₃	Pr-i	Me	CH ₂	4-Me	H	Me	85-86
3-5	CF ₃	Pr-i	Me	CH ₂	H	H	Pr-c	144-145
3-6	CF ₃	Pr-i	Me	CH ₂	4-F	H	Pr-c	131-132
3-7	CF ₃	Pr-i	Me	CH ₂	4-Cl	H	Pr-c	99-100
3-8	CF ₃	Pr-i	Me	CH ₂	4-Me	H	Pr-c	82-83
3-9	CF ₃	Pr-i	Me	CH ₂	H	Me	H	
3-10	CF ₃	Pr-i	Me	CH ₂	4-F	Me	H	
3-11	CF ₃	Pr-i	Me	CH ₂	4-Cl	Me	H	
3-12	CF ₃	Pr-i	Me	CH ₂	4-Me	Me	H	
3-13	Me	Pr-i	Me	CH ₂	H	Me	H	
3-14	Me	Pr-i	Me	CH ₂	4-F	Me	H	
3-15	Me	Pr-i	Me	CH ₂	4-Cl	Me	H	
3-16	Me	Pr-i	Me	CH ₂	4-Me	Me	H	
3-17	Pr-i	Pr-i	Me	CH ₂	H	Me	H	
3-18	Pr-i	Pr-i	Me	CH ₂	4-F	Me	H	
3-19	Pr-i	Pr-i	Me	CH ₂	4-Cl	Me	H	
3-20	Pr-i	Pr-i	Me	CH ₂	4-Me	Me	H	
3-21	Me	Bu-t	Me	CH ₂	H	Me	H	
3-22	Me	Bu-t	Me	CH ₂	4-F	Me	H	
3-23	Me	Bu-t	Me	CH ₂	4-Cl	Me	H	
3-24	Me	Bu-t	Me	CH ₂	4-Me	Me	H	
3-25	Et	Et	Me	CH ₂	H	Et	H	
3-26	Et	Et	Me	CH ₂	4-F	Et	H	


20170304 10802001

Table 32


Compound No.	R ₁	R ₂	R ₃	Z	X _n	R ₇	R ₈	m. p. (° C) or refractive index (n _D ²⁰)
3-27	Et	Et	Me	CH ₂	4-Cl	Et	H	
3-28	Et	Et	Me	CH ₂	4-Me	Et	H	
3-29	CF ₃	Pr-i	Me	CH ₂	H	H	SMe	
3-30	CF ₃	Pr-i	Me	CH ₂	4-F	H	SMe	
3-31	CF ₃	Pr-i	Me	CH ₂	4-Cl	H	SMe	
3-32	CF ₃	Pr-i	Me	CH ₂	4-Me	H	SMe	
3-33	CF ₃	Ph	Me	CH ₂	H	Me	H	
3-34	CF ₃	Ph	Me	CH ₂	4-F	Me	H	
3-35	CF ₃	Ph	Me	CH ₂	4-Cl	Me	H	
3-36	CF ₃	Ph	Me	CH ₂	4-Me	Me	H	
3-37	CF ₃	Pr-i	Me	CH ₂	H	CF ₃	H	
3-38	CF ₃	Pr-i	Me	CH ₂	4-F	CF ₃	H	
3-39	CF ₃	Pr-i	Me	CH ₂	4-Cl	CF ₃	H	
3-40	CF ₃	Pr-i	Me	CH ₂	4-Me	CF ₃	H	
3-41	OMe	Pr-i	Me	CH ₂	4-Cl	OMe	H	107-109
3-42	CF ₃	Pr-i	Me	O	4-Cl	H	Me	104-107
3-43	CF ₃	Pr-i	Me	O	4-Cl	H	Pr-c	1.5178

10070804 0310
 2017-04-08 10:00

Table 33

					
Compound No.	R ¹	R ²	R ³	Ar	m.p. (°C) or refractive index (n _D ²⁰)
4-1	CF ₃	Pr-i	Me	Ph(4-Cl)	1.5246
4-2	Et	Pr-i	Me	Ph	1.5446
4-3	Et	Pr-i	Me	Ph(4-F)	1.5399
4-4	Et	Pr-i	Me	Ph(3-F)	1.541
4-5	Et	Pr-i	Me	Ph(2-F)	1.5441
4-6	Et	Pr-i	Me	Ph(4-Cl)	1.5562
4-7	Et	Pr-i	Me	Ph(4-Me)	1.5475
4-8	Et	Pr-i	Me	Ph(4-CN)	1.5527
4-9	Et	Pr-i	Me	Ph(4-OMe)	102-103
4-10	Et	Pr-i	Me	Ph(4-NO ₂)	106-107
4-11	Pr-i	Pr-i	Me	Ph(4-F)	93-95
4-12	CH ₂ OMe	Pr-i	Me	Ph(4-F)	1.5365
4-13	CH(OEt) ₂	Pr-i	Me	Ph(4-F)	1.5234
4-14	Et	Pr	CH ₂ C≡CH	Ph(4-F)	1.5445
4-15	CF ₃	Pr-i	Me	Ph	1.518
4-16	Pr-i	Pr-i	Me	Ph(4-CF ₃)	
4-17	CF ₃	Pr-i	Me	Ph(4-F)	
4-18	CF ₃	Pr-i	Me	Ph(3-F)	
4-19	CF ₃	Pr-i	Me	Ph(2-F)	
4-20	CF ₃	Pr-i	Me	Ph(4-Me)	
4-21	CF ₃	Pr-i	Me	Ph(4-CN)	
4-22	CF ₃	Pr-i	Me	Ph(4-OMe)	
4-23	CF ₃	Pr-i	Me	Ph(4-NO ₂)	
4-24	CF ₃	Pr-i	CH ₂ C≡CH	Ph(4-F)	
4-25	CF ₃	Pr-i	Me	Ph(2-Me)	
4-26	Et	Pr-i	Me	Ph(2-Me)	1.5512
4-27	CF ₃	Pr-i	Me	Ph(3-Me)	
4-28	Et	Pr-i	Me	Ph(3-Me)	1.5499

2077ED" 4030/001

Compound No.	R ¹	R ²	R ³	Ar	m. p. (° C) or refractive index (n _D ²⁰)
4-29	CF ₃	Pr-i	CH ₂ C≡CH	Ph(4-F)	
4-30	Et	Pr-i	CH ₂ C≡CH	Ph(4-Cl)	
4-31	CF ₃	Pr-i	CH ₂ C≡CH	Ph(4-Cl)	
4-32	Et	Pr-i	CH ₂ C≡CH	Ph	
4-33	CF ₃	Pr-i	CH ₂ C≡CH	Ph	
4-34	Et	Pr-i	CH ₂ C≡CH	Ph(4-Me)	
4-35	CF ₃	Pr-i	CH ₂ C≡CH	Ph(4-Me)	
4-36	CF ₂ Cl	Pr-i	Me	Ph	1.5382
4-37	CF ₂ Cl	Pr-i	Me	Ph(4-F)	1.4929
4-38	Pr-i	Pr-i	Me		132-133
4-39	Pr-i	Pr-i	Me		
4-40	Pr-i	Pr-i	Me	Ph(3-F)	
4-41	Pr-i	Pr-i	Me	Ph(2-F)	
4-42	Pr-i	Pr-i	Me	Ph(4-Me)	
4-43	Pr-i	Pr-i	Me	Ph(4-CN)	
4-44	Pr-i	Pr-i	Me	Ph(4-OMe)	
4-45	Pr-i	Pr-i	Me	Ph(4-NO ₂)	
4-46	Pr-i	Pr-i	CH ₂ C≡CH	Ph(4-F)	
4-47	Pr-i	Pr-i	Me	Ph(2-Me)	
4-48	Pr-i	Pr-i	Me	Ph(3-Me)	
4-49	Pr-i	Pr-i	CH ₂ C≡CH	Ph(4-F)	
4-50	Pr-i	Pr-i	CH ₂ C≡CH	Ph(4-Cl)	
4-51	Pr-i	Pr-i	CH ₂ C≡CH	Ph	
4-52	Pr-i	Pr-i	CH ₂ C≡CH	Ph(4-Me)	
4-53	Et	Pr-i	Me	Ph(4-CF ₃)	1.5117
4-54	Et	Et	Me	Ph(4-F)	1.5462
4-55	Et	Pr-i	Me	2-thienyl	109-110





Table 35

							
Compound No.	R ¹	R ²	p	Q	q	Xn	m.p. (°C) or refractive index (n _D ²⁰)
5-1	CF ₃	Pr-i	2	O	0	H	126-128
5-2	CF ₃	Pr-i	2	O	0	4-F	1.5279
5-3	CF ₃	Pr-i	2	O	0	4-Cl	
5-4	CF ₃	Pr-i	2	O	0	4-Me	
5-5	CF ₃	Pr-i	3	O	0	H	
5-6	CF ₃	Pr-i	3	O	0	4-F	
5-7	CF ₃	Pr-i	3	O	0	4-Cl	
5-8	CF ₃	Pr-i	3	O	0	4-Me	
5-9	CF ₃	Pr-i	2	O	1	H	93-95
5-10	CF ₃	Pr-i	2	O	1	4-F	1.5090
5-11	CF ₃	Pr-i	2	O	1	4-Cl	
5-12	CF ₃	Pr-i	2	O	1	4-Me	
5-13	CF ₃	Pr-i	3	O	1	H	1.5181
5-14	CF ₃	Pr-I	3	O	1	4-F	
5-15	CF ₃	Pr-i	3	O	1	4-Cl	
5-16	CF ₃	Pr-i	3	O	1	4-Me	
5-17	CF ₃	Pr-i	3	S	0	H	
5-18	CF ₃	Pr-i	3	S	0	4-F	
5-19	CF ₃	Pr-i	3	S	0	4-Cl	
5-20	CF ₃	Pr-i	3	S	0	4-Me	
5-21	CF ₃	Pr-i	3	S	1	H	
5-22	CF ₃	Pr-i	3	S	1	4-F	
5-23	CF ₃	Pr-i	3	S	1	4-Cl	
5-24	CF ₃	Pr-i	3	S	1	4-Me	
5-25	CF ₃	Pr-i	2	S	1	H	138-140


2017040804001

Table 36

Compound No.	R ¹	R ²	p	Q	q	Xn	m. p. (° C) or refractive index (n _D ²⁰)
5-26	CF ₃	Pr-i	2	S	1	4-F	
5-27	CF ₃	Pr-i	2	S	1	4-Cl	
5-28	CF ₃	Pr-i	2	S	1	4-Me	
5-29	Et	Pr-i	3	O	0	H	
5-30	Et	Pr-i	3	O	0	4-F	
5-31	Et	Pr-i	3	O	0	4-Cl	
5-32	Et	Pr-i	3	O	0	4-Me	
5-33	Et	Pr-i	2	O	1	H	
5-34	Et	Pr-i	2	O	1	4-F	
5-35	Et	Pr-i	2	O	1	4-Cl	
5-36	Et	Pr-i	2	O	1	4-Me	
5-37	Et	Pr-i	3	O	1	H	
5-38	Et	Pr-I	3	O	1	4-F	
5-39	Et	Pr-i	3	O	1	4-Cl	
5-40	Et	Pr-i	3	O	1	4-Me	
5-41	Et	Pr-i	3	S	0	H	
5-42	Et	Pr-i	3	S	0	4-F	
5-43	Et	Pr-i	3	S	0	4-Cl	
5-44	Et	Pr-i	3	S	0	4-Me	
5-45	Et	Pr-i	3	S	1	H	
5-46	Et	Pr-i	3	S	1	4-F	
5-47	Et	Pr-i	3	S	1	4-Cl	
5-48	Et	Pr-i	3	S	1	4-Me	

10070804-031106

Table 37

				
Compound No.	R ¹	R ²	R ³	m.p. (° C), refractive index (n _D ²⁰) or NMR (δ (ppm), 300MHz, CDCl ₃)
6-1	Pr-i	Pr-i	Me	44-45
6-2	Pr-i	Et	Me	1.4902
6-3	Et	Pr-i	Me	0.86(3H,d); 0.99(3H,d); 1.32(3H,t); 1.65(1H,br); 1.85-1.95(1H,m); 2.23(3H,s); 2.77-2.95(2H,m); 3.58(1H,d); 8.68(1H,s); 9.02(1H,s)
6-4	Pr	Pr-i	Me	0.86(3H,d); 0.99(3H,d); 1.00(3H,t); 1.44(1H,br); 1.73-1.83(2H,m); 1.83-1.95(1H,m); 2.23(3H,s); 2.68-2.90(2H,m); 3.59(1H,d); 8.69(1H,s); 9.01(1H,s)
6-5	Pr-i	Pr	Me	1.4929
6-6	Et	Bu-t	Me	74-75
6-7	Bu-t	Et	Me	1.02(3H,t); 1.46(9H,s); 1.65-1.72(1H,m); 2.33(3H,s); 4.16(1H,t); 8.85(1H,s); 9.00(1H,s)
6-8	Pr-i	CH(OEt) ₂	Me	1.4794
6-9	CH(OEt) ₂	Pr-i	Me	0.85(3H,d); 0.99(3H,d); 1.24(3H,t); 1.45(1H,br); 1.95-2.04(1H,m); 2.23(1H,s); 3.53-3.66(2H,m); 3.72-4.04(2H,m); 4.03(1H,d); 5.57(1H,s); 8.87(1H,s); 9.09(1H,s)



20170404 1007804.031107

Table 38

Compound No.	R ¹	R ²	R ³	m.p. (° C), refractive index (n _D ²⁰) or NMR (δ (ppm), 300MHz, CDCl ₃)
6-10	CH(OEt) ₂	Pr-n	Me	1.4811
6-11	CH(OEt) ₂	Bu-t	Me	1.4781
6-12	Pr	Pr	Me	1.4978
6-13	Et	Pr	Me	
6-14	Pr	Et	Me	
6-15	Pr-i	CH ₂ OMe	Me	1.29(3H,d), 1.29(3H,d), 2.29(3H,s), 3.39(3H,s), 3.30-3.46(2H,m), 3.30-3.46(1H,m), 4.1(1H,dd), 8.80(1H,s), 9.07(1H,s)
6-16	CH ₂ OMe	Pr-i	Me	0.83(3H,d); 1.01(3H,d); 1.89-2.63(1H,m); 2.22(3H,s); 3.46(3H,s); 3.61(1H,d); 4.64(2H,q); 8.80(1H,s); 9.10(1H,s)
6-17	SMe	Pr-i	Me	1.5509
6-18	Pr-i	Pr-i	CH ₂ C≡CH	0.86(3H,d); 1.01(3H,d); 1.88-1.95(1H,m); 2.22(1H,t); 2.95(1H,dd); 3.38-3.48(1H,m); 3.38-3.44(1H,dd); 4.04(1H,d); 8.71(1H,s); 9.06(1H,s)
6-19	Pr-i	Et	CH ₂ C≡CH	
6-20	Et	Pr-i	CH ₂ C≡CH	1.5185
6-21	Pr	Pr-i	CH ₂ C≡CH	46-48
6-22	Pr-i	Pr	CH ₂ C≡CH	0.86(3H,d); 0.93(3H,d); 1.29(3H,d); 1.29(3H,d); 1.27-1.42(2H,m); 1.55-1.70(2H,m); 2.23(1H,t); 3.03(1H,dd); 3.40(1H,dd); 3.37-3.50(1H,m); 4.29(1H,t); 8.74(1H,s); 9.05(1H,s)
6-23	Et	Bu-t	CH ₂ C≡CH	0.95(9H,s); 1.33(3H,t); 2.22(1H,t); 2.88(1H,dd); 2.93(2H,q); 3.41(1H,dd); 4.11(1H,s); 8.79(1H,s); 9.02(1H,s)

20170804 03:10


Table 39

Compound No.	R ¹	R ²	R ³	m.p. (° C), refractive index (n _D ²⁰) or NMR (δ (ppm), 300MHz, CDCl ₃)
6-24	Bu-t	Et	CH ₂ C≡CH	0.87(3H,t); 0.94(3H,t); 1.18-1.45(2H,m); 1.33(3H,t); 1.55-1.74(2H,m); 2.45(1H,t); 2.87(2H,q); 3.04(1H,dd); 3.43(1H,dd); 4.25(1H,t); 8.75(1H,s); 9.01(1H,s)
6-25	Pr	Pr	CH ₂ C≡CH	
6-26	Et	Pr	CH ₂ C≡CH	
6-27	Pr	Et	CH ₂ C≡CH	0.89(3H,t); 0.94(3H,t); 1.47(1H,br); 1.66(3H,d); 1.68(3H,d); 1.60-1.81(2H,m); 2.05(3H,s); 2.07(3H,s); 2.29(3H,s); 2.33(3H,s); 3.77(1H,t); 3.86(1H,t); 4.33(1H,q); 4.42(1H,q); 8.71(1H,s); 8.77(1H,s); 9.08(1H,s)
6-28	Et	CH(Me)(SMe)	N(Me)	
6-29	Ph	Pr-i	N(Me)	
6-30	Pr-i	Me	N(Me)	1.5632
6-31	Bu-t	Me	N(Me)	1.5012
6-32	Pr-i	Ph	N(Me)	72-73
6-33	CMe(OMe) ₂	Pr-i	N(Me)	1.5598
6-34	Pr-i		N(Me)	75-76
6-35	Pr-i	CH=NOMe	N(Me)	79-78
6-36		Pr-i	N(Me)	1.5079
6-37	Et	Et	N(Me)	1.5089
				1.5049

20750-4080-007

The compound of the present invention can be produced, for example, by the following processes, but is not restricted to such processes. Further, syntheses of intermediates will also be described.

5 Process 1



In the formulae, R^1 , R^2 , R^7 and R^8 have the same meanings as defined above, respectively, and R^{13} is a C_1 - C_6 alkyl group.

Namely, in step (1-1), 1 equivalent of a compound represented by the formula [II-1] is reacted with from 1 to 10 equivalents of a compound represented by the formula [II-2] in acetic anhydride to obtain a compound represented by the formula [II-4]. Here, from 0.01 to 1.0 equivalent of a catalyst (such as zinc chloride) may be added, as the case requires.

25 The reaction is carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux

temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be
5 purified by distillation or column chromatography, as the case requires.

Then, in step (1-2), 1 equivalent of a compound represented by the formula [II-4] is reacted with from 1 to 10 equivalents of a Lewis acid salt of a compound
10 represented by the formula [II-6] in the presence of from 1 to 10 equivalents of a base in an inert solvent to obtain a compound represented by the formula [II-7]. By this reaction, in some cases, a compound represented by the formula [II-8] will also be obtained as a by-product.

15 Here, the inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The base may, for example, be an alkali metal such
20 as sodium or potassium, an alkali metal alkoxide such as sodium methoxide or potassium tert-butoxide, or an alkali metal hydride such as sodium hydride or potassium hydride.

The Lewis acid may, for example, be acetic acid or
25 hydrochloric acid.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

20070804 03:10

out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 hour to 24 hours, although it varies depending upon the compound. The desired product can be isolated
5 from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Further, in step (1-3), 1 equivalent of a compound represented by the formula [II-1] is reacted with from 1
10 to 10 equivalents of a compound represented by the formula [II-3] in an inert solvent or without using any solvent, to obtain a compound represented by the formula [II-5].

Here, the inert solvent may, for example, be a
15 hydrocarbon such as n-hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be
20 completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

25 Further, in step (1-4), 1 equivalent of a compound represented by the formula [II-5] is reacted with from 1 to 5 equivalents of a Lewis acid salt of a compound


represented by the formula [II-6] in an inert solvent in the presence of from 1 to 10 equivalents of a base to obtain a compound represented by the formula [II-7]. In this reaction, sometimes, a compound represented by the
5 formula [II-8] will also be obtained as a by-product.

The inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The base may, for example, be an alkali metal such
10 as sodium or potassium, an alkali metal alkoxide such as sodium methoxide or potassium tert-butoxide, or an alkali metal hydride such as sodium hydride or potassium hydride.

The Lewis acid may, for example, be acetic acid or
15 hydrochloric acid.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed
20 in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 2

15 L^1 represents a halogen atom, and R^1 , R^2 , R^7 and R^8 in the formulae, have the same meanings as defined above, respectively.

Namely, in step (2-1), 1 equivalent of a compound represented by the formula [II-7] is reduced with from 0.5 to 10 equivalents of a reducing agent (such as a borane-tert-butylamine complex or sodium borohydride) in an inert solvent to obtain a compound represented by the formula [III-3].

25 The inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol, tert-butyl alcohol or methyl alcohol.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from
5 the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

In step (2-2), 1 equivalent of a compound represented by the formula [III-1] is reacted with from 1
10 to 10 equivalents of a compound represented by the formula [III-2] in an inert solvent in the presence of from 1 to 10 equivalents of magnesium, or an alkyl lithium such as methyl lithium, ethyl lithium or n-butyl lithium, to obtain a compound represented by the
15 formula [III-3].

Here, the inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

20 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -100°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon
25 the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the

10070804.031102


case requires.

Further, the compound represented by the formula [III-1] as the intermediate to be used in the above production process, can be synthesized, for example, by a method disclosed in e.g. the specification of international application W097/37978.

In step (2-3), 1 equivalent of a compound represented by the formula [III-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [III-5] in an inert solvent in the presence of from 1 to 10 equivalents of magnesium or an alkyl lithium such as methyl lithium, ethyl lithium or n-butyllithium, to obtain a compound represented by the formula [III-3].

Here, the inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -100°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 3

In the formulae, L^2 represents a C_1 - C_6 alkyl group or a phenyl group which may be substituted by a C_1 - C_6 alkyl group, and R^1 , R^2 , R^3 , R^7 , R^8 and L^1 have the same meanings as defined above, respectively.

Namely, in step (3-1), 1 equivalent of a compound represented by the formula $[III-3]$ is chlorinated with from 1 to 10 equivalents of a chlorinating agent (such as thionyl chloride or hydrogen chloride) in an inert solvent, to obtain a compound represented by the formula $[IV-1]$.

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-

hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

In step (3-2), 1 equivalent of a compound represented by the formula [IV-1] is reacted with from 1 to 10 equivalents of a compound represented by the formula [IV-3] in an inert solvent, to obtain a compound represented by the formula [IV-4].

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be

10070804, 031107

purified by distillation or column chromatography, as the case requires.

Further, in step (3-3), 1 equivalent of a compound represented by the formula [III-3] is reacted with from 1 to 10 equivalents of a compound represented by the formula [IV-8] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [IV-2].

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or a pyridine such as pyridine.

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from

the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Further, in step (3-4), 1 equivalent of a compound
5 represented by the formula [IV-2] is reacted with from 2 to 10 equivalents of a compound represented by the formula [IV-3] in an inert solvent, to obtain a compound represented by the formula [IV-4].

Here, the inert solvent may, for example, be an
10 alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

15 The reaction may be carried in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound.

20 The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

In step (3-5), 1 equivalent of a compound
25 represented by the formula [III-3] is azidated with from 1 to 10 equivalents of an azidation agent such as tosyl azide, diphenylphosphoryl azide, sodium azide, lithium

azide or hydrogen azide in the presence or absence of boron trifluoridediethylether complex, triphenyl phosphine and trifluoroacetic acid in an inert solvent, to obtain a compound represented by the formula [IV-5].

5 Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or
10 dimethylsulfoxide, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

2070804-03110
The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux
15 temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the
20 case requires.

In step (3-6), 1 equivalent of a compound represented by the formula [IV-5] is treated with from 1 to 10 equivalents of reducing agent such as magnesium, lithium aluminum hydride, sodium borohydride,
25 triphenylphosphine, or iron, or subjected to a hydrogenation catalytic reduction with a catalyst such as palladium carbon, platinum carbon or Raney Nickel, to

obtain a compound represented by the formula [IV-6] in an inert solvent.

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or
5 dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, an alcohol such as methyl alcohol or ethyl alcohol, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen
10 stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from
15 the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

In step (3-7), 1 equivalent of a compound represented by the formula [IV-6] is reacted with from 1
20 to 10 equivalents of a compound represented by the formula [IV-7] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [IV-4].

Here, the inert solvent may, for example, be a
25 halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, an alcohol such as methyl


10070804 031103

alcohol or ethyl alcohol, a hydrocarbon such as n-hexane, benzene, toluene or xylene, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a pyridine such as pyridine, or water.

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 4



In the formulae, R¹, R², R³, R⁷, R⁸, Z and Ar have the same meanings as defined above, respectively.

10070804-031102
ACCEPTED

Namely, in step (4-1), 1 equivalent of a compound represented by the formula [IV-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [V-1] in an inert solvent in the presence or
5 absence of from 1 to 10 equivalents of a base, or 1 equivalent of a compound represented by the formula [IV-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [V-2] in an inert solvent in the presence of from 1 to 10 equivalents of a condensing
10 agent (such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride or 1,1'-carbonylbis-1H-imidazole), to obtain the desired compound of the present invention represented by the formula [V].


Here, the inert solvent may, for example, be a
15 halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or an aprotic polar solvent such as acetonitrile, N,N-
20 dimethylformamide or dimethylsulfoxide.

The base may, for example, be an inorganic base such as potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide, or an organic base such
25 as pyridine or triethylamine.

Each reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 5



In the formulae, R^1 , R^2 , R^3 , R^7 , R^8 , Z and Ar have the same meanings as defined above, respectively.


Namely, in step (5-1), 1 equivalent of the compound of the present invention represented by the formula [V] is reacted with from 0.3 to 10 equivalents of diphosphorus pentasulfide or a Lawson reagent in an inert solvent, to obtain the desired compound of the present invention represented by the formula [VI].

Here, the inert solvent may, for example, be a hydrocarbon such as n-hexane, benzene, toluene or xylene, or a pyridine such as pyridine.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux

temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 6



In the formulae, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^{6a} , R^7 , R^8 , Ar and L^1 have the same meanings as defined above, respectively.

Namely, in step (6-1), 1 equivalent of a compound of

the formula [IV-4] is reacted with from 0.5 to 5 equivalents of a compound represented by the formula [VII-1] or a compound represented by the formula [VII-2] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the desired compound of the present invention represented by the formula [VII-3].

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide..

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, an alcohol such as methyl alcohol, isopropyl alcohol or ethyl alcohol, a hydrocarbon such as n-hexane, benzene, toluene or xylene, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed

in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (6-2), 1 equivalent of the compound of the present invention represented by the formula [VII-3] is reacted with from 1 to 10 equivalents of a compound represented by the formula [VII-4] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the desired product of the present invention represented by the formula [VII].

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

The reaction may be carried out in a nitrogen

stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

In step (6-3), 1 equivalent of a compound represented by the formula [IV-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [VII-5] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [VII-6].

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, an alcohol such as methyl alcohol or ethyl alcohol, a hydrocarbon such as n-hexane, benzene, toluene or xylene, an aprotic polar solvent such

as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried
5 out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and
10 may be purified by distillation or column chromatography, as the case requires.

Then, in step (6-4), step (6-5) and step (6-6), 1 equivalent of a compound represented by the formula [VII-6] is reacted with from 1 to 10 equivalents of a compound
15 represented by the formula [VII-7], a compound represented by the formula [VII-8] and a compound represented by the formula [VII-9] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the compound of the present invention
20 represented by the formula [VII], a compound represented by the formula [VII'] and a compound represented by the formula [VII''].


The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-
25 undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium

2025 RELEASE UNDER E.O. 14176

hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 7

15 In the formulae, R^1 , R^2 , R^7 , R^8 , Z and Ar have the same meanings as defined above, respectively, and R^{13a} is a $\text{C}_1\text{-C}_6$ alkyl group.

20 Namely, in step (7-1), 1 equivalent of a compound represented by the formula [VIII-1] is reacted with from 1 to 10 equivalents of paraformaldehyde in an inert solvent (depending upon the conditions, using a Dean Stark or adding a catalyst), to obtain a compound represented by the formula [VIII-2].

Here, the inert solvent may, for example, be a hydrocarbon such as n-hexane, benzene, toluene or xylene.

25 The catalyst may, for example, be an organic base such as triethylamine.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be
5 isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (7-2), 1 equivalent of the compound represented by the formula [VIII-2] is reacted with from
10 1 to 10 equivalents of a compound represented by the formula [V-1] in an inert solvent, to obtain a compound represented by the formula [VIII-3].

Here, the inert solvent may, for example, be a hydrocarbon such as n-hexane, benzene, toluene or xylene.

15 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon
20 the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Further, in step (7-3), 1 equivalent of the compound
25 of the formula [VIII-3] is reacted with from 1 to 4 equivalents of a compound represented by the formula [VIII-4] in an inert solvent in the presence or absence

10070804-031102
"0070804-031102"


of from 1 to 10 equivalents of a base, to obtain the compound of the present invention, represented by the formula [VIII].

Here, the inert solvent may, for example, be a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The base may, for example, be an inorganic base such as potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide, or an organic base such as pyridine or triethylamine.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

20 Process 8



In the formulae, R^1 , R^2 , R^3 , R^7 , R^8 and Ar have the

same meanings as defined above, respectively.

Namely, in step (8-1), 1 equivalent of a compound represented by the formula [IV-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [IX-1] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the desired compound of the present invention represented by the formula [IX].


The base may, for example, be an inorganic base such as potassium carbonate, sodium carbonate, potassium hydrogencarbonate, sodium hydrogencarbonate, sodium hydroxide or potassium hydroxide, or an organic base such as pyridine or triethylamine.

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and

may be purified by distillation or column chromatography, as the case requires.

Process 9



In the formulae, R^1 , R^7 , R^8 and L^1 have the same meanings as defined above, respectively, and each of R^{21} and R^{22} is a hydrogen atom or a C_1 - C_6 alkyl group, R^{23} is a C_1 - C_6 alkoxy group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_1 - C_6 alkylthio group, a cyano group or NR^9R^{10} , and R^9 and R^{10} have the same meanings as defined above, respectively.

15 Namely, in step (9-1), 1 equivalent of a compound represented by the formula [X-1] is halogenated with from 1 to 10 equivalents of a chlorinating agent (such as sulfuryl chloride, N-chlorosuccinimide or chlorine) in an inert solvent, to obtain a compound represented by the
20 formula [X-2].

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as chloroform or dichloromethane, an ether such as diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-
25 hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen atmosphere, as the case requires. The reaction is

carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be
5 isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (9-2), 1 equivalent of the compound represented by the formula [X-2] is reacted with from 1
10 to 10 equivalents of a compound represented by the formula [X-3] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [X-4].

The base may, for example, be sodium hydride,
15 pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-
20 butoxide.


Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-
25 hexane, benzene, toluene or xylene or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

10070804-03110

out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Process 10



In the formulae, $R^2, R^3, R^7, R^8, R^9, R^{10}, W, L^1$ and Ar

have the same meanings as defined above, respectively,
R^{13b} is a C₁-C₆ alkyl group, or a C₁-C₄ saturated carbon
chain, two of which may be bonded to each other, R^{13c} is a
C₁-C₆ alkyl group, each of R¹⁴ and R¹⁵ is a hydrogen atom,
5 a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl
group or a C₃-C₆ cycloalkyl group, and s is 0 or 1.

Namely, in step (10-1), 1 equivalent of a compound
represented by the formula [XI-1] is reacted with from
0.9 to 20 equivalents of an acid such as hydrochloric
10 acid or sulfuric acid in an inert solvent, to obtain the
desired compound of the present invention represented by
the formula [XI-2].

Here, the inert solvent may, for example, be an
alcohol such as ethyl alcohol, isopropyl alcohol or
15 methyl alcohol, a ketone such as acetone or methyl ethyl
ketone, water, or a mixed solution thereof.

The reaction may be carried out in a nitrogen stream
as the case requires. The reaction is carried out at an
optional temperature from -10°C to the reflux temperature
20 in the reaction system and will be completed in from 1 to
24 hours, although it varies depending upon the compound.
The desired product can be isolated from the reaction
solution by a usual method and may be purified by
distillation or column chromatography, as the case
25 requires.

Then, in step (10-2), 1 equivalent of the compound
of the present invention represented by the formula [XI-

2] is reacted with from 1 to 10 equivalents of hydroxylamine hydrochloride in an inert solvent in the presence of sodium acetate, potassium acetate, sodium carbonate or potassium carbonate, to obtain the desired compound of the present invention represented by the formula [XI-3].

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide, or a diethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (10-3), 1 equivalent of a compound represented by the formula [XI-3] is reacted with from 1 to 10 equivalents of a dehydrating agent in an inert solvent, to obtain the compound of the present invention

represented by the formula [XI-4].

The dehydrating agent may, for example, be 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,1'-carbonyldiimidazole, thionyl chloride, phosphorus
5 pentachloride, methanesulfonyl chloride, diphosgene, p-toluene sulfonyl chloride, or acetic anhydride.

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as dichloromethane, chloroform or carbon tetrachloride, an alcohol such as
10 ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

15 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies
20 depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (10-4), 1 equivalent of the compound
25 of the present invention represented by the formula [XI-4] is reacted with from 1 to 10 equivalents of a compound represented by the formula [XI-5] and with of from 1 to

10 equivalents of an alkyl lithium such as methyl lithium, ethyl lithium or n-butyllithium, or magnesium in an inert solvent, to obtain a compound represented by the formula [XI-6].

5 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies
10 depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Here, the inert solvent may, for example be an ether
15 such as diethyl ether, tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

Further, in step (10-5), 1 equivalent of the compound of the present invention represented by the
20 formula [XI-9] is reacted with from 0.9 to 20 equivalents of an acid such as hydrochloric acid or sulfuric acid in an inert solvent, to obtain the desired compound of the present invention represented by the formula [XI-6].

Here, the inert solvent may, for example, be an
25 alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, a ketone such as acetone or methyl ethyl ketone, water, or a mixed solution thereof.

20070804-031102

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (10-6), 1 equivalent of the compound of the present invention represented by the formula [XI-6] is reacted with from 1 to 10 equivalents of a compound represented by the formula [XI-7] in an inert solvent in the presence of 1 to 10 equivalents of sodium acetate, potassium acetate, sodium carbonate or potassium carbonate, to obtain the desired compound of the present invention represented by the formula [XI-8].

Here, the inert solvent may, for example be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried

out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Then, in step (10-7), 1 equivalent of the compound of the present invention represented by the formula [XI-2] is reacted with from 1 to 10 equivalents of an oxidizing agent such as potassium permanganate, peracetic acid, hydrogen peroxide, m-chloroperbenzoic acid or sodium hypochlorite in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base such as sodium hydroxide or potassium hydroxide, to obtain the desired compound of the present invention represented by the formula [XI-10].

Here, the inert solvent may, for example, be a ketone such as acetone or methyl ethyl ketone, an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, water or a mixed solution thereof.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies

depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

5 Then, in step (10-8), 1 equivalent of the compound of the present invention represented by the formula [XI-10] is reacted with from 1 to 50 equivalents of a compound represented by the formula [XI-11] in an inert solvent or without using any solvent in the presence of
10 e.g. sulfuric acid or p-toluene sulfonic acid, to obtain the desired compound of the present invention represented by the formula [XI-12].

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or
15 methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

20 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies
25 depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography,

10070804-031103

as the case requires.

In step (10-9), 1 equivalent of the compound of the present invention represented by the formula [XI-10] is reacted with from 1 to 10 equivalents of a chlorinating agent such as thionyl chloride in an inert solvent, to
5 obtain a compound represented by the formula [XI-13].

Here, the inert solvent may, for example, be a halogenated hydrocarbon such as dichloromethane, chloroform or carbon tetrachloride, an ether such as
10 diethyl ether, tetrahydrofuran or dioxane, or a hydrocarbon such as n-hexane, benzene, toluene or xylene.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to
15 the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography,
20 as the case requires.

Then, in step (10-10), 1 equivalent of the compound represented by the formula [XI-13] is reacted with from 1 to 3 equivalents of a compound represented by the formula [XI-11] in an inert solvent in the presence or absence of
25 from 1 to 6 equivalents of a base, to obtain the desired compound of the present invention represented by the formula [XI-12].

10070804.031102

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Further, in step (10-11), 1 equivalent of the compound of the present invention represented by the formula [XI-10] is reacted with from 1 to 3 equivalents

of a compound represented by the formula [XI-15] in an inert solvent in the presence or absence of from 1 to 6 equivalents of a base by using a peptidizing agent such as 1,1'-carbonylbis-1H-imidazole or N,N'-

5 dicyclohexylcarbodiimide, to obtain the desired compound of the present invention represented by the formula [XI-14].

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-

10 undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

15 Here, the inert solvent may, for example, be a halogenated hydrocarbon such as dichloromethane, chloroform or carbon tetrachloride, an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, 20 an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen 25 stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be

completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.


In step (10-12), 1 equivalent of the compound represented by the formula [XI-13] is reacted with from 1 to 3 equivalents of a compound represented by the formula [XI-15] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the desired compound of the present invention represented by the formula [XI-14].

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from room temperature to the reflux temperature in the reaction system and will be completed in from 1 to 100 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

10 Process 11



20

In the formulae, R^1 , R^2 , R^7 , R^8 , Q and Ar have the same meanings as defined above, respectively, Ms is a methanesulfonyl group, p is 2, 3 or 4, and q is 1 or 0.

Namely, in steps (11-1) and (11-2), 1 equivalent of a compound represented by the formula [IV-1] or a compound represented by the formula [IV-2] is reacted with from 0.9 to 3 equivalents of a compound represented

25

by the formula [XII-1] in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [XII-2].

5 The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium
10 hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether,
15 tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

20 The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon
25 the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the

case requires.

Then, in step (11-3), 1 equivalent of the compound represented by the formula [XII-2] is reacted with from 1 to 10 equivalents of phosgene or thiophosgene in an inert solvent in the presence or absence of from 1 to 10 equivalents of a base, to obtain the desired compound of the present invention, as represented by the formula [XII].


The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-butoxide.

Here, the inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, a halogenated hydrocarbon such as dichloromethane, chloroform or carbon tetrachloride, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be

purified by distillation or column chromatography, as the case requires.

Process 12



In the formulae, R^{1a} is a hydrogen atom, a C_1 - C_6 alkyl group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_1 - C_6 alkoxy C_1 - C_6 alkyl group, a C_3 - C_6 cycloalkyl group, a phenyl group or a C_1 - C_4 haloalkyl group, R^{16} is a hydrogen atom, a C_1 - C_6 alkyl group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_1 - C_6 alkoxy C_1 - C_6 alkyl group, a C_3 - C_6 cycloalkyl group or a phenyl group, Y is an oxygen atom, a sulfur atom or NR^9 , R^9 has the same meaning as defined above, and r is 1 or 2.

Namely, in step (12-1), 1 equivalent of a compound represented by the formula [XIII-1] is reacted with from 1 to 10 equivalents of N-methylformanilide or N,N-dimethylformamide and from 1 to 20 equivalents of phosphorus oxychloride in an inert solvent or without using any solvent, to obtain a compound represented by the formula [XIII-2].

Here, the inert solvent may, for example, be an ether such as diethyl ether, tetrahydrofuran or dioxane, a halogenated hydrocarbon such as dichloromethane, chloroform, carbon tetrachloride, chlorobenzene or
5 dichlorobenzene, a hydrocarbon such as n-hexane, benzene, toluene or xylene, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux
10 temperature in the reaction system and will be completed in from 1 to 24 hours, although it depends upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case
15 requires.

Then, in step (12-2), 1 equivalent of the compound represented by the formula [XIII-2] is reacted with from 1 to 3 equivalents of a compound represented by the formula [XIII-3] in an inert solvent in the presence or
20 absence of from 1 to 10 equivalents of a base, to obtain a compound represented by the formula [XIII-4].

The base may, for example, be sodium hydride, pyridine, triethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, sodium hydroxide, potassium hydroxide, calcium
25 hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium methoxide or potassium tert-

butoxide.

Here, the solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Further, in step (12-3), 1 equivalent of the compound represented by the formula [XIII-2] is subjected to hydrogenation and reacted in an inert solvent by using from 1 to 8 equivalents of manganese oxide and from 0.01 to 4 equivalents of a catalyst such as palladium carbon or Raney Nickel, to obtain a compound represented by the formula [XIII-5].

Here, the inert solvent may, for example, be an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether,

tetrahydrofuran or dioxane, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine or water.

The reaction is carried out at an optional
5 temperature from -10°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by
10 distillation or column chromatography, as the case requires.

Then, in step (12-4), 1 equivalent of the compound represented by the formula [XIII-5] is subjected to an oxidation reaction in an inert solvent by using from 1 to
15 10 equivalents of oxalyl chloride, from 1 to 10 equivalents of dimethylsulfoxide and from 1 to 10 equivalents of triethylamine or the like, to obtain a compound represented by the formula [XIII-6].

Here, the inert solvent may, for example, be a
20 halogenated hydrocarbon such as dichloromethane, chloroform or carbon tetrachloride, an alcohol such as ethyl alcohol, isopropyl alcohol or methyl alcohol, an ether such as diethyl ether, tetrahydrofuran or dioxane, an aprotic polar solvent such as acetonitrile, N,N-
25 dimethylformamide or dimethylsulfoxide, a hydrocarbon such as n-hexane, benzene, toluene or xylene, a pyridine such as pyridine, or water.

The reaction may be carried out in a nitrogen stream, as the case requires. The reaction is carried out at an optional temperature from -80°C to the reflux temperature in the reaction system and will be completed in from 1 to 24 hours, although it varies depending upon the compound. The desired product can be isolated from the reaction solution by a usual method and may be purified by distillation or column chromatography, as the case requires.

Now, the processes for production, a formulation method and the application of the compound of the present invention will be described in detail with reference to Examples. Further, the processes for production of intermediates in the synthesis of the compound of the present invention will also be described.

PREPARATION EXAMPLE 1

Preparation of N-methyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]phenylacetamide (compound No. 1-8 of the present invention)

6g (26 mmol) of 4-trifluoromethyl-5-[1-(N-methylamino)-2-methylpropyl]pyrimidine and 3.6g (26 mmol) of potassium carbonate were dissolved in 150 ml of acetonitrile, and 4g (26 mmol) of phenylacetyl chloride was dropwise added, followed by stirring at room temperature for 3 hours. To the reaction solution, 200 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with

water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the obtained crude crystals were washed with n-hexane to obtain 7.7g (yield: 85%) of N-methyl-N-[2-methyl-1-(4-
5 trifluoromethylpyrimidin-5-yl)propyl]phenylacetamide as colorless transparent crystals (melting point: 106-109°C).

PREPARATION EXAMPLE 2

Preparation of N-methyl-N-[2-methyl-1-(4-
10 trifluoromethylpyrimidin-5-yl)propyl]-2-pyridylacetamide (compound No. 2-3 of the present invention)

0.3g (1.7 mmol) of 2-pyrimidinylacetate hydrochloride and 0.18g (1.8 mmol) of triethylamine were dissolved in 30 ml of tetrahydrofuran, and 0.28g (1.7
15 mmol) of 1,1'-carbonylbis-1H-imidazole was added, followed by stirring at room temperature for 1 hour. Then, 0.4g (1.7 mmol) of 4-trifluoromethyl-5-[1-(N-methylamino)-2-methylpropyl]pyrimidine was added, followed by heating and refluxing for further 3 hours.
20 To the reaction solution, 100 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the obtained crude
25 product was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate:methanol=4.5:4.5:1) to obtain 0.2g (yield: 33%)

of N-methyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]-2-pyridylacetamide as colorless transparent crystals (melting point: 99-100°C).

PREPARATION EXAMPLE 3

- 5 Preparation of N-methyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]phenylthioacetamide (compound No. 1-142 of the present invention)

0.45g (1.3 mmol) of N-methyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]phenylthioacetamide
10 and 0.52g (1.3 mmol) of a Lawson reagent were dissolved in 30 ml of toluene, followed by heating and refluxing for 30 hours. To the reaction solution, 100 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then
15 dried with anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=3:1) to obtain 0.12g (yield: 26%) of N-methyl-N-
20 [2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]phenylthioacetamide as slightly yellow crystals (melting point: 93-94°C).

PREPARATION EXAMPLE 4

- Preparation of N-methoxymethyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]-4-
25 chlorophenylacetamide (compound No. 1-105 of the present invention)

1.0g (4.6 mmol) of 4-trifluoromethyl-5-[1-amino-2-methylpropyl]pyrimidine, 0.23g (6.9 mmol) of paraformaldehyde and 0.1g (9.9 mmol) of triethylamine were dissolved in 50 ml of toluene. Heating and refluxing were carried out for 1 hour while removing water from the reaction system by means of Dean's Stark. The reaction solution was returned to room temperature, and 0.86g (4.6 mmol) of 4-chlorophenylacetylchloride was dropwise added, followed by stirring for further 2 hours. To this solution, 10 ml of a toluene solution containing 0.2g (6.2 mmol) of methanol and 0.5g (4.9 mmol) of triethylamine, was dropwise added, followed by stirring at room temperature for 1 hour. To the reaction solution, 100 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=3:1) to obtain 0.5g (yield: 26%) of N-methoxymethyl-N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)propyl]-4-chlorophenylacetamide as colorless transparent crystals (melting point: 142-145°C).

PREPARATION EXAMPLE 5

Preparation of N-methyl-N-[2-methyl-1-(4-chlorodifluoromethylpyrimidin-5-yl)propyl]-N'-(4-

methylphenyl)urea (compound No. 1-37 of the present invention)

0.50g (2.1 mmol) of 4-chlorodifluoromethyl-5-[1-(N-methylamino)-2-methylpropyl]pyrimidine and 0.28g (2.1
5 mmol) of 4-methylphenyl isocyanate were dissolved in 30 ml of isopropyl ether, followed by stirring at room temperature for 1 hour. Precipitated crystals were collected by filtration to obtain 0.65g (yield: 84%) of
10 N-methyl-N-[2-methyl-1-(4-chlorodifluoromethylpyrimidin-5-yl)propyl]-N'-(4-methylphenyl)urea as colorless transparent crystals (melting point: 135-137°C).

PREPARATION EXAMPLE 6

Preparation of 1,3-dimethyl-1-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-3-phenylurea
15 (compound No. 1-424 of the present invention)

0.8g (3.4 mmol) of 4-trifluoromethyl-5-[1-(N-methylamino)-2-methylpropyl]pyridine was dissolved in 30 ml of chloroform, and 5 ml of a chloroform solution of 0.45g (3.8 mmol) of phenyl isocyanate was dropwise added,
20 followed by stirring at room temperature for 10 hours. To the reaction solution, 50 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled
25 off under reduced pressure, and the obtained crude crystals were washed with n-hexane to obtain 1.0g (yield: 83%) of 1-methyl-1-[2-methyl-1-(4-trifluoromethyl-

10070804-031102

pyrimidin-5-yl)-propyl]-3-phenylurea. 0.5g (1.4 mmol) of the obtained 1-methyl-1-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-3-phenylurea was dissolved in 30 ml of tetrahydrofuran, and 0.06g (2.5 mmol) of sodium hydride was added, followed by stirring at room temperature for 0.5 hour. Then, 0.22g (1.6 mmol) of methyl iodide was dropwise added, followed by stirring at room temperature for 4 hours. To the reaction solution, 50 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the obtained crude product was purified by silica gel chromatography (developing solvent/n-hexane:ethyl acetate 9:1 to 3:1) to obtain 0.28g (yield: 53.8%) of 1,3-dimethyl-1-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-3-phenylurea as colorless crystals (melting point: 104-105°C).

PREPARATION EXAMPLE 7

Preparation of N-[1-(4-ethyl-pyrimidin-5-yl)-2-methylpropyl]-4-fluoro-N-methyl-benzenesulfonamide (compound No. 4-3 of the present invention)

0.4g (0.2 mmol) of [1-(4-ethyl-pyrimidin-5-yl)-propyl]-methyl-amine was dissolved in 20 ml of pyridine, and 0.43g (0.22 mmol) of p-fluorobenzenesulfonyl chloride was dropwise added, followed by stirring at room temperature for 10 hours. To the reaction solution, 50

ml of water was added, followed by extraction with diethyl ether. The obtained organic phase was washed twice with 30 ml of a dilute citric acid aqueous solution and then dried over anhydrous magnesium sulfate. Diethyl
5 ether was distilled off under reduced pressure, and the obtained crude product was purified by silica gel chromatography (developing solvent/n-hexane:ethyl acetate 4:1 to 1:1) to obtain 0.4g (yield: 56%) of (N-[1-(4-ethyl-pyrimidin-5-yl)-2-methylpropyl]-4-fluoro-N-methyl-
10 benzenesulfonamide as a colorless oil ($n_D^{20}=1.5399$).

PREPARATION EXAMPLE 8

Preparation of 1-(4-chlorobenzyl)-1,3-dimethyl-3-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-urea (compound No. 1-532 of the present invention)

15 0.16g (1.0 mmol) of (4-chlorobenzyl)-methylamine was dissolved in 30 ml of pyridine, and 0.3g (1.0 mmol) of N-methyl-N-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-carbamoyl chloride was dropwise added, followed by stirring at room temperature for 10 hours. To the
20 reaction solution, 50 ml of water was added, followed by extraction with diethyl ether. The obtained organic phase was washed twice with 30 ml of a dilute citric acid aqueous solution, followed by drying over anhydrous magnesium sulfate. Diethyl ether was distilled off under
25 reduced pressure, and the obtained crude product was purified by silica gel chromatography (developing solvent/n-hexane:ethyl acetate=8:1 to 3:1) to obtain

0.22g (yield: 52%) of 1-(4-chlorobenzyl)-1,3-dimethyl-3-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-urea as colorless crystals (melting point: 95-98°C).

PREPARATION EXAMPLE 9

- 5 Preparation of N-[1-(4-diethoxymethylpyrimidin-5-yl)-2-methylpropyl]-N-methyl-2-phenyl acetamide (compound No. 1-453 of the present invention)

8.3g (0.031 mol) of [1-(4-diethoxymethylpyrimidin-5-yl)-2-methylpropyl]methylamine and 6.4g (46 mmol) of
10 potassium carbonate were added to 100 ml of acetonitrile, and then 5.8g (0.038 mol) of phenylacetyl chloride was dropwise added at room temperature and reacted for 2 hours. After completion of the reaction, the product was poured into water and extracted with ethyl acetate. The
15 organic layer was washed with an aqueous citric acid solution, water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:5 to ethyl
20 acetate), to obtain 8.4g (yield: 70%) of N-[1-(4-diethoxymethylpyrimidin-5-yl)-2-methylpropyl]-N-methyl-2-phenyl acetamide as colorless viscous liquid ($n_D^{20}=1.5253$).

PREPARATION EXAMPLE 10

- 25 Preparation of N-[1-(4-formylpyrimidin-5-yl)-2-methylpropyl]-N-methyl-4-fluorophenylacetamide (compound No. 1-523 of the present invention)

8.4g (2.1 mmol) of N-[1-(4-diethoxymethylpyrimidin-5-yl)-2-methylpropyl]-N-methyl-4-fluorophenylacetamide was dissolved in 100 ml of acetone, and 13 ml of 6N hydrochloric acid was added and reacted at room temperature for 5 hours. After completion of the reaction, the reaction solution was concentrated, and an aqueous sodium hydrogencarbonate solution was added to alkaline, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous citric acid solution, water and an aqueous sodium chloride solution, in this order, dried and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:5 to ethyl acetate) to obtain 5.3g (yield: 77%) of N-[1-(4-formylpyrimidin-5-yl)-2-methylpropyl]-N-methyl-4-fluorophenylacetamide as colorless viscous liquid ($n_D^{20}=1.5466$).

PREPARATION EXAMPLE 11

Preparation of N-[1-(4-hydroxyiminomethylpyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide (compound No. 1-500 of the present invention)

1.0g (3.2 mmol) of N-[1-(4-formylpyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide was dissolved in 30 ml of methanol, and 0.45g (6.5 mmol) of hydroxylamine hydrochloride and 0.63g (6.4 mmol) of potassium acetate were added and reacted at room temperature for 1 hour. After completion of the reaction, the product was poured

into water and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium hydrogencarbonate solution, an aqueous citric acid solution, water and an aqueous sodium chloride solution, in this order, dried and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1 to ethyl acetate) to obtain 0.45g (yield: 43%) of N-[1-(4-hydroxyiminomethylpyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide as colorless crystals (melting point: 171-172°C).

PREPARATION EXAMPLE 12

Preparation of N-[1-(4-cyanopyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide (compound No. 1-504 of the present invention)

0.25g (0.77 mmol) of N-[1-(4-hydroxyiminomethylpyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide was dissolved in 30 ml of chloroform, and 0.16g (0.83 mmol) of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride was added and reacted at room temperature for 8 hours. After completion of the reaction, the solvent was distilled off, and water was added, followed by extraction with ethyl acetate. The organic layer was washed with water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1 to ethyl

acetate) to obtain 0.19g (yield: 88%) of N-[1-(4-cyanopyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide as colorless crystals (melting point: 80-81°C).

5 PREPARATION EXAMPLE 13

Preparation of 2-(4-chlorophenyl)-N-[1-(4,6-dimethoxypyrimidin-5-yl)-2-methylpropyl]-N-methylacetamide (compound No. 3-41 of the present invention)

0.80g (3.8 mmol) of 1-(4,6-dimethoxypyrimidin-5-yl)-
10 2-methylpropylamine, 0.59g (4.2 mmol) of methyl iodide
and 0.46g (4.6 mmol) of triethylamine were added to 10 ml
of N,N-dimethylacetamide and reacted at 80°C for 1 hour.
After completion of the reaction, the product was poured
into water and extracted with toluene. The organic layer
15 was washed with water and an aqueous sodium chloride
solution in this order, dried and concentrated, and the
obtained oily product was supplied to the subsequent
reaction without purification. 0.20g (0.89 mmol) of this
oily product and 0.22g (1.6 mmol) of potassium carbonate
20 were added to 20 ml of acetonitrile, and then 0.30g (1.6
mmol) of 4-chlorophenylacetyl chloride was added at room
temperature and reacted overnight. After completion of
the reaction, the product was poured into water and
extracted with ethyl acetate. The organic layer was
25 washed with an aqueous citric acid solution, water and an
aqueous sodium chloride solution in this order, dried and
concentrated, and the obtained oily product was purified

10070804-034102

by preparative HPLC (ethyl acetate:n-hexane=1:1) to obtain 0.21g (yield: 15%, 2 steps) of 2-(4-chlorophenyl)-N-[1-(4,6-dimethoxypyrimidin-5-yl)-2-methylpropyl]-N-methyl acetamide as colorless crystals (melting point: 107-109°C).

PREPARATION EXAMPLE 14

Preparation of 1-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)-propyl]-3-phenylimidazolin-2-one (compound No. 5-1 of the present invention)

1.05g (4.2 mol) of 5-(1-chloro-2-methylpropyl)-4-trifluoromethylpyrimidine and 0.61 (4.2 mol) of N-phenylethylenediamine were added to 10 ml of isopropyl alcohol, followed by stirring at room temperature for 6 hours. After completion of the reaction, the reaction solution was concentrated, then poured into water and extracted with ethyl acetate, and purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1 to ethyl acetate) to obtain 0.38g of N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)-propyl]-N'-phenylethane-1,2-diamine. Then, 0.38g (1 mmol) of N-[2-methyl-1-(4-trifluoromethylpyrimidin-5-yl)-propyl]-N'-phenylethane-1,2-diamine and 0.5g (5 mmol) of triethylamine were added to 10 ml of dichloromethane, and a dichloromethane solution containing 0.2g (2 mmol) of phosgene was dropwise added under cooling with ice. After the dropwise addition, stirring was further continued at room temperature for 1 hour to terminate the reaction. After

termination of the reaction, the product was poured into water, washed with an aqueous sodium hydrogencarbonate solution, dried and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1 to ethyl acetate) to obtain 0.25g (yield: 61%) of 1-[2-methyl-1-(4-trifluoromethyl-pyrimidin-5-yl)-propyl]-3-phenylimidazolin-2-one as colorless crystals (melting point: 126-128°C).

PREPARATION EXAMPLE 15

- 10 Preparation of 5-(1-{{2-(4-chlorophenyl)-propionyl}methylamino}-2-methylpropyl)-pyrimidine-4-carboxylic acid (compound No. 1-718 of the present invention)

A solution comprising 1.0g (3.2 mmol) of N-[1-(4-formylpyrimidin-5-yl)-2-methylpropyl]-N-methylphenylacetamide and 10 ml of tetrahydrofuran, was added to a solution comprising 0.23g (4.1 mmol) of potassium hydroxide and 10 ml of water. Then, 0.88g (5.56 mmol) of potassium permanganate was further added. Then, the mixture was heated at 80°C for 3 hours. After completion of the reaction, sodium sulfite was added, followed by filtration. The filtrate was acidified with hydrochloric acid and then extracted with ethyl acetate, and the extract was washed with an aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated to obtain a crude product. This crude product was dissolved in a mixed solution of toluene,

ether and acetone, followed by extraction with an aqueous potassium hydroxide solution. Then, extract was acidified with diluted hydrochloric acid and extracted with ethyl acetate. The extract was dried over magnesium sulfate, concentrated and further washed with isopropyl ether to obtain 0.33g (yield: 32%) of 5-(1-([2-(4-chlorophenyl)-propionyl]methylamino)-2-methylpropyl)-pyrimidine-4-carboxylic acid (diastereomer A-isomer) as slightly blown crystals (melting point: 168-170°C).

10 PREPARATION EXAMPLE 16

Preparation of 5-(1-([2-(4-chlorophenyl)-propionyl]methylamino)-2-methylpropyl)-pyrimidine-4-carboxylic acid methyl ester (diastereomer A-isomer) (compound No. 1-592 of the present invention)

15 A few drops of concentrated sulfuric acid were added to a methanol solution of 2.00g (5.32 mmol) of 5-(1-([2-(4-chlorophenyl)-propionyl]methylamino)-2-methylpropyl)-pyrimidine-4-carboxylic acid, followed by heating and refluxing for 5 hours. After completion of the reaction, water was added, followed by extraction with ethyl acetate, and the extract was washed with an aqueous sodium chloride solution, dried over magnesium sulfate and concentrated, and the obtained oily product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1 to ethyl acetate) to obtain 0.59g (yield: 28%) of 5-(1-([2-(4-chlorophenyl)-propionyl]methylamino)-2-methylpropyl)-pyrimidine-4-

carboxylic acid methyl ester (diastereomer A-isomer) as colorless oily product.

Examples for preparation of intermediates

REFERENCE EXAMPLE 1

- 5 Preparation of 3-ethoxymethylene-1,1,1-trifluoro-5-methyl-2,4-hexanedione

A mixture comprising 213g (1.17 mol) of 1,1,1-trifluoro-5-methyl-2,4-hexanedione, 242g (1.64 mol) of ethyl orthoformate and 166g (1.63 mol) of acetic
10 anhydride, was heated and refluxed for 6 hours. The solvent was distilled off under reduced pressure to obtain 146g (yield: 67%) of 3-ethoxymethylene-1,1,1-trifluoro-5-methyl-2,4-hexanedione.

REFERENCE EXAMPLE 2

- 15 Preparation of 5-isopropylcarbonyl-4-trifluoromethylpyrimidine

46g (0.85 mol) of sodium methoxide was dissolved in 700 ml of methanol, and 76g (0.73 mol) of formamidine acetate was added, followed by stirring at room
20 temperature for 15 minutes. Then, 146g (0.61 mol) of 3-ethoxymethylene-1,1,1-trifluoro-5-methyl-2,4-hexanedione was added under cooling with ice, followed by heating and refluxing for further 2 hours. The solvent was distilled off under reduced pressure, and 1,000 ml of ice water was
25 added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate

was distilled off under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=6:1) to obtain 89g (yield: 67%) of 5-

5 isopropylcarbonyl-4-trifluoromethylpyrimidine as slightly yellow liquid.

REFERENCE EXAMPLE 3

Preparation of 5-(1-hydroxy-2-methylpropyl)-4-trifluoromethylpyrimidine

10 25g (115 mmol) of 5-isopropylcarbonyl-4-trifluoromethylpyrimidine was dissolved in 100 ml of ethanol, and under cooling with ice, 6g (69 mmol) of a borane-tert-butylamine complex was added, followed by stirring for 2 hours. Further, 20 ml of acetone was
15 added, followed by stirring for 0.5 hour. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=1:1) to obtain
20 22g (yield: 87%) of 5-(1-hydroxy-2-methylpropyl)-4-trifluoromethylpyrimidine as slightly yellow liquid ($n_D^{20}=1.4481$).

REFERENCE EXAMPLE 4

Preparation of 5-(1-chloro-2-methylpropyl)-4-trifluoromethylpyrimidine

25 22g (100 mmol) of 5-(1-hydroxy-2-methylpropyl)-4-trifluoromethylpyrimidine was dissolved in 150 ml of chloroform, and 25 ml (342 mmol) of thionyl chloride was

added. The reaction mixture was heated and refluxed for 2 hours. The solvent and thionyl chloride was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing

5 solvent/n-hexane:ethyl acetate=6:1) to obtain 11.6g (yield: 49%) of 5-(1-chloro-2-methylpropyl)-4-trifluoromethylpyrimidine as brown liquid (refractive index n_D^{20} : 1.4558).

REFERENCE EXAMPLE 5

10 Preparation of 5-[1-(N-methylamino)-2-methylpropyl]-4-trifluoromethylpyrimidine

4.5g (19 mmol) of 5-(1-chloro-2-methylpropyl)-4-trifluoromethylpyrimidine was dissolved in 50 ml of isopropyl alcohol, and 10 ml (161 mmol) of a 50%
15 methylamine aqueous solution was added, followed by stirring at room temperature for 8 hours. The solvent was distilled off under reduced pressure, and 100 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with
20 water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure to obtain 3.4g (yield: 77%) of 5-[1-(N-methylamino)-2-methylpropyl]-4-trifluoromethylpyrimidine as slightly yellow liquid (refractive index n_D^{20} : 1.4529).

25 REFERENCE EXAMPLE 6

Preparation of 4-ethoxymethylene-2,6-dimethyl-3,5-heptanedione

A mixture comprising 17.2g (110 mmol) of 2,6-dimethyl-3,5-heptanedione, 22.8g (153 mmol) of ethyl orthoformate and 31.5g (309 mmol) of acetic anhydride, was reacted for 2 hours at 110°C. The solvent was
5 distilled off under reduced pressure to obtain 11.5g (yield: 49%) of 4-ethoxymethylene-2,6-dimethyl-3,5-heptanedione.

REFERENCE EXAMPLE 7

Preparation of 5-isopropylcarbonyl-4-isopropylpyrimidine
10 11.5g (60 mmol) of a 28% sodium methoxide solution was dissolved in 100 ml of methanol, and 5.6g (54 mmol) of formamidine acetate was added, followed by stirring at room temperature for 15 minutes. Then, 11.5g (54 mmol) of 4-ethoxymethylene-2,6-dimethyl-3,5-heptanedione was
15 added under cooling with ice. The reaction mixture was further reacted at 50°C for one hour. The solvent was distilled off under reduced pressure, and 200 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then
20 dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=4:1) to obtain 9.2g (yield: 89%) of 5-isopropylcarbonyl-4-isopropylpyrimidine as slightly yellow liquid.
25

REFERENCE EXAMPLE 8

Preparation of 5-(1-hydroxy-2-methylpropyl)-4-

isopropylpyrimidine

9.2g (48 mmol) of 5-isopropylcarbonyl-4-isopropylpyrimidine was dissolved in 50 ml of ethanol, and under cooling with ice, 2.5g (29 mmol) of a borane-tert-butylamine complex was added, followed by stirring for 2 hours. Further, 20 ml of acetone was added, followed by stirring for 0.5 hour. The solvent was distilled off under reduced pressure, and 200 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure to obtain 8.3g (yield: 89%) of the desired product i.e. 5-(1-hydroxy-2-methylpropyl)-4-isopropylpyrimidine.

REFERENCE EXAMPLE 9

Preparation of 5-(1-methylsulfonyloxy-2-methylpropyl)-4-isopropylpyrimidine

8.3g (43 mmol) of 5-(1-hydroxy-2-methylpropyl)-4-isopropylpyrimidine was dissolved in 10 ml of pyridine, and under cooling with ice, 9.8g (86 mmol) of methylsulfonyl chloride was dropwise added. The reaction mixture was reacted at room temperature for 2 hours, and then, 100 ml of ice water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with an aqueous citric acid solution and water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure to

obtain 10.6g (yield: 90%) of 5-(1-methylsulfonyloxy-2-methylpropyl)-4-isopropylpyrimidine.

[¹H-NMR (300MHz, CDCl₃, TMS δ (ppm)) 0.91 (3H, d), 1.14 (3H, d), 1.31 (3H, dd), 2.1-2.2 (1H, m), 2.89 (3H, s), 3.2-3.3 (3H, m), 5.56 (1H, d),
5 8.68 (1H, s), 9.14 (1H, s)]

REFERENCE EXAMPLE 10

Preparation of 5-[1-(N-methylamino)-2-methylpropyl]-4-isopropylpyrimidine

10.6g (39 mmol) of 5-(1-methylsulfonyloxy-2-methylpropyl)-4-isopropylpyrimidine was dissolved in 50 ml of isopropyl alcohol, and 10 ml (129 mmol) of a 40% methylamine aqueous solution was added, followed by stirring at room temperature for 8 hours. After completion of the reaction, the solvent was distilled off under reduced pressure, and 100 ml of water was added, followed by extraction with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (developing solvent=ethyl acetate) to obtain 2.9g (yield: 36%) of 5-[1-(N-methylamino)-2-methylpropyl]-4-isopropylpyrimidine as slightly yellow crystals (melting point: 37-39°C).

REFERENCE EXAMPLE 11

25 Preparation of 5-(1-hydroxy-2-methylpropyl)-4-methylthiopyrimidine

10.6g (52 mmol) of 5-bromo-4-methylthiopyrimidine

was dissolved in 100 ml of tetrahydrofuran, and at -60°C, 36 ml of a n-butyllithium hexane solution (1.6 mol/l) was dropwise added. After stirring at -60°C for 30 minutes, 4.1g (57 mmol) of isobutylaldehyde was dropwise added and
5 further reacted for 1 hour. The reaction solution was poured into water and extracted with ethyl acetate. The obtained organic layer was washed with water and then dried over anhydrous magnesium sulfate. Ethyl acetate was distilled off under reduced pressure, and the residue
10 was purified by silica gel column chromatography (developing solvent/n-hexane:ethyl acetate=3:2) to obtain 2.9g (yield: 28%) of 5-(1-hydroxy-2-methylpropyl)-4-methylthiopyrimidine as slightly yellow crystals (melting point: 123-127°C).

15 REFERENCE EXAMPLE 12

Preparation of 2-bromo-1-(4-ethylpyrimidin-5-yl)-propan-1-one

49.2g (0.30 mol) of 1-(4-ethylpyrimidin-5-yl)propan-1-one was dissolved in 500 ml of carbon tetrachloride,
20 and 53g (0.30 mol) of N-bromosuccinimide and 0.3g of azoisobutyronitrile were added, followed by refluxing for 2 hours. After cooling, crystals were removed by filtration, and the filtrate was concentrated and the obtained oily product was purified by column
25 chromatography (ethyl acetate:n-hexane=1:4 to 1:2) to obtain 64.3g (yield: 89%) of 2-bromo-1-(4-ethylpyrimidin-5-yl)-propan-1-one as yellow liquid.

REFERENCE EXAMPLE 13

Preparation of 1-(4-ethylpyrimidin-5-yl)-2-methylthio-propan-1-one

10.0g (0.041 mol) of 2-bromo-1-(4-ethylpyrimidin-5-yl)propan-1-one was dissolved in 40 ml of isopropyl alcohol, and 21g (0.045 mol) of a 15% sodium methythiolate aqueous solution was added under cooling with ice and then reacted at room temperature for 1 hour. After completion of the reaction, the product was poured into water and extracted with ethyl acetate. The organic layer was washed with an aqueous sodium chloride solution, dried and concentrated to obtain 9.5g of crude 1-(4-ethylpyrimidin-5-yl)-2-methylthio-propan-1-one. The product was used for the subsequent reaction without purification.

REFERENCE EXAMPLE 14

Preparation of 4,6-dichloropyrimidine-5-carboaldehyde

To 65.0g (0.89 mol) of N,N-dimethylformamide, 356g (2.3 mol) of phosphorus oxychloride was added at a temperature of at most 20°C under cooling with ice, followed by stirring at room temperature for 10 minutes. 50.0g (0.45 mol) of 4,6-dihydroxypyrimidine was slowly added under cooling with ice. After completion of the addition, when the temperature-rising was terminated, the mixture was reacted at 90°C for 3 hours. Excess phosphorus oxychloride was distilled off under reduced pressure, and 300 ml of chloroform was added, and the

10070804.034402
mixture was slowly added into ice water. The organic layer was washed with an aqueous sodium hydrogencarbonate solution, water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained
5 crude crystals were washed with n-hexane to obtain 43.8g (yield: 55%) of 4,6-dichloropyrimidine-5-carboaldehyde as brown crystals (melting point: 65-66°C).

REFERENCE EXAMPLE 15

Preparation of 4,6-dimethoxypyrimidine-5-carboaldehyde
10 43.6g (246 mmol) of 4,6-dichloropyrimidine-5-carboaldehyde was dissolved in 200 ml of methanol, and 120g (622 mmol) of 28% sodium methoxide was added under cooling with ice and then reacted for 2 hours at room temperature. After completion of the reaction, the
15 solvent was distilled off, and an aqueous citric acid solution was added, followed by extraction with ethyl acetate. The organic layer was washed with an aqueous sodium hydrogencarbonate solution, an aqueous citric acid solution, water and an aqueous sodium chloride solution
20 in this order, dried and concentrated, and the obtained crude crystals were washed with isopropyl ether to obtain 8.3g (yield: 20%) of 4,6-dimethoxypyrimidine-5-carboaldehyde.

REFERENCE EXAMPLE 16

25 Preparation of 1-(4,6-dimethoxypyrimidin-5-yl)-3-methylbutan-2-ol

0.81g (33 mmol) of magnesium was added to 30 ml of

10070804.034102

tetrahydrofuran, and 4.1g (33 mmol) of 2-bromopropane was added to prepare a tetrahydrofuran solution of isopropyl magnesium bromide. 2.8g (17 mmol) of 4,6-dimethoxypyrimidine-5-carboaldehyde was dissolved in 50 ml of tetrahydrofuran, and the solution was added to the above tetrahydrofuran solution at room temperature and reacted overnight. The reaction solution was poured into an aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with an aqueous citric acid solution, water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained oily product was purified by column chromatography (ethyl acetate:n-hexane=1:4) to obtain 1.9g (yield: 54%) of 1-(4,6-dimethoxy pyrimidin-5-yl)-3-methylbutan-2-ol as slightly yellow crystals.

REFERENCE EXAMPLE 17

Preparation of 5-(2-azide-3-methylbutyl)-4,6-dimethoxypyrimidine

1.05g (5 mmol) of 1-(4,6-dimethoxypyrimidin-5-yl)-3-methylbutan-2-ol was dissolved in 10 ml of toluene, and under cooling with ice, 1.01g (10 mmol) of trimethylsilylazide and 1.42g (10 mmol) of boron trifluoride diethyl ether complex were added sequentially and then reacted for 7 hours at room temperature. After completion of the reaction, the product was poured into water and extracted with toluene. The organic layer was washed with an aqueous sodium hydrogencarbonate solution,

water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained oily product was purified by column chromatography (ethyl acetate:n-hexane=1:9) to obtain 1.22g (yield: 100%) of 5-(2-azide-3-methylbutyl)-4,6-dimethoxypyrimidine as colorless liquid.

[¹H-NMR (300MHz, CDCl₃, TMS δ (ppm)) 0.70 (3H, d), 1.13 (3H, d), 2.44 (1H, m), 4.00 (6H, s), 4.38 (1H, d), 8.39 (1H, s)]

10 REFERENCE EXAMPLE 18

Preparation of 1-(4,6-dimethoxypyrimidin-5-yl)-2-methylpropylamine

1.2g (5.1 mmol) of 5-(2-azide-3-methylbutyl)-4,6-dimethoxypyrimidine was dissolved in 20 ml of methanol, and under cooling with ice, 1.5g (0.062 mol) of magnesium was added and reacted overnight. After completion of the reaction, the solvent was distilled off, and ether was added. Insolubles were filtered off, followed by extraction with diluted hydrochloric acid. An aqueous sodium hydroxide solution was added to alkaline, followed by extraction with toluene. The organic layer was washed with water and an aqueous sodium chloride solution in this order, dried and concentrated, and the obtained oily product was purified by column chromatography (ethyl acetate:n-hexane=1:1) to obtain 0.80g (yield: 75%) of 1-(4,6-dimethoxypyrimidin-5-yl)-2-methylpropylamine as colorless crystals.

10070804, 034102

[¹H-NMR (300 MHz, CDCl₃, TMS δ (ppm)) 0.70 (3 H, d), 1.07 (3 H, d), 1.71 (2 H, s), 2.02 (1 H, m), 3.78 (1 H, d), 3.97 (6 H, s), 8.33 (1 H, s)]

Now, the physical properties (¹H-NMR values
5 (CDCl₃/TMS δ (ppm)) of the compounds of the present
invention prepared in accordance with the methods
disclosed in processes 1 to 12, will be shown in Tables
40 to 43.

10070804.031103

Table 40

Compound No.	NMR (δ (ppm), 300MHz, TMS- CDCl_3)
1-016	0. 81 (3H, d) 、1. 01 (3H, d) 、2. 75-2. 87 (1 H, m) 、2. 90 (1H, s) 、3. 60 (2H, dd) 、3. 78 (3 H, s) 、5. 44 (1H, d) 、6. 83 (2H, d) 、7. 11 (2 H, d) 、9. 23 (1H, s) 、9. 25 (1H, s)
1-034	0. 29-0. 32 (1H, m) 、0. 75-0. 77 (3H, m) 、1. 48-1. 60 (1H, m) 、2. 99 (3H, s) 、3. 70 (2H, s) 、4. 84 (1H, d) 、7. 17-7. 33 (5H, m) 、9. 25 (1H, s) 、9. 31 (1H, s)
1-195	0. 76-0. 81 (3H, t, 3H, t) 、0. 91-0. 98 (3 H, t, 3H, t) 、1. 36-1. 41 (3H, d, 3H, d) 、2. 64-2. 90 (1H, m, 1H, m) 、2. 75 (3H, s) 、2. 85 (3H, s) 、3. 69-3. 80 (1H, q, 1H, q) 、5. 13 (1 H, d) 、5. 51 (1H, d) 、7. 17-7. 31 (5H, m, 5H, m) 、9. 22 (1H, s) 、9. 23 (1H, s) 、9. 27 (1H, s) 、9. 30 (1H, s) 、mixture of diastereoisomers
1-329	0. 80 (3H, d) 、1. 07 (3H, d) 、1. 45 (3H, s) 、1. 50 (3H, s) 、2. 39 (3H, s) 、2. 67-2. 80 (1 H, m) 、5. 58 (1H, d) 、7. 08 (2H, d) 、7. 25 (2 H, d) 、9. 15 (1H, s) 、9. 27 (1H, s)
1-488	2. 76 (3H, s) 、2. 88 (3H, s) 、3. 70 (3H, s) 、3. 72 (3H, s) 、3. 77 (2H, s) 、3. 79 (2H, s) 、7. 36-7. 73 (9H, m, 9H, m) 、8. 57 (1H, s) 、8. 61 (1H, s) 、9. 25 (1H, s) 、9. 27 (1H, s) 、mixture of diastereoisomers
1-490	2. 76 (3H, s) 、2. 88 (3H, s) 、3. 70 (3H, s) 、3. 72 (3H, s) 、3. 77 (2H, s) 、3. 79 (2H, s) 、6. 70-7. 40 (8H, m, 8H, m) 、8. 55 (1H, s) 、8. 60 (1H, s) 、9. 25 (1H, s) 、9. 27 (1H, s) 、mixture of diastereoisomers
1-526	0. 89 (3H, d) 、0. 98 (3H, d) 、2. 48-2. 60 (1 H, m) 、2. 68 (3H, s) 、2. 92 (3H, s) 、3. 63 (2 H, s) 、5. 38 (1H, d) 、7. 05-7. 28 (5H, m) 、8. 94 (1H, s) 、9. 13 (1H, s)

2025040904001

Table 41

Compound No.	NMR (δ (ppm), 300MHz, TMS-CDCl ₃)
1-562	0. 79 (3H, d), 0. 89 (3H, d), 0. 89 (3H, d), 1. 12 (3H, t), 1. 16 (3H, d), 1. 29 (3H, t), 1. 25 (3H, d), 1. 52 (3H, d), 1. 88 (1H, t), 2. 27 (1H, t), 2. 04-2. 94 (3H, m, 3H, m), 3. 44-3. 56 (1H, m, 1H, m), 3. 69-3. 81 (2H, m), 3. 90-4. 00 (2H, m), 5. 77 (2H, d, 2H, d), 7. 19-7. 35 (5H, m, 5H, m), 8. 59 (1H, s), 8. 61 (1H, s), 9. 00 (1H, s), 9. 08 (1H, s), mixture of diastereoisomers
1-592	0. 90 (3H, d), 1. 01 (3H, d), 1. 36 (3H, d), 2. 53-2. 65 (1H, m), 2. 73 (3H, s), 3. 78 (1H, q), 4. 01 (3H, s), 5. 70 (1H, d), 6. 99 (2H, d), 7. 18 (2H, d), 8. 89 (1H, s), 9. 16 (1H, s)
1-593	0. 80 (3H, d), 0. 92 (3H, d), 1. 36 (3H, d), 2. 40-2. 50 (1H, m), 2. 62 (3H, s), 3. 68 (1H, q), 4. 02 (3H, s), 5. 76 (1H, d), 7. 14 (2H, d), 7. 27 (2H, d), 8. 92 (1H, s), 9. 19 (1H, s)
1-595	0. 80 (3H, d), 0. 91 (3H, d), 1. 35 (3H, d), 1. 45 (3H, t), 2. 40-2. 50 (1H, m), 2. 63 (3H, s), 3. 67 (1H, q), 4. 51 (2H, q), 5. 78 (1H, d), 7. 14 (2H, d), 7. 27 (2H, d), 8. 92 (1H, s), 9. 19 (1H, s)
1-651	0. 94 (3H, t, 3H, t), 1. 47 (3H, d), 1. 66 (3H, d), 1. 88-1. 98 (2H, m, 2H, m), 2. 08 (3H, s), 2. 09 (3H, s), 2. 61 (3H, s), 2. 68 (3H, s), 3. 74 (2H, dd, 2H, dd), 4. 29 (1H, q, 1H, q), 6. 03 (1H, t), 6. 12 (1H, t), 7. 23-7. 37 (5H, m, 5H, m), 8. 61 (1H, s), 8. 63 (1H, s), 9. 09 (1H, s), 9. 11 (1H, s), mixture of diastereoisomers
1-652	0. 94 (3H, t, 3H, t), 1. 49 (3H, d), 1. 65 (3H, d), 1. 91-1. 99 (2H, m, 2H, m), 2. 07 (3H, s), 2. 63 (3H, s), 2. 70 (3H, s), 3. 70 (2H, s, 2H, s), 4. 25-4. 32 (1H, m, 1H, m), 6. 01 (1H, t), 6. 11 (1H, t), 6. 99-7. 28 (4H, m, 4H, m), 8. 62 (1H, s), 8. 64 (1H, s), 9. 10 (1H, s), 9. 11 (1H, s), mixture of diastereoisomers

10070804, 031101

Table 42

Compound No.	NMR (δ (ppm), 300MHz, TMS-CDCl ₃)
1-872	0. 77 (3H, d) 、 0. 97 (3H, d) 、 1. 37 (3H, d) 、 2. 85 (3H, s) 、 2. 81-2. 91 (1H, m) 、 3. 77 (1H, q) 5. 14 (1H, d) 、 7. 16-7. 29 (5H, m) 9. 22 (1H, s) 、 9. 29 (1H, s)
1-873	0. 80 (3H, d) 、 1. 15 (3H, d) 、 2. 43 (3H, s) 、 2. 76-2. 84 (1H, m) 、 3. 18 (3H, s) 、 5. 23 (1H, d) 、 6. 77 (2H, d) 、 7. 02 (1H, t) 、 7. 15 (2H, d) 9. 16 (1H, s) 、 9. 26 (1H, s)
1-877	0. 82 (3H, t) 、 0. 93 (3H, t) 、 1. 72 (3H, s) 、 1. 78 (3H, s) 、 1. 86-1. 92 (2H, m) 、 2. 77 (3H, s) 、 3. 01 (3H, s) 、 3. 70 (2H, s) 、 4. 06 (2H, s) 、 3. 70-4. 20 (4H, m) 、 5. 86 (1H, t) 、 6. 09 (1H, t) 、 7. 14-7. 30 (4H, m) 、 8. 70 (1H, s) 、 8. 80 (1H, s) 、 9. 13 (1H, s) 、 9. 22 (1H, s)
1-878	0. 89 (3H, t) 、 0. 97 (3H, t) 、 1. 70-1. 90 (2H, m) 、 1. 90-2. 10 (2H, m) 、 2. 66 (3H, s) 、 2. 70 (3H, s) 、 2. 94 (3H, s) 、 3. 00 (3H, s) 、 3. 62 (2H, s) 、 3. 73 (2H, dd) 、 5. 62 (1H, t) 、 5. 70-5. 79 (1H, m) 、 7. 05-7. 27 (4H, m, 4H, m) 、 8. 68 (1H, s) 、 8. 83 (1H, s) 、 9. 15 (1H, s) 、 9. 20 (1H, s)
2-58	0. 44-0. 53 (2H, m) 、 0. 55-0. 65 (H, m) 、 1. 16 (3H, s) 、 3. 13 (3H, s) 、 3. 80 (2H, s) 、 5. 64 (1H, s) 、 6. 63 (1H, d) 、 6. 75 (1H, d) 、 9. 12 (1H, s) 、 9. 26 (1H, s)
2-75	0. 89 (3H, d) 、 0. 99 (3H, d) 、 1. 23 (3H, t) 、 2. 43-2. 51 (1H, m) 、 2. 71-3. 05 (2H, m) 、 2. 77 (3H, s) 、 3. 80 (2H, dd) 、 5. 72 (1H, d) 、 6. 65 (1H, d) 、 6. 74 (1H, d) 、 8. 61 (1H, s) 、 9. 06 (1H, s)

20170710 10:00:00

Table 43

Compound No.	NMR (δ (ppm), 300MHz, TMS-CDCl ₃)
4-26	0. 78 (3H, t), 1. 11-1. 21 (3H, m), 1. 31 (3H, t), 2. 36 (3H, s), 2. 58 (3H, s), 2. 44-2. 67 (1H, m), 2. 77 (3H, s), 2. 86 (3H, s), 2. 88-3. 16 (2H, m), 5. 02 (1H, dd), 7. 04-7. 45 (4H, m), 8. 52 (1H, s), 8. 69 (1H, s), 9. 01 (1H, s), 9. 10 (1H, s)
4-28	0. 77 (3H, d), 1. 15 (3H, d), 1. 31 (3H, t), 2. 31 (3H, s), 2. 33-2. 43 (1H, m), 2. 80 (3H, s), 2. 89-3. 17 (2H, m), 5. 02 (1H, d), 7. 22-7. 35 (4H, m), 8. 52 (1H, s), 9. 01 (1H, s)
4-36	0. 77 (3H, d), 1. 12 (3H, d), 2. 48-2. 58 (1H, m), 3. 04 (3H, s), 5. 09 (1H, d), 7. 35-7. 39 (2H, m), 7. 46-7. 54 (3H, m), 9. 05 (1H, s), 9. 21 (1H, s)
4-37	0. 77 (3H, d), 1. 13 (3H, d), 2. 53-2. 59 (1H, m), 3. 02 (3H, s), 5. 1 (1H, d), 7. 04-7. 08 (2H, m), 7. 54-7. 58 (2H, m), 9. 06 (1H, s), 9. 24 (1H, s)
4-54	0. 86 (3H, t), 1. 34 (3H, t), 1. 63-2. 09 (2H, m), 2. 76 (3H, s), 2. 91-3. 09 (2H, m), 5. 27 (1H, dd), 7. 17-7. 21 (2H, m), 7. 72-7. 79 (2H, m), 8. 47 (1H, s), 9. 06 (1H, s)
5-13	0. 79 (3H, d), 1. 16 (3H, d), 1. 83-1. 90 (2H, m), 2. 91-2. 99 (1H, m), 3. 07-3. 14 (3H, m), 3. 32-3. 40 (1H, m), 4. 40 (1H, d), 4. 68 (1H, d), 5. 02 (1H, d), 7. 20-7. 33 (5H, m), 9. 25 (1H, s), 9. 46 (1H, s)

20170804 10070804

The herbicide of the present invention comprises the pyrimidine derivative represented by the formula [I] as an active ingredient.

In order to use the compound of the present invention as a herbicide, the compound of the present invention may be used by itself, but it may be used as formulated in e.g. a dust, a wettable powder, an emulsifiable concentrate, a microgranule or a granule by incorporating a carrier, a surfactant, a dispersant or an adjuvant which are commonly used for formulations. The carrier to be used for formulation may, for example, be a solid carrier such as talc, bentonite, clay, kaolin, diatomaceous earth, white carbon, vermiculite, calcium carbonate, slaked lime, silica sand, ammonium sulfate or urea, or a liquid carrier such as isopropyl alcohol, xylene, cyclohexane or methylnaphthalene.

The surfactant and the dispersant may, for example, be a metal salt of an alkylbenzene sulfonic acid, a metal salt of dinaphthylmethanedisulfonic acid, an alcohol/sulfuric acid ester, an alkylaryl sulfonate, lignin sulfonate, polyoxyethylene glycol ether, polyoxyethylene alkylaryl ether, and polyoxyethylene sorbitan monoalkylate. The adjuvant may, for example, be carboxymethylcellulose, polyethylene glycol or gum Arabic. In the actual use, it may be applied as diluted to a proper concentration or may be directly applied.

The herbicide of the present invention can be used

by application to foliage, application to soil or application to water surface. The blend proportion of the active ingredient may suitably be selected, as the case requires. However, in the case of a dust or a granule, it is preferably selected within a range of from 0.01 to 10% (weight), preferably from 0.05 to 5% (weight). Further, in the case of an emulsifiable concentrate and a wettable powder, it is preferably selected within a range of from 1 to 50% (weight), preferably from 5 to 30% (weight).

The dose of the herbicide of the present invention varies depending upon the type of the compound to be used, the objective weeds, the germination tendency, the environmental conditions as well as the formulation to be used. However, when it is used as it is, in the case of a dust or a granule, the dose is preferably selected within a range of from 0.1g to 5 kg, preferably from 1g to 1 kg, per 10 ares as an active ingredient. Further, in a case where it is used in a liquid state as in the case of an emulsifiable concentrate or wettable powder, the dose is preferably selected within a range of from 0.1 to 50,000 ppm, preferably from 10 to 10,000 ppm.

Further, the compound of the present invention may be used in combination with an insecticide, a fungicide, another herbicide, a plant growth regulator, a fertilizer, etc., as the case requires.

Now, the formulation method will be described in

detail with reference to typical Formulation Examples. However, the compounds, the types of the additives and the blend ratios are not limited thereto and may be varied within wide ranges. In the following description,
5 "parts" means "parts by weight".

FORMULATION EXAMPLE 1: WETTABLE POWDER

To 10 parts of compound (1-8), 0.5 part of polyoxyethyleneoctylphenyl ether, 0.5 part of a sodium salt of β -naphthalene sulfonic acid formalin condensate,
10 20 parts of diatomaceous earth and 69 parts of clay were mixed and pulverized to obtain a wettable powder.

FORMULATION EXAMPLE 2: WETTABLE POWDER

To 10 parts of compound (1-8), 0.5 part of polyoxyethyleneoctylphenyl ether, 0.5 part of a sodium
15 salt of β -naphthalene sulfonic acid formalin condensate, 20 parts of diatomaceous earth, 5 parts of white carbon and 64 parts of clay were mixed and pulverized to obtain a wettable powder.

FORMULATION EXAMPLE 3: WETTABLE POWDER

20 To 10 parts of compound (1-8), 0.5 part of polyoxyethyleneoctylphenyl ether, 0.5 part of a sodium salt of β -naphthalene sulfonic acid formalin condensate, 20 parts of diatomaceous earth, 5 parts of white carbon and 64 parts of calcium carbonate, were mixed and
25 pulverized to obtain a wettable powder.

FORMULATION EXAMPLE 4: EMULSIFIABLE CONCENTRATE

To 30 parts of compound (1-8), 60 parts of a mixture

10070804.03110

of equal amounts of xylene and isophorone, and 10 parts of a mixture comprising a surfactant polyoxyethylenesorbitan alkylate, a polyoxyethylene alkylaryl polymer and an alkylaryl sulfonate, were added, followed by thorough stirring to obtain an emulsifiable concentrate.

FORMULATION EXAMPLE 5: GRANULE

10 parts of compound (1-8), 80 parts of an extender having talc and bentonite mixed in a ratio of 1:3, 5 parts of white carbon, 5 parts of a mixture comprising a surfactant polyoxyethylenesorbitan alkylate, a polyoxyethylene alkylaryl polymer and an alkylaryl sulfonate, and 10 parts of water were mixed and thoroughly kneaded to obtain a paste, which was extruded through a screen having openings having a diameter of 0.7 mm, then dried and cut into a length of from 0.5 to 1 mm to obtain a granule.

Now, the effects of the compound of the present invention will be described with reference to Test Examples.

TEST EXAMPLE 1: TESTS OF HERBICIDAL EFFECTS BY FLOODED PADDY FIELD TREATMENT

In a 100 cm² plastic pot, paddy field soil was filled and paddled. Then, seeds of barnyard grass (Eo) and monochoria (Mo) were sown, and water was introduced to a depth of 3 cm. Next day, a wettable powder prepared in accordance with Formulation Example 1 was diluted with

water and dropwise applied to the water surface. The dose was 100g of the active ingredient per 10 ares. Thereafter, cultivation was carried out in a green house, and on the 21st day after the treatment, the herbicidal effects were examined in accordance with the standards as identified in Table 44. The results are shown in Tables 45 to 52.

Table 44

Index number	Herbicidal effects (growth-inhibition degree) and phytotoxicity
5	Herbicidal effect or phytotoxicity for controlling more than 90%
4	Herbicidal effect or phytotoxicity of at least 70% and less than 90%
3	Herbicidal effect or phytotoxicity of at least 50% and less than 70%
2	Herbicidal effect or phytotoxicity of at least 30% and less than 50%
1	Herbicidal effect or phytotoxicity of at least 10% and less than 30%
0	Herbicidal effect or phytotoxicity of at least 0% and less than 10%

Table 45

Compound No.	Dose (gai/10a)	EO	MO
1-4	100	5	5
1-8	100	5	5
1-9	100	5	5
1-10	100	5	5
1-12	100	5	5
1-13	100	5	5
1-15	100	5	5
1-16	100	5	5
1-17	100	5	5
1-18	100	5	5
1-19	100	5	5
1-20	100	5	5
1-21	100	5	5
1-22	100	5	5
1-23	100	5	5
1-24	100	5	5
1-25	100	5	5
1-26	100	5	5
1-27	100	5	5
1-32	100	5	5
1-33	100	5	5
1-34	100	5	5
1-35	100	5	5
1-36	100	5	5
1-37	100	5	5
1-38	100	5	5
1-39	100	5	5
1-40	100	5	5
1-41	100	5	5
1-42	100	5	5
1-43	100	5	5
1-44	100	5	5
1-45	100	5	5
1-46	100	5	5
1-47	100	5	5
1-48	100	5	5
1-49	100	5	5
1-50	100	5	5
1-51	100	5	5
1-52	100	5	5
1-53	100	5	5
1-54	100	5	5
1-55	100	5	5
1-56	100	5	5
1-57	100	5	5
1-58	100	5	5
1-59	100	5	5
1-60	100	5	5
1-61	100	5	5
1-62	100	5	5
1-63	100	5	5
1-64	100	5	5
1-65	100	5	5

10070804 031101

Table 46

Compound No.	Dose (gai/10a)	EO	Mo
1-66	100	5	5
1-67	100	5	5
1-68	100	5	5
1-70	100	5	5
1-71	100	5	5
1-72	100	5	5
1-74	100	5	5
1-75	100	5	5
1-76	100	5	5
1-78	100	5	5
1-80	100	5	5
1-81	100	5	5
1-82	100	5	5
1-83	100	5	5
1-84	100	5	5
1-85	100	5	5
1-86	100	5	5
1-87	100	5	5
1-88	100	5	5
1-89	100	5	5
1-90	100	5	5
1-91	100	5	5
1-93	100	5	5
1-94	100	5	5
1-95	100	5	5
1-96	100	5	5
1-97	100	5	5
1-98	100	5	5
1-99	100	5	5
1-100	100	5	5
1-101	100	5	5
1-102	100	5	5
1-103	100	5	5
1-104	100	5	5
1-105	100	5	5
1-106	100	5	5
1-107	100	5	5
1-111	100	5	4
1-112	100	5	5
1-113	100	5	5
1-114	100	5	5
1-115	100	5	5
1-116	100	5	5
1-118	100	5	5
1-119	100	5	5
1-120	100	5	5
1-121	100	5	5
1-122	100	5	5
1-123	100	5	5
1-124	100	5	5
1-125	100	5	5
1-126	100	5	5
1-127	100	5	5

2015040804 031101

Table 47

Compound No.	Dose (gai/10a)	EO	Mo
1-128	100	5	4
1-129	100	5	5
1-130	100	5	5
1-131	100	5	5
1-132	100	5	5
1-133	100	5	5
1-134	100	5	5
1-135	100	5	5
1-136	100	5	5
1-137	100	5	5
1-138	100	5	5
1-139	100	5	5
1-140	100	5	5
1-141	100	5	5
1-142	100	5	5
1-143	100	5	5
1-144	100	5	5
1-145	100	5	5
1-146	100	5	5
1-147	100	5	5
1-148	100	5	5
1-150	100	5	5
1-151	100	5	5
1-152	100	5	5
1-153	100	5	5
1-154	100	5	5
1-155	100	5	5
1-156	100	5	5
1-159	100	5	5
1-160	100	5	5
1-161	100	5	5
1-162	100	5	5
1-163	100	5	5
1-164	100	5	5
1-165	100	5	5
1-166	100	5	5
1-167	100	5	5
1-168	100	5	5
1-169	100	5	5
1-170	100	5	5
1-171	100	5	5
1-172	100	5	5
1-173	100	5	5
1-174	100	5	5
1-175	100	5	5
1-177	100	5	5
1-178	100	5	4
1-180	100	5	5
1-181	100	5	5
1-182	100	5	5
1-183	100	5	5
1-184	100	5	5
1-185	100	5	5

2070804-03100T

Table 48

Compound No.	Dose (gai/10a)	E _o	Mo
1-186	100	5	5
1-187	100	5	5
1-188	100	5	5
1-189	100	5	5
1-190	100	5	5
1-191	100	5	5
1-192	100	5	5
1-193	100	5	5
1-194	100	5	5
1-195	100	5	5
1-196	100	5	5
1-197	100	5	5
1-198	100	5	5
1-200	100	5	5
1-214	100	5	5
1-217	100	5	5
1-218	100	5	5
1-219	100	5	5
1-220	100	5	5
1-221	100	5	5
1-222	100	5	5
1-225	100	5	5
1-226	100	5	5
1-228	100	5	5
1-234	100	5	5
1-249	100	5	5
1-250	100	5	5
1-251	100	5	5
1-254	100	5	5
1-265	100	5	5
1-266	100	5	5
1-267	100	5	5
1-270	100	5	5
1-273	100	5	5
1-274	100	5	5
1-305	100	5	5
1-306	100	5	5
1-307	100	5	5
1-310	100	5	5
1-321	100	5	5
1-322	100	5	5
1-323	100	5	5
1-324	100	5	5
1-325	100	5	5
1-327	100	5	5
1-328	100	5	5
1-329	100	5	5
1-330	100	5	5
1-331	100	5	5
1-333	100	5	5
1-334	100	5	5
1-335	100	5	5
1-401	100	5	5

10070804 031109

Table 49

Compound No.	Dose (gai/10a)	Eo	Mo
1-402	100	5	5
1-403	100	5	5
1-404	100	5	5
1-407	100	5	5
1-409	100	5	5
1-410	100	5	5
1-411	100	5	5
1-412	100	5	5
1-413	100	5	5
1-414	100	5	5
1-415	100	5	5
1-416	100	5	5
1-417	100	5	5
1-418	100	5	5
1-419	100	5	5
1-420	100	5	5
1-421	100	5	5
1-422	100	5	5
1-424	100	5	5
1-425	100	5	5
1-426	100	5	5
1-427	100	5	5
1-428	100	5	5
1-429	100	5	5
1-430	100	5	5
1-431	100	5	5
1-432	100	5	5
1-433	100	5	5
1-434	100	5	5
1-435	100	5	5
1-436	100	5	5
1-437	100	5	5
1-438	100	5	5
1-439	100	5	5
1-441	100	5	5
1-442	100	5	5
1-443	100	5	5
1-444	100	5	5
1-445	100	5	5
1-446	100	5	5
1-447	100	5	5
1-448	100	5	5
1-449	100	5	5
1-450	100	5	5
1-451	100	5	5
1-452	100	5	5
1-454	100	5	5
1-455	100	5	5
1-458	100	5	5
1-459	100	5	5
1-460	100	5	5
1-461	100	5	5
1-463	100	5	5

201104080200F

Table 50

Compound No.	Dose (gai/10a)	EO	MO
1-464	100	5	5
1-465	100	5	5
1-469	100	5	5
1-473	100	5	5
1-476	100	5	5
1-482	100	5	5
1-483	100	5	5
1-484	100	5	5
1-485	100	5	5
1-486	100	5	5
1-487	100	5	5
1-488	100	5	5
1-489	100	5	5
1-490	100	5	5
1-491	100	5	5
1-492	100	5	5
1-493	100	5	5
1-494	100	5	5
1-495	100	5	5
1-496	100	5	5
1-497	100	5	5
1-498	100	5	5
1-499	100	5	5
1-500	100	5	5
1-501	100	5	5
1-502	100	5	5
1-504	100	5	5
1-505	100	5	5
1-506	100	5	5
1-507	100	5	5
1-510	100	5	5
1-511	100	5	5
1-517	100	5	5
1-518	100	5	5
1-519	100	5	5
1-520	100	5	5
1-521	100	5	5
1-524	100	5	5
1-526	100	5	5
1-527	100	5	5
1-528	100	5	5
1-529	100	5	5
1-530	100	5	5
1-532	100	5	5
1-533	100	5	5
1-535	100	5	5
1-536	100	5	5
1-537	100	5	5
1-538	100	5	5
1-539	100	5	5
1-540	100	5	5
1-541	100	5	5
1-546	100	5	5

10070804-034102

Table 51

Compound No.	Dose (gai/10a)	EO	MO
1-547	100	5	5
1-548	100	5	5
1-549	100	5	5
1-550	100	5	5
1-551	100	5	5
1-553	100	5	5
1-555	100	5	5
1-558	100	5	5
1-559	100	5	5
1-560	100	5	5
1-561	100	5	5
1-562	100	5	5
1-563	100	5	5
1-565	100	5	5
1-566	100	5	5
1-567	100	5	5
1-569	100	5	5
1-571	100	5	4
1-572	100	5	5
1-573	100	5	5
1-579	100	5	5
1-584	100	5	5
1-586	100	5	5
1-589	100	5	5
1-591	100	5	5
1-592	100	5	5
1-593	100	5	5
1-594	100	5	5
1-595	100	5	5
1-597	100	5	5
1-598	100	5	5
1-599	100	5	5
1-600	100	5	5
1-602	100	5	5
1-603	100	5	5
1-604	100	5	5
1-606	100	5	5
1-607	100	5	5
1-608	100	5	5
1-609	100	5	5
1-611	100	5	5
1-614	100	5	5
1-615	100	5	5
1-624	100	5	5
1-626	100	5	5
1-627	100	5	5
1-637	100	5	5
1-639	100	5	5
1-640	100	5	5
1-641	100	5	5
2-1	100	5	5
2-2	100	5	5
2-3	100	5	5

10070804-0310

Table 52

Compound No.	Dose (gai/10a)	EO	MO
2-5	100	5	5
2-6	100	5	5
2-7	100	5	5
2-8	100	5	5
2-9	100	5	5
2-10	100	5	5
2-11	100	5	5
2-12	100	5	5
2-13	100	5	5
2-14	100	5	5
2-19	100	5	5
2-20	100	5	5
2-23	100	5	5
2-24	100	5	5
2-25	100	5	5
2-31	100	5	5
2-32	100	5	5
2-41	100	5	5
2-42	100	5	5
2-44	100	5	5
2-46	100	5	5
2-48	100	5	5
2-50	100	5	5
2-51	100	5	5
2-52	100	5	5
2-53	100	5	5
2-54	100	5	5
2-55	100	5	5
2-56	100	5	5
2-57	100	5	5
2-58	100	5	5
2-59	100	5	5
2-60	100	5	5
2-61	100	5	5
2-62	100	5	5
2-63	100	5	5
2-71	100	5	5
2-72	100	5	5
2-73	100	5	5
2-74	100	5	5
2-75	100	5	5
2-77	100	5	5
2-78	100	5	5
2-80	100	5	4
4-1	100	5	5
4-2	100	5	5

"207ED" 408D/00T

TEST EXAMPLE 2: TEST OF HERBICIDAL EFFECTS BY UPLAND SOIL
TREATMENT

In a 80 cm² plastic pot, upland soil was filled, and seeds of barnyard grass (Ec) and green foxtail (Se) were
5 sown and covered with soil. A wettable powder prepared in accordance with Formulation Example 1 was diluted with water and uniformly applied to the soil surface by means of a small size spray at a rate of 1000 per 10 ares, so that the dose of the active ingredient would be 100g per
10 10 ares. Thereafter, cultivation was carried out in a green house, and on the 21st day after the treatment, the herbicidal effects were examined in accordance with the standards as identified in Table 44. The results are shown in Tables 53 to 60.

10070804 031103

Table 53

Compound No.	Dose (gai/10a)	Ec	Se
1-8	100	5	5
1-9	100	5	5
1-10	100	4	4
1-12	100	5	5
1-13	100	5	5
1-15	100	5	5
1-16	100	4	5
1-17	100	4	4
1-20	100	5	5
1-21	100	5	5
1-22	100	5	5
1-23	100	5	5
1-24	100	5	5
1-25	100	5	5
1-26	100	5	5
1-27	100	5	5
1-32	100	5	5
1-33	100	5	5
1-34	100	5	5
1-35	100	5	5
1-36	100	5	5
1-37	100	5	5
1-38	100	5	4
1-40	100	5	4
1-41	100	5	5
1-42	100	5	5
1-45	100	5	5
1-46	100	5	5
1-47	100	5	5
1-48	100	5	5
1-49	100	5	4
1-50	100	5	5
1-51	100	5	5
1-52	100	5	5
1-53	100	5	5
1-54	100	5	5
1-55	100	5	5
1-56	100	5	5
1-57	100	5	5
1-58	100	5	5
1-59	100	5	5
1-60	100	5	5
1-61	100	5	5
1-62	100	4	4
1-63	100	5	5
1-64	100	5	5
1-65	100	5	5
1-66	100	5	5
1-67	100	5	5
1-68	100	5	5
1-70	100	5	5
1-71	100	5	5
1-72	100	5	4

10070804.031103

Table 54

Compound No.	Dose (gai/10a)	Ec	Se
1-74	100	5	5
1-75	100	5	5
1-76	100	5	5
1-77	100	5	5
1-78	100	5	5
1-80	100	5	5
1-81	100	5	5
1-83	100	5	5
1-85	100	5	5
1-87	100	5	5
1-88	100	5	5
1-89	100	5	5
1-90	100	5	5
1-91	100	4	5
1-92	100	5	5
1-95	100	5	5
1-96	100	5	5
1-97	100	5	5
1-98	100	5	5
1-99	100	5	5
1-100	100	5	5
1-101	100	5	5
1-102	100	5	5
1-103	100	5	5
1-105	100	5	5
1-106	100	5	4
1-111	100	5	5
1-112	100	5	5
1-113	100	5	4
1-114	100	5	5
1-115	100	5	5
1-116	100	5	4
1-118	100	5	5
1-119	100	5	4
1-120	100	5	4
1-121	100	5	4
1-122	100	5	5
1-123	100	5	5
1-124	100	5	5
1-125	100	5	5
1-126	100	5	5
1-127	100	5	5
1-128	100	5	5
1-130	100	5	5
1-131	100	5	5
1-133	100	5	5
1-134	100	5	5
1-135	100	5	5
1-136	100	5	5
1-137	100	5	5
1-138	100	5	5
1-139	100	5	5
1-140	100	5	5

10070804 034402

Table 55

Compound No.	Dose (gai/10a)	Ec	Se
1-141	100	5	5
1-142	100	5	5
1-143	100	5	5
1-144	100	5	5
1-145	100	5	5
1-146	100	4	4
1-147	100	5	5
1-148	100	5	5
1-150	100	5	5
1-151	100	5	5
1-152	100	5	5
1-153	100	5	5
1-155	100	4	4
1-159	100	5	5
1-160	100	5	5
1-161	100	5	5
1-162	100	5	4
1-163	100	5	5
1-164	100	5	5
1-165	100	5	5
1-166	100	5	5
1-167	100	5	5
1-168	100	5	5
1-169	100	5	5
1-170	100	5	5
1-171	100	5	4
1-172	100	5	5
1-173	100	5	5
1-174	100	5	5
1-177	100	4	4
1-180	100	5	5
1-181	100	5	5
1-182	100	5	5
1-186	100	5	5
1-187	100	5	5
1-190	100	4	4
1-192	100	5	5
1-193	100	5	5
1-194	100	5	5
1-195	100	5	5
1-196	100	5	5
1-197	100	5	5
1-198	100	5	5
1-200	100	5	5
1-214	100	5	5
1-217	100	5	5
1-218	100	5	5
1-219	100	5	5
1-220	100	5	5
1-222	100	5	5
1-225	100	5	5
1-226	100	5	4
1-228	100	5	5

10070804-031102

Table 56

Compound No.	Dose (gai/10a)	Ec	Se
1-234	100	5	5
1-249	100	5	5
1-250	100	4	5
1-251	100	5	5
1-254	100	5	5
1-265	100	5	5
1-266	100	5	5
1-267	100	5	5
1-270	100	5	5
1-273	100	5	5
1-274	100	5	5
1-305	100	5	5
1-306	100	5	5
1-307	100	5	5
1-310	100	5	5
1-321	100	5	5
1-323	100	4	4
1-326	100	4	4
1-327	100	5	5
1-328	100	5	5
1-329	100	5	5
1-330	100	5	5
1-331	100	5	5
1-332	100	5	5
1-333	100	5	5
1-334	100	5	5
1-335	100	5	5
1-401	100	5	5
1-402	100	5	5
1-403	100	5	5
1-404	100	5	5
1-407	100	5	5
1-409	100	5	5
1-410	100	5	5
1-411	100	5	5
1-412	100	5	5
1-414	100	4	5
1-416	100	5	5
1-417	100	5	5
1-418	100	5	5
1-419	100	5	5
1-424	100	5	5
1-425	100	5	5
1-426	100	5	5
1-427	100	5	5
1-428	100	5	5
1-429	100	5	5
1-430	100	5	5
1-431	100	5	5
1-432	100	5	5
1-433	100	5	5
1-434	100	5	5
1-435	100	5	5

10070804-031103

Table 57

Compound No.	Dose (gai/10a)	Ec	Se
1-436	100	5	5
1-437	100	5	5
1-438	100	5	5
1-439	100	5	4
1-441	100	5	5
1-442	100	5	5
1-443	100	5	5
1-444	100	5	5
1-445	100	5	5
1-446	100	5	5
1-447	100	5	5
1-448	100	5	4
1-449	100	5	5
1-450	100	5	5
1-451	100	5	5
1-452	100	5	5
1-454	100	4	5
1-455	100	5	5
1-458	100	5	4
1-459	100	5	5
1-460	100	5	5
1-461	100	5	5
1-463	100	4	5
1-464	100	5	5
1-465	100	5	5
1-466	100	4	4
1-471	100	5	4
1-473	100	5	4
1-476	100	5	5
1-482	100	5	5
1-483	100	5	4
1-484	100	5	5
1-485	100	5	5
1-488	100	5	5
1-489	100	5	5
1-490	100	5	5
1-492	100	5	5
1-493	100	5	5
1-494	100	5	5
1-495	100	5	5
1-496	100	5	4
1-497	100	5	5
1-498	100	5	5
1-499	100	5	4
1-502	100	4	4
1-504	100	5	5
1-505	100	5	5
1-506	100	5	5
1-507	100	5	5
1-508	100	5	5
1-511	100	4	4
1-517	100	5	5
1-518	100	5	5

10070804-034102

Table 58

Compound No.	Dose (gai/10a)	Ec	Se
1-519	100	5	5
1-520	100	5	5
1-521	100	5	5
1-523	100	4	5
1-524	100	5	5
1-526	100	5	5
1-527	100	5	5
1-528	100	5	5
1-529	100	5	5
1-530	100	5	5
1-531	100	4	4
1-532	100	5	5
1-533	100	5	5
1-535	100	5	5
1-536	100	5	5
1-537	100	5	5
1-538	100	5	5
1-539	100	5	5
1-540	100	5	5
1-541	100	5	4
1-546	100	5	5
1-547	100	5	5
1-548	100	5	5
1-549	100	5	5
1-550	100	5	5
1-551	100	5	5
1-553	100	5	5
1-555	100	5	5
1-558	100	5	5
1-559	100	5	5
1-560	100	5	5
1-561	100	5	4
1-562	100	5	5
1-563	100	5	5
1-565	100	5	5
1-566	100	5	5
1-567	100	5	5
1-569	100	5	5
1-571	100	5	5
1-572	100	5	5
1-573	100	5	4
1-579	100	5	5
1-584	100	5	5
1-586	100	5	5
1-589	100	5	5
1-591	100	5	5
1-592	100	5	5
1-594	100	5	5
1-597	100	4	4
1-598	100	5	4
1-600	100	4	5
1-602	100	5	5
1-603	100	4	4

20170804 10070804

Table 59

Compound No.	Dose (gai/10a)	Ec	Se
1-604	100	5	4
1-606	100	5	5
1-607	100	4	4
1-608	100	5	5
1-609	100	5	4
1-611	100	5	5
1-614	100	5	5
1-616	100	5	5
1-617	100	5	5
1-618	100	5	5
1-619	100	5	5
1-620	100	5	5
1-621	100	5	5
1-622	100	4	5
1-623	100	5	4
1-624	100	5	5
1-625	100	4	5
1-626	100	5	4
1-627	100	5	5
1-636	100	4	4
1-639	100	5	5
1-640	100	4	4
1-641	100	5	4
1-642	100	4	4
1-646	100	4	4
2-1	100	5	4
2-2	100	5	4
2-6	100	5	4
2-7	100	5	5
2-8	100	5	5
2-9	100	5	5
2-10	100	5	5
2-11	100	5	5
2-12	100	5	5
2-13	100	5	5
2-14	100	5	5
2-19	100	5	5
2-20	100	5	5
2-23	100	5	5
2-24	100	5	5
2-25	100	5	5
2-31	100	5	5
2-32	100	5	5
2-44	100	5	5
2-46	100	5	5
2-47	100	4	5
2-50	100	5	5
2-51	100	5	5
2-52	100	5	5
2-53	100	5	5
2-54	100	5	5
2-55	100	5	5
2-56	100	5	5

20750-4080/007

Table 60

Compound No.	Dose (gai/10a)	Ec	Se
2-57	100	5	5
2-58	100	5	5
2-59	100	5	4
2-60	100	5	5
2-61	100	5	5
2-62	100	5	5
2-63	100	5	4
2-71	100	5	5
2-72	100	5	5
2-73	100	5	5
2-74	100	5	5
2-75	100	5	5
2-77	100	5	5
2-78	100	5	5
2-79	100	5	5
4-1	100	5	5
4-2	100	5	4

10070804.034102

TEST EXAMPLE 3: TEST OF HERBICIDAL EFFECTS BY FOLIAGE
TREATMENT IN UPLAND FIELD

In a 80 cm² plastic pot, upland soil was filled, and seeds of barnyard grass (Ec) and green foxtail (Se) were
5 sown and cultured in a green house for 2 weeks. Then, a wettable powder prepared in accordance with Formulation Example 1 was diluted with water and applied to the entire foliage from above the plants by means of a small size spray at a rate of 1000 per 10 ares so that the dose
10 of the active ingredient would be 100g per 10 ares. Thereafter, cultivation was carried out in a green house, and on the 14th day after the treatment, the herbicidal effects were examined in accordance with the standards of Table 44. The results are shown in Tables 61 to 64.

10070804 031102

Table 61

Compound No.	Dose (gai/10a)	Ec	Se
1-1	100	4	4
1-8	100	5	4
1-9	100	5	4
1-10	100	4	4
1-12	100	5	4
1-13	100	5	4
1-21	100	4	4
1-22	100	4	4
1-24	100	4	4
1-26	100	4	4
1-27	100	4	4
1-41	100	5	4
1-42	100	4	4
1-46	100	4	4
1-47	100	4	4
1-48	100	5	4
1-50	100	4	4
1-53	100	4	4
1-54	100	5	4
1-55	100	4	4
1-56	100	4	4
1-57	100	5	4
1-58	100	4	4
1-59	100	4	4
1-60	100	4	4
1-61	100	4	4
1-66	100	5	4
1-78	100	5	4
1-81	100	4	4
1-83	100	5	4
1-87	100	4	4
1-88	100	4	4
1-89	100	5	4
1-92	100	5	4
1-95	100	5	5
1-96	100	5	5
1-98	100	4	4
1-100	100	5	5
1-107	100	4	4
1-111	100	4	4
1-112	100	4	5
1-113	100	4	4
1-122	100	4	4
1-127	100	4	4
1-129	100	5	5
1-133	100	5	4
1-137	100	5	4
1-142	100	4	4
1-143	100	4	4
1-144	100	4	4
1-152	100	4	4
1-153	100	4	4
1-164	100	4	4

20750 4080/007

Table 62

Compound No.	Dose (gai/10a)	Ec	Se
1-172	100	5	5
1-186	100	5	4
1-192	100	4	4
1-193	100	5	4
1-194	100	5	4
1-195	100	5	4
1-196	100	5	4
1-198	100	4	4
1-214	100	4	4
1-218	100	4	4
1-220	100	5	5
1-221	100	4	4
1-251	100	4	4
1-267	100	4	4
1-270	100	4	4
1-330	100	4	4
1-331	100	4	4
1-333	100	4	4
1-334	100	4	4
1-401	100	5	5
1-402	100	5	4
1-403	100	4	4
1-404	100	5	4
1-407	100	4	4
1-409	100	4	4
1-410	100	4	4
1-411	100	4	4
1-412	100	4	4
1-416	100	5	4
1-417	100	4	5
1-419	100	4	5
1-424	100	4	4
1-426	100	4	4
1-427	100	4	4
1-428	100	4	4
1-430	100	4	4
1-431	100	4	4
1-432	100	5	4
1-434	100	4	4
1-435	100	4	4
1-436	100	4	4
1-437	100	4	4
1-441	100	4	4
1-442	100	4	4
1-445	100	5	5
1-446	100	5	4
1-447	100	5	4
1-449	100	4	4
1-450	100	4	4
1-451	100	4	4
1-452	100	4	4
1-454	100	4	4
1-455	100	4	4

2017E040302001

Table 63

Compound No.	Dose (gai/10a)	Ec	Se
1-459	100	4	4
1-461	100	4	4
1-463	100	4	4
1-464	100	4	4
1-473	100	5	4
1-482	100	5	4
1-484	100	5	5
1-486	100	4	4
1-488	100	5	4
1-489	100	4	4
1-490	100	4	4
1-492	100	5	4
1-493	100	4	4
1-494	100	5	4
1-496	100	4	4
1-497	100	4	4
1-504	100	5	4
1-505	100	5	5
1-506	100	4	4
1-507	100	4	4
1-508	100	4	4
1-517	100	4	4
1-519	100	4	4
1-526	100	5	4
1-527	100	4	4
1-528	100	4	4
1-529	100	5	4
1-530	100	4	4
1-532	100	5	4
1-536	100	4	4
1-537	100	4	4
1-538	100	4	4
1-539	100	4	4
1-540	100	4	4
1-541	100	4	4
1-546	100	4	4
1-547	100	4	4
1-558	100	4	4
1-559	100	4	4
1-560	100	4	4
1-561	100	5	4
1-563	100	5	4
1-565	100	5	4
1-566	100	4	4
1-569	100	5	4
1-571	100	4	4
1-572	100	4	4
1-579	100	4	4
1-584	100	4	4
1-586	100	5	4
1-589	100	4	4
1-591	100	4	4
1-592	100	5	4

2017E04080/001

Table 64

Compound No.	Dose (gai/10a)	Ec	Se
1-594	100	5	5
1-598	100	4	4
1-600	100	5	4
1-602	100	4	4
1-606	100	4	4
1-607	100	4	4
1-609	100	4	4
1-611	100	4	4
1-617	100	4	4
1-619	100	4	4
1-622	100	4	4
1-642	100	4	4
2-11	100	5	4
2-12	100	5	4
2-23	100	4	4
2-25	100	5	4
2-46	100	4	4
2-50	100	4	4
2-51	100	4	4
2-53	100	4	4
2-57	100	5	5
2-60	100	4	4
2-61	100	4	4
2-62	100	4	4
2-71	100	5	4
2-74	100	4	4
2-75	100	5	4
2-79	100	4	4
4-2	100	5	4

10070804_031103

TEST EXAMPLE 4: TEST OF SELECTIVITY FOR A CROP PLANT BY
FLOODED PADDY FIELD TREATMENT

In a 100 cm² plastic pot, a paddy field soil was filled and paddled. Then, seeds of barnyard grass (Eo) and monochoria (Mo) were sown, and rice (Or) of second leaf stage was transplanted, and water was introduced to a depth of 3 cm. Next day, a wettable powder prepared in accordance with Formulation Example 1 was diluted with water and dropwise applied to the water surface. The dose was 25g of the active ingredient per 10 ares. Thereafter, cultivation was carried out in a green house, and on the 21st day after the treatment, the herbicidal effects were examined in accordance with the standards of Table 44. The results are shown in Tables 65 to 69.

10070804.03402

Table 65

Compound No.	Dose (gai/10a)	EO	Mo	Or
1-4	25	5	4	1
1-13	25	5	5	1
1-16	25	5	5	1
1-17	25	5	5	1
1-18	25	5	4	1
1-20	25	5	5	1
1-21	25	5	5	1
1-22	25	5	5	1
1-23	25	5	5	1
1-26	25	5	5	1
1-33	25	5	5	1
1-34	25	5	5	1
1-36	25	5	5	1
1-38	25	5	5	0
1-39	25	5	5	0
1-40	25	5	5	0
1-41	25	5	5	0
1-42	25	5	5	0
1-43	25	5	5	1
1-44	25	5	5	0
1-45	25	5	5	0
1-46	25	5	5	0
1-47	25	5	5	0
1-48	25	5	5	1
1-49	25	5	5	0
1-50	25	5	5	1
1-51	25	5	5	1
1-52	25	5	5	1
1-53	25	5	5	1
1-54	25	5	5	1
1-55	25	5	5	1
1-59	25	5	5	0
1-60	25	5	5	1
1-61	25	5	5	1
1-62	25	5	5	1
1-63	25	5	5	1
1-67	25	5	5	1
1-72	25	5	5	0
1-74	25	5	5	0
1-76	25	5	5	0
1-78	25	5	5	1
1-81	25	5	5	0
1-82	25	5	5	0
1-83	25	5	5	1
1-84	25	5	5	0
1-85	25	5	5	0
1-86	25	5	5	0
1-87	25	5	5	1
1-89	25	5	5	0
1-91	25	5	5	1
1-93	25	5	5	0
1-97	25	5	5	0
1-98	25	5	5	1

10070804.031102

Table 66

Compound No.	Dose (gai/10a)	EO	Mo	Or
1-99	25	5	5	1
1-103	25	5	5	1
1-104	25	5	5	1
1-106	25	5	5	0
1-107	25	5	5	0
1-113	25	5	5	0
1-116	25	5	5	0
1-118	25	5	3	0
1-119	25	5	5	0
1-120	25	5	5	0
1-121	25	5	5	1
1-123	25	5	5	1
1-124	25	5	5	0
1-125	25	5	5	0
1-126	25	5	5	1
1-130	25	5	5	1
1-131	25	5	5	1
1-132	25	5	5	0
1-133	25	5	5	1
1-134	25	5	5	0
1-135	25	5	5	1
1-136	25	5	5	1
1-137	25	5	5	1
1-139	25	5	5	0
1-140	25	5	5	0
1-141	25	5	5	1
1-144	25	5	5	1
1-145	25	5	5	1
1-146	25	5	5	1
1-147	25	5	5	1
1-150	25	5	5	1
1-152	25	5	5	1
1-153	25	5	5	1
1-161	25	5	5	0
1-162	25	5	5	0
1-166	25	5	5	1
1-167	25	5	5	1
1-168	25	5	5	1
1-169	25	5	5	1
1-170	25	5	5	1
1-171	25	5	5	1
1-172	25	5	5	1
1-175	25	5	5	0
1-180	25	5	5	1
1-181	25	5	5	1
1-182	25	5	5	1
1-183	25	5	5	0
1-188	25	5	5	0
1-189	25	5	5	0
1-190	25	5	5	0
1-197	25	5	5	0
1-200	25	5	5	1
1-217	25	5	5	1

"1070804" 031102

Table 67

Compound No.	Dose (gai/10a)	EO	Mo	Or
1-218	25	5	5	1
1-219	25	5	5	1
1-220	25	5	5	1
1-221	25	5	5	1
1-225	25	5	5	0
1-226	25	5	5	1
1-228	25	5	5	0
1-234	25	5	5	1
1-250	25	5	5	1
1-251	25	5	5	1
1-306	25	5	5	1
1-321	25	5	5	1
1-324	25	5	5	1
1-325	25	5	5	1
1-329	25	5	5	1
1-333	25	5	5	1
1-334	25	5	5	0
1-401	25	5	5	1
1-404	25	5	5	1
1-412	25	5	5	1
1-416	25	5	5	1
1-417	25	5	5	1
1-418	25	5	5	1
1-425	25	5	5	1
1-436	25	5	5	1
1-439	25	5	5	1
1-441	25	5	5	1
1-442	25	5	5	1
1-443	25	5	5	1
1-444	25	5	5	1
1-448	25	5	5	1
1-452	25	5	5	0
1-454	25	5	5	1
1-455	25	5	5	1
1-459	25	5	5	1
1-461	25	5	5	1
1-465	25	5	5	0
1-473	25	5	5	1
1-483	25	5	5	1
1-484	25	5	5	1
1-485	25	5	5	1
1-486	25	5	5	1
1-487	25	5	5	1
1-489	25	5	5	1
1-490	25	5	5	0
1-491	25	5	5	0
1-492	25	5	5	0
1-493	25	5	5	1
1-494	25	5	5	1
1-495	25	5	5	0
1-496	25	5	5	1
1-498	25	5	5	0
1-504	25	5	5	1

10070804-0310
"COTED" 40802001

Table 68

Compound No.	Dose (gai/10a)	EO	Mo	Or
1-505	25	5	5	0
1-506	25	5	5	1
1-507	25	5	5	1
1-511	25	5	5	0
1-517	25	5	5	1
1-519	25	5	5	1
1-520	25	5	5	1
1-521	25	5	5	1
1-527	25	5	5	1
1-528	25	5	5	1
1-529	25	5	5	1
1-530	25	5	5	1
1-532	25	5	5	1
1-533	25	5	5	1
1-541	25	5	5	1
1-547	25	5	5	1
1-548	25	5	5	1
1-549	25	5	5	0
1-551	25	5	5	0
1-553	25	5	5	1
1-558	25	5	5	1
1-566	25	5	5	1
1-567	25	5	5	1
1-569	25	5	5	1
1-572	25	5	5	1
1-573	25	5	5	1
1-579	25	5	5	1
1-584	25	5	5	1
1-589	25	5	5	1
1-591	25	5	5	1
1-593	25	5	4	0
1-594	25	5	5	1
1-598	25	5	5	1
1-599	25	5	5	1
1-604	25	5	5	1
1-606	25	5	5	1
1-607	25	5	5	1
1-608	25	5	5	1
1-609	25	5	5	1
1-611	25	5	5	1
1-614	25	5	5	1
1-615	25	5	5	1
1-624	25	5	5	1
1-626	25	5	5	1
1-627	25	5	5	1
1-639	25	5	4	1
2-1	25	5	5	0
2-2	25	5	5	1
2-7	25	5	5	1
2-8	25	5	5	0
2-19	25	5	5	1
2-20	25	5	5	1
2-25	25	5	5	1

201704080200T

Table 69

Compound No.	Dose (gai/10a)	EO	Mo	Or
2-31	25	5	5	0
2-32	25	5	5	1
2-42	25	5	5	0
2-48	25	5	5	1
2-50	25	5	5	1
2-55	25	5	5	1
2-56	25	5	5	1
2-57	25	5	5	1
2-58	25	5	5	1
2-71	25	5	5	1
2-73	25	5	5	1
2-74	25	5	5	1
2-75	25	5	5	1
2-78	25	5	5	1
4-1	25	5	5	1
4-2	25	5	5	1

10070804-031102

TEST EXAMPLE 5: TEST OF SELECTIVITY FOR A CROP PLANT BY
SOIL TREATMENT IN UPLAND FIELD

In a 80 cm² plastic pot, upland soil was filled, and
seeds of barnyard grass (Ec), green foxtail (Se), soybean
5 (G1), wheat (Tr) and corn (Ze) were sown and covered with
soil. A wettable powder prepared in accordance with
Formulation Example 1 was diluted with water and
uniformly applied to the soil surface by a small size
spray at a rate of 1000 per 10 ares so that the dose of
10 the active ingredient would be 25g per 10 ares.
Thereafter, cultivation was carried out in a green house,
and on the 21st day after the treatment, the herbicidal
effects were examined in accordance with the standards of
Table 44. The results are shown in Table 70.

20250403 10:31:02

Table 70

Compound No.	Dose (gai/10a)	Ec	Se	Gl	Tr	Ze
1-15	25	5	5	-	1	1
1-23	25	5	5	-	2	1
1-33	25	4	4	0	2	1
1-42	25	5	5	0	0	0
1-45	25	4	5	0	2	0
1-46	25	5	5	1	3	0
1-48	25	4	5	0	1	0
1-49	25	5	5	1	0	3
1-50	25	4	5	3	3	0
1-51	25	5	5	0	1	0
1-53	25	4	5	1	2	0
1-54	25	4	5	0	1	0
1-55	25	5	4	1	1	0
1-56	25	5	5	0	4	3
1-58	25	5	5	0	3	0
1-59	25	5	5	0	1	0
1-60	25	5	5	1	2	0
1-61	25	5	5	1	3	0
1-64	25	4	4	2	3	0
1-65	25	5	5	0	0	0
1-68	25	4	4	0	2	2
1-70	25	5	4	1	4	1
1-71	25	5	5	-	3	0
1-75	25	4	4	0	3	2
1-76	25	4	4	0	2	2
1-77	25	5	5	1	3	2
1-78	25	5	5	0	1	0
1-80	25	5	5	0	5	1
1-81	25	4	4	0	1	0
1-83	25	5	5	1	2	1
1-84	25	4	4	0	1	0
1-85	25	4	4	0	1	0
1-89	25	4	5	0	2	2
1-95	25	5	5	1	0	0
1-97	25	4	4	3	1	0
1-98	25	4	5	0	1	1
1-99	25	4	4	0	3	0
1-100	25	5	5	0	2	2


10070804 "034102"

INDUSTRIAL APPLICABILITY

The compound of the present invention represented by the formula [I] exhibits excellent herbicidal effects over a wide range from preemergence to the growing period of various weeds which are problematic in upland fields, including, for example, broad leaf weeds such as smartweed, slender amaranth, lambsquarters, chickweed, velvetleaf, prickly sida, hemp sesbania, morning glory and cocklebur, perenial and annual cyperaceous weeds such as purple nutsedge, yellow nutsedge, himekugu, chufa and rice flatsedge, and grass weeds such as barnyard grass, crab grass, green foxtail, annual bluegrass, Johnson grass, water foxtail and wild oat. Further, it can control annual weeds such as barnyard grass, umbrella plant and monochoria, and perenial weeds such as Japanese ribbon wapato, arrowhead, water nutgrass, water chestnut, Japanese bulrush and narrowleaf waterplantain, which germinate in paddy fields. On the other hand, the herbicide of the present invention has high safety to crop plants and exhibits particularly high safety to rice, wheat, barley, corn, grain solgum, soybean, cotton, beet, etc.

CLAIMS


1. A pyrimidine derivative represented by the formula
(I)



- 5 wherein R¹ is a hydrogen atom (except for a case where R²=hydrogen atom, and W=SO₂), a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylcarbonyl C₁-C₆ alkyl group, a hydroxyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₃-C₆ cycloalkyl group (this group may be
- 10 substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₂-C₆ alkynyloxy group, a C₃-C₆ cycloalkyloxy group, a phenyl group (this group
- 15 may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a cyano C₁-C₆ alkyl group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a
- 20 C₁-C₆ alkylthio group (except for a case where R²=phenyl group, and W=SO₂), a C₂-C₆ alkenylthio group, a C₂-C₆ alkynylthio group, a C₃-C₆ cycloalkylthio group, a C₁-C₆ alkylsulfinyl group, a C₂-C₆ alkenylsulfinyl group, a

C₂-C₆ alkynylsulfinyl group, a C₃-C₆ cycloalkylsulfinyl
 group, a C₁-C₆ alkylsulfonyl group, a C₂-C₆
 alkenylsulfonyl group, a C₂-C₆ alkynylsulfonyl group, a
 C₃-C₆ cycloalkylsulfonyl group, a C₁-C₆ hydroxyalkyl group,
 5 a C₂-C₇ acyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a
 cyano group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆
 alkoxycarbonyl C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl
 C₂-C₆ alkenyl group, a carboxyl group, a carboxyl C₁-C₆
 alkyl group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆
 10 alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl
 group, a dioxolanyl group (this group may be substituted
 by a C₁-C₆ alkyl group), an aldehyde group, an oxiranyl
 group, a NR⁹R¹⁰ group or a CONR⁹R¹⁰ group, R⁹ is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 15 alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy
 C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a
 C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group or a C₁-C₆
 alkylsulfonyl group, R¹⁰ is a C₁-C₆ alkyl group, a C₂-C₆
 alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl
 20 group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio
 C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl
 group, a C₁-C₆ alkylsulfonyl group, a C₁-C₆ alkoxycarbonyl
 group or a benzyloxycarbonyl group, here R⁹ and R¹⁰ may,
 together with the carbon atom to which they are bonded,
 25 form a 5- to 7-membered saturated ring, R² is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl


group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₂-C₇ acyl group, a cyano group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), a cyano C₁-C₆ alkyl group, a C₁-C₆ hydroxyalkyl group, a C₁-C₆ alkoxy carbonyl group, a C₁-C₆ alkoxy carbonyl C₁-C₆ alkyl group, a CR¹¹R¹²NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a CR¹¹R¹²CONR⁹R¹⁰ group or a group represented by any one of the formulae R²-1 to R²-13:



(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a

C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a
 C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆
 alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆
 alkylsufonyl group, a cyano group, a nitro group or a
 5 C₁-C₄ haloalkyl group, n is an integer of from 1 to 3,
 when n is an integer of 2 or 3, the plurality of X may be
 the same or different, and two adjacent lower alkoxy
 groups may be bonded to each other to form a C₁-C₃
 alkylenedioxy group), each of R¹¹ and R¹² is a hydrogen
 10 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group or a C₁-C₆ alkoxy group, R³ is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group, a C₁-C₆ alkoxy group, a di C₁-C₆ alkylamino
 group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl
 15 group, a cyano C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl C₁-C₆
 alkyl group, an oxiranyl C₁-C₆ alkyl group or a C₁-C₆
 alkoxycarbonyl C₁-C₆ alkyl group, W is a -C(=Q)Z- group
 or a -SO₂- group, Q is an oxygen atom or a sulfur atom, Z
 is an oxygen atom, a sulfur atom, a -NR⁶- group, a
 20 -CH₂CH₂- group, a -CH=CH- group, a -C(R⁴)R⁵- group, a
 -C(R⁴)R⁵-Q- group, a -Q-C(R⁴)R⁵- group, a -C(=Q)- group, a
 -NR⁶NR^{6a}- group or a -NR⁶C(R⁴)R⁵- group, each of R⁴ and R⁵
 is a hydrogen atom, a C₁-C₆ alkyl group, a halogen atom,
 a C₁-C₆ alkoxy group or a C₁-C₆ alkylthio group, each of
 25 R⁶ and R^{6a} is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆
 alkenyl group or a C₂-C₆ alkynyl group, here R³ and R⁶ may,
 together with the carbon atom to which they are bonded,


form a 5- to 7-membered cyclic urea, Ar is a group represented by any one of the formulae Ar-1 to Ar-17:



(wherein X' is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n' is an integer of from 1 to 3, m is an integer of from 0 to 3, when n' is an integer of 2 or 3, the plurality of X' may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), R⁷ is a

hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group, and R⁸ is a hydrogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group.


2. A pyrimidine derivative represented by the formula (I)



wherein R¹ is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylcarbonyl C₁-C₆ alkyl group, a hydroxyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₂-C₆ alkynyloxy group, a C₃-C₆ cycloalkyloxy group, a phenyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a C₁-C₆ alkylthio group, a C₂-C₆ alkenylthio group, a C₂-C₆ alkynylthio group, a C₃-C₆

cycloalkylthio group, a C₁-C₆ alkylsulfinyl group, a C₂-C₆ alkenylsulfinyl group, a C₂-C₆ alkynylsulfinyl group, a C₃-C₆ cycloalkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a C₂-C₆ alkenylsulfonyl group, a C₂-C₆ alkynylsulfonyl group, a C₃-C₆ cycloalkylsulfonyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano group, a cyano C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkoxy carbonyl C₁-C₆ alkyl group, a C₁-C₆ alkoxy carbonyl C₂-C₆ alkenyl group, a carboxyl group, a carboxyl C₁-C₆ alkyl group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), an aldehyde group, an oxiranyl group, a NR⁹R¹⁰ group or a CONR⁹R¹⁰ group, R⁹ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group or a C₁-C₆ alkylsulfonyl group, R¹⁰ is a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkylsulfonyl group, a C₁-C₆ alkoxycarbonyl group or a benzyloxycarbonyl group, here R⁹ and R¹⁰ may, together with the carbon atom to which they are bonded, form a 5- to 7-membered saturated ring, R² is a hydrogen


atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₂-C₇ acyl group, a cyano group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), a cyano C₁-C₆ alkyl group, a C₁-C₆ hydroxyalkyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, a CR¹¹R¹²NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a CR¹¹R¹²CONR⁹R¹⁰ group or a group represented by any one of the formulae R²-1 to R²-13:



(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group,

a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsufonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n is an integer of from 1 to 3, when n is an integer of 2 or 3, the plurality of X may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), each of R¹¹ and R¹² is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group or a C₁-C₆ alkoxy group, R³ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a di C₁-C₆ alkylamino group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl C₁-C₆ alkyl group, an oxiranyl C₁-C₆ alkyl group or a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, W is a -C(=Q)Z- group, Q is an oxygen atom or a sulfur atom, Z is an oxygen atom, a sulfur atom, a -NR⁶- group, a -CH₂CH₂- group, a -CH=CH- group, a -C(R⁴)R⁵- group, a -C(R⁴)R⁵-Q- group, a -Q-C(R⁴)R⁵- group, a -C(=Q)- group, a -NR⁶NR^{6a}- group or a -NR⁶C(R⁴)R⁵- group, each of R⁴ and R⁵ is a hydrogen atom, a C₁-C₆ alkyl group, a halogen atom, a C₁-C₆ alkoxy group or a C₁-C₆ alkylthio group, each of R⁶ and R^{6a} is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆

alkenyl group or a C₂-C₆ alkynyl group, here R³ and R⁶ may, together with the carbon atom to which they are bonded, form a 5- to 7-membered cyclic urea, Ar is a group represented by any one of the formulae Ar-1 to Ar-17:



5

(wherein X' is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n' is an integer of from 1 to 3, m is an integer of from 0 to 3, when n' is an integer of 2 or 3, the plurality of X' may be the same or different,


10

15

and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), R⁷ is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group, and R⁸ is a hydrogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group.

3. A pyrimidine derivative represented by the formula


(I)




wherein R¹ is a halogen atom, a C₁-C₆ alkyl group, an oxo C₁-C₆ alkyl group, a hydroxyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₂-C₆ alkynyloxy group, a C₃-C₆ cycloalkyloxy group, a phenyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆

alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a C₂-C₆ alkenylthio group, a C₂-C₆ alkynylthio group, a C₃-C₆ cycloalkylthio group, a C₁-C₆ alkylsulfinyl group, a C₂-C₆ alkenylsulfinyl group, a C₂-C₆ alkynylsulfinyl group, a C₃-C₆ cycloalkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a C₂-C₆ alkenylsulfonyl group, a C₂-C₆ alkynylsulfonyl group, a C₃-C₆ cycloalkylsulfonyl group, a hydroxyalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano group, a cyano C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl C₂-C₆ alkenyl group, a carboxyl group, a carboxyl C₁-C₆ alkyl group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), an aldehyde group, an oxiranyl group, a NR⁹R¹⁰ group or a CONR⁹R¹⁰ group, R⁹ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group or a C₁-C₆ alkylsulfonyl group, R¹⁰ is a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkylsulfonyl group, a C₁-C₆ alkoxycarbonyl group or a benzyloxycarbonyl group, here R⁹ and R¹⁰ may,

together with the carbon atom to which they are bonded, form a 5- to 7-membered saturated ring, R^2 is a hydrogen atom, a C_1-C_6 alkyl group, a C_2-C_6 alkenyl group, a C_2-C_6 alkynyl group, a C_1-C_6 alkylthio group, a C_1-C_4 haloalkyl group, a C_1-C_6 alkoxy group, a C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkylthio C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group (this group may be substituted by a halogen atom, a C_1-C_6 alkyl group, a C_1-C_6 alkoxy group or a C_1-C_4 haloalkyl group), a C_2-C_7 acyl group, a cyano group, a di C_1-C_6 alkoxy C_1-C_6 alkyl group, a C_1-C_6 alkoxyimino C_1-C_6 alkyl group, a hydroxyimino C_1-C_6 alkyl group, a dioxolanyl group (this group may be substituted by a C_1-C_6 alkyl group), a cyano C_1-C_6 alkyl group, a C_1-C_6 hydroxyalkyl group, a C_1-C_6 alkoxycarbonyl group, a C_1-C_6 alkoxycarbonyl C_1-C_6 alkyl group, a $CR^{11}R^{12}NR^9R^{10}$ group, a $CONR^9R^{10}$ group, a $CR^{11}R^{12}CONR^9R^{10}$ group or a group represented by any one of the formulae R^2-1 to R^2-13 :



(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsufonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n is an integer of from 1 to 3, when n is an integer of 2 or 3, the plurality of X may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), each of R¹¹ and R¹² is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group or a C₁-C₆ alkoxy group, R³ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a di C₁-C₆ alkylamino group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl C₁-C₆ alkyl group, an oxiranyl C₁-C₆ alkyl group or a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, W is a -SO₂- group, Ar is a group represented by any one of the formulae Ar-1 to Ar-17:




(wherein X' is a hydrogen atom, a halogen atom, an alkyl group, a C_2 - C_6 alkenyl group, a C_2 - C_6 alkynyl group, a C_1 - C_6 alkoxy group, a C_1 - C_6 alkoxy C_1 - C_6 alkyl group, a NR^9R^{10} group, a $CONR^9R^{10}$ group, a C_1 - C_4 haloalkoxy group, a C_2 - C_6 alkenyloxy group, a C_3 - C_6 cycloalkyloxy group, a C_2 - C_7 acyl group, a C_1 - C_6 alkoxycarbonyl group, a C_1 - C_6 alkylthio group, a C_1 - C_6 alkylsulfinyl group, a C_1 - C_6 alkylsufonyl group, a cyano group, a nitro group or a C_1 - C_4 haloalkyl group, n' is an integer of from 1 to 3, m is an integer of from 0 to 3, when n' is an integer of 2 or 3, the plurality of X' may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C_1 - C_3 alkylenedioxy group), R^7 is a hydrogen atom, a halogen atom, a C_1 - C_6 alkyl group, a C_1 - C_6 alkoxy group, a C_1 - C_6 alkylthio group, a C_1 - C_4

haloalkyl group or a C₃-C₆ cycloalkyl group, and R⁸ is a hydrogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group.

4. A pyrimidine derivative represented by the formula


5 (I)



wherein R¹ is a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylcarbonyl C₁-C₆ alkyl group, a hydroxyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₂-C₆ alkynyloxy group, a C₃-C₆ cycloalkyloxy group, a phenyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a C₁-C₆ alkylthio group (except for a case where R²=phenyl group, and W=SO₂), a C₂-C₆ alkenylthio group, a C₂-C₆ alkynylthio group, a C₃-C₆ cycloalkylthio group, a C₁-C₆

alkylsulfinyl group, a C₂-C₆ alkenylsulfinyl group, a C₂-C₆ alkynylsulfinyl group, a C₃-C₆ cycloalkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a C₂-C₆ alkenylsulfonyl group, a C₂-C₆ alkynylsulfonyl group, a C₃-C₆ cycloalkylsulfonyl group, a C₁-C₆ hydroxyalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano group, a cyano C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, a C₁-C₆ alkoxycarbonyl C₂-C₆ alkenyl group, a carboxyl group, a carboxyl C₁-C₆ alkyl group, a di C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), an aldehyde group, an oxiranyl group, a NR⁹R¹⁰ group or a CONR⁹R¹⁰ group, R⁹ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group or a C₁-C₆ alkylsulfonyl group, R¹⁰ is a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkylsulfonyl group, a C₁-C₆ alkoxycarbonyl group or a benzyloxycarbonyl group, here R⁹ and R¹⁰ may, together with the carbon atom to which they are bonded, form a 5- to 7-membered saturated ring, R² is a C₁-C₆ alkyl group, a


C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆
 alkylthio group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy
 group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio
 C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group (this group
 5 may be substituted by a halogen atom, a C₁-C₆ alkyl group,
 a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a C₂-C₇
 acyl group, a cyano group, a di C₁-C₆ alkoxy C₁-C₆ alkyl
 group, a C₁-C₆ alkoxyimino C₁-C₆ alkyl group, a
 hydroxyimino C₁-C₆ alkyl group, a dioxolanyl group (this
 10 group may be substituted by a C₁-C₆ alkyl group), a cyano
 C₁-C₆ alkyl group, a C₁-C₆ hydroxyalkyl group, a C₁-C₆
 alkoxycarbonyl group, a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl
 group, a CR¹¹R¹²NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a
 CR¹¹R¹²CONR⁹R¹⁰ group or a group represented by any one of
 15 the formulae R²-1 to R²-13:



(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆
 alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group,

a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a
 NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a
 C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a
 C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆
 5 alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆
 alkylsufonyl group, a cyano group, a nitro group or a
 C₁-C₄ haloalkyl group, n is an integer of from 1 to 3,
 when n is an integer of 2 or 3, the plurality of X may be
 the same or different, and two adjacent lower alkoxy
 10 groups may be bonded to each other to form a C₁-C₃
 alkylenedioxy group), each of R¹¹ and R¹² is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 alkynyl group or a C₁-C₆ alkoxy group, R³ is a hydrogen
 atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆
 15 alkynyl group, a C₁-C₆ alkoxy group, a di C₁-C₆ alkylamino
 group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl
 group, a cyano C₁-C₆ alkyl group or a C₃-C₆ cycloalkyl
 C₁-C₆ alkyl group, W is a -C(=Q)Z- group or a -SO₂- group,
 Q is an oxygen atom or a sulfur atom, Z is an oxygen atom,
 20 a sulfur atom, a -NR⁶- group, a -C(R⁴)R⁵- group, a
 -C(R⁴)R⁵-Q- group, a -NR⁶NR^{6a}- group or a -NR⁶C(R⁴)R⁵-
 group, each of R⁴ and R⁵ is a hydrogen atom, a C₁-C₆ alkyl
 group, a halogen atom or a C₁-C₆ alkoxy group, each of R⁶
 and R^{6a} is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆
 25 alkenyl group or a C₂-C₆ alkynyl group, here R³ and R⁶ may,
 together with the carbon atom to which they are bonded,
 form a 5- to 7-membered cyclic urea, Ar is a group


represented by any one of the formulae Ar-1 to Ar-17:



(wherein X' is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsufonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n' is an integer of from 1 to 3, m is an integer of from 0 to 3, when n' is an integer of 2 or 3, the plurality of X' may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), R⁷ is a hydrogen atom or a halogen atom, and R⁸ is a hydrogen


atom.

5. A pyrimidine derivative represented by the formula
(I)




- 5 wherein R^1 is a C_1 - C_6 alkyl group, a C_1 - C_6 alkylcarbonyl
 C_1 - C_6 alkyl group, a C_3 - C_6 cycloalkyl group (this group
 may be substituted by a halogen atom, a C_1 - C_6 alkyl group,
 a C_1 - C_6 alkoxy group or a C_1 - C_4 haloalkyl group), a C_1 - C_4
 haloalkyl group, a C_1 - C_6 alkoxy group, a phenyl group
 10 (this group may be substituted by a halogen atom, a C_1 - C_6
 alkyl group, a C_1 - C_6 alkoxy group, a C_1 - C_4 haloalkyl group,
 a C_1 - C_4 haloalkoxy group, a cyano group, a nitro group, a
 C_1 - C_6 alkylthio group, a C_1 - C_6 alkylsulfinyl group or a
 C_1 - C_6 alkylsulfonyl group), a C_1 - C_6 alkylthio group
 15 (except for a case where R^2 =phenyl group, and $W=SO_2$), a
 C_1 - C_6 alkylsulfinyl group, a C_2 - C_7 acyl group, a C_1 - C_6
 alkoxy C_1 - C_6 alkyl group, a cyano group, a cyano C_1 - C_6
 alkyl group, a C_1 - C_6 alkoxycarbonyl group, a C_1 - C_6
 alkoxycarbonyl C_2 - C_6 alkenyl group, a carboxyl group, a
 20 di C_1 - C_6 alkoxy C_1 - C_6 alkyl group or a C_1 - C_6 alkoxyimino
 C_1 - C_6 alkyl group, R^2 is a C_1 - C_6 alkyl group, a C_1 - C_4
 haloalkyl group, a C_1 - C_6 alkoxy C_1 - C_6 alkyl group, a C_1 - C_6

alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group
 (this group may be substituted by a halogen atom, a C₁-C₆
 alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl
 group) a C₂-C₇ acyl group, or a group represented by
 5 either the formula R²-1 or R²-6:




(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆
 alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group,
 a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a
 10 NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a
 C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a
 C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆
 alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆
 alkylsulfonyl group, a cyano group, a nitro group or a
 15 C₁-C₄ haloalkyl group, n is an integer of from 1 to 3,
 when n is an integer of 2 or 3, the plurality of X may be
 the same or different, and two adjacent lower alkoxy
 groups may be bonded to each other to form a C₁-C₃
 alkylenedioxy group), R⁹ is a hydrogen atom, a C₁-C₆ alkyl
 20 group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a
 C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a
 C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group,
 a C₂-C₇ acyl group or a C₁-C₆ alkylsulfonyl group, R¹⁰ is a

C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₄ haloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group, a C₂-C₇ acyl group, a C₁-C₆ alkylsulfonyl group, a C₁-C₆ alkoxycarbonyl group or a benzyloxycarbonyl group, here R⁹ and R¹⁰ may, together with the carbon atom to which they are bonded, form a 5- to 7-membered saturated ring, each of R¹¹ and R¹² is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group or a C₁-C₆ alkoxy group, R³ is a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group or a cyano C₁-C₆ alkyl group, W is a -C(=Q)Z- group or a -SO₂- group, Q is an oxygen atom or a sulfur atom, Z is a -NR⁶- group, a -C(R⁴)R⁵- group, a -C(R⁴)R⁵-Q- group, a -NR⁶NR^{6a}- group or a -NR⁶C(R⁴)R⁵- group, each of R⁴ and R⁵ is a hydrogen atom, a C₁-C₆ alkyl group, a halogen atom or a C₁-C₆ alkoxy group, each of R⁶ and R^{6a} is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group or a C₂-C₆ alkynyl group, here R³ and R⁶ may, together with the carbon atom to which they are bonded, form a 5- to 7-membered cyclic urea, Ar is a group represented by either the formula Ar-1, Ar-6 or Ar-14:



(wherein X is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a NR⁹R¹⁰ group, a CONR⁹R¹⁰ group, a C₁-C₄ haloalkoxy group, a C₂-C₆ alkenyloxy group, a C₃-C₆ cycloalkyloxy group, a C₂-C₇ acyl group, a C₁-C₆ alkoxycarbonyl group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group, a C₁-C₆ alkylsulfonyl group, a cyano group, a nitro group or a C₁-C₄ haloalkyl group, n is an integer of from 1 to 3, m is an integer of from 2 or 3, when n is an integer of 2 or 3, the plurality of X may be the same or different, and two adjacent lower alkoxy groups may be bonded to each other to form a C₁-C₃ alkylenedioxy group), R⁷ is a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group, and R⁸ is a hydrogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkylthio group, a C₁-C₄ haloalkyl group or a C₃-C₆ cycloalkyl group.

6. A pyrimidine derivative represented by an intermediate represented by the formula (II)




wherein R¹ is a C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a phenyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a C₁-C₆ alkoxy C₁-C₆ alkyl group, a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group) or a di C₁-C₆ alkoxy C₁-C₆ alkyl group, R² is a C₁-C₆ alkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a C₁-C₆ alkylthio C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group or a C₁-C₄ haloalkyl group), a phenyl group (this group may be substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a thienyl group (this group may be

substituted by a halogen atom, a C₁-C₆ alkyl group, a C₁-C₆ alkoxy group, a C₁-C₄ haloalkyl group, a C₁-C₄ haloalkoxy group, a cyano group, a nitro group, a C₁-C₆ alkylthio group, a C₁-C₆ alkylsulfinyl group or a C₁-C₆ alkylsulfonyl group), a di C₁-C₆ alkoxy C₁-C₆ alkyl group or a dioxolanyl group (this group may be substituted by a C₁-C₆ alkyl group), R³ is a hydrogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₂-C₆ alkynyl group, a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, a cyano C₁-C₆ alkyl group, a C₃-C₆ cycloalkyl C₁-C₆ alkyl group, an oxiranyl C₁-C₆ alkyl group or a C₁-C₆ alkoxycarbonyl C₁-C₆ alkyl group, R⁷ is a hydrogen atom or a C₁-C₆ alkoxy group, and R⁸ is a hydrogen atom, a C₁-C₆ alkyl group or a C₃-C₆ cycloalkyl group.

7. A herbicide containing the pyrimidine derivative as defined in any one of Claims 1 to 5, as an active ingredient.

ABSTRACT

Pyrimidine derivatives having excellent herbicidal activities for crop plants and selectivity between crop plants and weeds, are presented. Pyrimidine derivatives
 5 represented by the following formula (I):



wherein R¹ is a hydrogen atom, an alkyl group, a haloalkyl group or the like; R² is an alkyl group, a phenyl group which may be substituted, or the like; R³ is
 10 a hydrogen atom, an alkyl group, an alkynyl group or the like; R⁷ is a hydrogen atom, a halogen atom, an alkyl group or the like; R⁸ is a hydrogen atom, an alkyl group or the like, W is a -C(=Q)Z- group or a -SO₂- group; Q is O or S; Z is O, S, a -C(R⁴)R⁵-, a -NR⁶ group or the like;
 15 each of R⁴ and R⁵ is a hydrogen atom, an alkyl group, an alkoxy group or the like; R⁶ is a hydrogen atom or an alkyl group; and Ar is a phenyl group which may be substituted, a pyridyl group which may be substituted, or the like, and herbicides containing such pyrimidine
 20 derivatives as active ingredients.

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2001 年 3 月 15 日 (15.03.2001)

PCT

(10) 国際公開番号
WO 01/17975 A1

(51) 国際特許分類⁷: C07D 239/26, 239/32, 401/12, 403/06, 405/04, 409/12, A01N 47/38, 43/54

(21) 国際出願番号: PCT/JP00/06165

(22) 国際出願日: 2000 年 9 月 8 日 (08.09.2000)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願平11/255029 1999 年 9 月 9 日 (09.09.1999) JP

(71) 出願人 (米国を除く全ての指定国について): クミアイ化学工業株式会社 (KUMIAI CHEMICAL INDUSTRY CO., LTD.) [JP/JP]; 〒110-0008 東京都台東区池之端1丁目4番26号 Tokyo (JP). イハラケミカル工業株式会社 (IHARA CHEMICAL INDUSTRY CO., LTD.) [JP/JP]; 〒110-0008 東京都台東区池之端1丁目4番26号 Tokyo (JP).

(72) 発明者; および

(75) 発明者/出願人 (米国についてのみ): 安田厚司 (YASUDA, Atsushi) [JP/JP]; 〒277-0843 千葉県柏市明原4丁目9番地の15 Chiba (JP). 高部文明 (TAKABE, Fumiaki) [JP/JP]. 山口幹夫 (YAMAGUCHI, Mikio) [JP/JP]; 〒437-1213 静岡県磐田郡福田町塩新田408番地の1 株式会社 ケイ・アイ研究所内 Shizuoka (JP). 漆畑育巳 (URUSHIBATA, Ikumi) [JP/JP]; 〒277-0885 千葉県柏市西原1丁目18番地の6 Chiba (JP). 山地充洋

(YAMAJI, Yoshihiro) [JP/JP]. 藤波 周 (FUJINAMI, Makoto) [JP/JP]; 〒439-0031 静岡県小笠郡菊川町加茂1809番地 Shizuoka (JP). 宮沢武重 (MIYAZAWA, Takeshige) [JP/JP]; 〒437-1403 静岡県小笠郡大東町岩滑1205-9 Shizuoka (JP).

(74) 代理人: 泉名謙治, 外 (SENMYO, Kenji et al.); 〒101-0042 東京都千代田区神田東松下町38番地 鳥本鋼業ビル Tokyo (JP).

(81) 指定国 (国内): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) 指定国 (広域): ARIPO 特許 (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), ユーラシア特許 (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), ヨーロッパ特許 (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI 特許 (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:
— 国際調査報告書

2文字コード及び他の略語については、定期発行される各PCTガゼットの巻頭に掲載されている「コードと略語のガイダンスノート」を参照。

(54) Title: PYRIMIDINE DERIVATIVES AND HERBICIDES CONTAINING THE SAME

(54) 発明の名称: ピリミジン誘導体及びそれを含有する除草剤



(57) Abstract: Pyrimidine derivatives represented by general formula (I) which have an excellent herbicidal activity and a selectivity on crops from weeds, and herbicides containing these pyrimidine derivatives as the active ingredient. In said formula, R¹ represents hydrogen, alkyl, haloalkyl, etc.; R² represents alkyl, optionally substituted phenyl, etc.; R³ represents hydrogen, alkyl, alkynyl, etc.; R⁷ represents hydrogen, halogeno, alkyl, etc.; R⁸ represents hydrogen, alkyl, etc.; W represents -C(=Q)Z- or -SO₂- (wherein Q represents O or S; and Z represents O, S, -C(R⁴)R⁵-, NR⁶-, etc. (wherein R⁴ and R⁵ represent each hydrogen, alkyl, alkoxy, etc.; and R⁶ represents hydrogen or alkyl)); and Ar represents optionally substituted phenyl, optionally substituted pyridyl, etc.

[続葉有]

2017040804001

WO 01/17975 A1

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

PYRIMIDINE DERIVATIVES AND

HERBICIDES CONTAINING THEM

上記発明の明細書は、

本書に添付されています。

the specification of which

☒ is attached hereto.

____月____日に提出され、米国出願番号または特許協定条約国際出願番号を____とし、
(該当する場合) _____に訂正されました。

☒ was filed on September 8, 2000
as United States Application Number or
PCT International Application Number
PCT/JP00/06165 and was amended on
_____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration

(日本語宣言書)

私は、米国法典第35編119条 (a) - (d) 項又は365条 (b) 項に基づき下記の、米国以外の国の少なくとも一カ国を指定している特許協力条約365 (a) 項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

11-255029

(Number)
(番号)

Japan

(Country)
(国名)

(Number)
(番号)

(Country)
(国名)

私は、第35編米国法典119条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条 (c) に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

PCT/JP00/06165

(Application No.)
(出願番号)

8/September/2000

(Filing Date)
(出願日)

(Application No.)
(出願番号)

(Filing Date)
(出願日)

私は、私自信の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed
優先権主張

9/September/1999

(Day/Month/Year Filed)
(出願年月日)

☒ Yes
はい

☐ No
いいえ

(Day/Month/Year Filed)
(出願年月日)

☐ Yes
はい

☐ No
いいえ

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Filing Date)
(出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

Pending

(Status: Patented, Pending, Abandoned)
(現況：特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)
(現況：特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration

(日本語宣言書)

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。

(弁理士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)



022850

書類送付先

Send Correspondence to:



022850

直接電話連絡先：(名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

(703) 413-3000

単独発明者または第一の共同発明者の氏名	Full name of sole or first joint inventor Atsushi Yasuda	
発明者の署名	日付	Inventor's signature A. Yasuda Date Jan. 22, 2002
住所	Residence Chiba, Japan JPX	
国籍	Citizenship Japanese	
郵便の宛先	Post Office Address 4-9-15, Akehara, Kashiwa-shi, Chiba 277-0843 Japan	
第二の共同発明者の氏名	Full name of second joint inventor, if any Fumiaki Takabe	
第二の共同発明者の署名	日付	Second joint Inventor's signature Fumiaki Takabe Date Jan. 24, 2002
住所	Residence Shizuoka, Japan JPX	
国籍	Citizenship Japanese	
郵便の宛先	Post Office Address c/o K·I CHEMICAL RESEARCH INSTITUTE CO., LTD. 408-1, Shioshinden, Fukude-cho, Iwata-gun, Shizuoka 437-1213 Japan	

(第三以降の共同発明者についても同様に記載し、署名すること)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第三の共同発明者の氏名	Full name of third joint inventor, if any <u>Ikumi Urushibata</u>		
第三の共同発明者の署名	日付	Third joint inventor's signature <u>Ikumi Urushibata</u>	Date <u>Jan. 23, 2002</u>
住所	Residence <u>Chiba, Japan</u>		
国籍	Citizenship <u>Japanese</u>		
郵便の宛先	Post Office Address <u>1-18-6, Nishihara, Kashiwa-shi,</u>		
	<u>Chiba 277-0885 Japan</u>		

第四の共同発明者の氏名	Full name of fourth joint inventor, if any <u>Mikio Yamaguchi</u>		
第四の共同発明者の署名	日付	Fourth joint inventor's signature <u>Mikio Yamaguchi</u>	Date <u>Jan. 24, 2002</u>
住所	Residence <u>Shizuoka, Japan</u>		
国籍	Citizenship <u>Japanese</u>		
郵便の宛先	Post Office Address <u>c/o K·I CHEMICAL RESEARCH</u> <u>INSTITUTE CO., LTD.</u>		
	<u>408-1, Shioshinden, Fukude-cho,</u> <u>Iwata-gun, Shizuoka 437-1213 Japan</u>		

第五の共同発明者の氏名	Full name of fifth joint inventor, if any <u>Yoshihiro Yamaji</u>		
第五の共同発明者の署名	日付	Fifth joint inventor's signature <u>Yoshihiro Yamaji</u>	Date <u>Feb. 1, 2002</u>
住所	Residence <u>Shizuoka, Japan</u>		
国籍	Citizenship <u>Japanese</u>		
郵便の宛先	Post Office Address <u>1809, Kamo, Kikugawa-cho, Ogasa-gun,</u>		
	<u>Shizuoka 439-0031 Japan</u>		

第六の共同発明者の氏名	Full name of sixth joint inventor, if any <u>Makoto Fujinami</u>		
第六の共同発明者の署名	日付	Sixth joint inventor's signature <u>Makoto Fujinami</u>	Date <u>Feb. 4, 2002</u>
住所	Residence <u>Shizuoka, Japan</u>		
国籍	Citizenship <u>Japanese</u>		
郵便の宛先	Post Office Address <u>1809, Kamo, Kikugawa-cho, Ogasa-gun,</u>		
	<u>Shizuoka 439-0031 Japan</u>		

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第七の共同発明者の氏名	Full name of seventh joint inventor, if any <u>Takeshige Miyazawa</u>		
第七の共同発明者の署名	日付	Seventh joint inventor's signature <u>Takeshige Miyazawa</u>	Date <u>Feb. 1. 2002</u>
住所	Residence <u>Shizuoka, Japan</u>		
国籍	Citizenship <u>Japanese</u>		
郵便の宛先	Post Office Address <u>1205-9, Iwaname, Daito-cho,</u>		
	<u>Ogasa-gun, Shizuoka 437-1403 Japan</u>		

第八の共同発明者の氏名	Full name of eighth joint inventor, if any		
第八の共同発明者の署名	日付	Eighth joint inventor's signature	Date
住所	Residence		
国籍	Citizenship		
郵便の宛先	Post Office Address		

第九の共同発明者の氏名	Full name of ninth joint inventor, if any		
第九の共同発明者の署名	日付	Ninth joint inventor's signature	Date
住所	Residence		
国籍	Citizenship		
郵便の宛先	Post Office Address		

第十の共同発明者の氏名	Full name of tenth joint inventor, if any		
第十の共同発明者の署名	日付	Tenth joint inventor's signature	Date
住所	Residence		
国籍	Citizenship		
郵便の宛先	Post Office Address		

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)